Table: monthly_update_prescription_drug_wac_inc , manufacturer_name like all*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	gross_sales_us_dollars	gross_sales_us_dollars_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000421	Aadi Bioscience, Inc.	04/14/2025	80803015350	Fyarro Intravenous Suspension Reconstituted 100 MG 1 vial	01/01/2025	343.57	7978.53	10/28/2040	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	04/28/2025	00074230630	RINVOQ TABLET EXTENDED RELEASE 24 HR 15 mg 30	01/02/2025	321.56	6752.77	03/09/2038	Single Source Drug	None	None	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	04/28/2025	00074231030	RINVOQ TABLET EXTENDED RELEASE 24 HR 30 mg 30	01/02/2025	321.56	6752.77	03/09/2038	Single Source Drug	None	None	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	04/28/2025	00074104328	RINVOQ TABLET EXTENDED RELEASE 24 HR 45 mg 28	01/02/2025	600.24	12605.04	03/09/2038	Single Source Drug	None	None	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	04/28/2025	00074106501	SKYRIZI ON-BODY WEARABLE INJECTOR 180 mg/1.2 mL (150 mg/mL) 1.2	01/02/2025	1366.13	22383.49	02/04/2034	Single Source Drug	None	None	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	04/28/2025	00074107001	SKYRIZI ON-BODY WEARABLE INJECTOR 360 mg/2.4 mL (150 mg/mL) 2.4	01/02/2025	1366.13	22383.49	02/04/2034	Single Source Drug	None	None	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	04/28/2025	00074210001	SKYRIZI PEN PEN INJECTOR (ML) 150 mg/mL 1	01/02/2025	1366.13	22383.49	02/04/2034	Single Source Drug	None	None	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	04/28/2025	00074105001	SKYRIZI SYRINGE (ML) 150 mg/mL 1	01/02/2025	1366.13	22383.49	02/04/2034	Single Source Drug	None	None	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000513	Acertis Pharmaceuticals LLC	04/25/2025	72989040930	PHENDIMETRAZINE TARTRATE EXTENDED RELEASE CAPSULES 1 PACK 30 CAPS 105 MG	03/01/2025	8.87	98.46	None	Innovator Multiple Source Drug	None	None	None	1	Acertis' pricing strategy is founded on a comprehensive analysis of various factors, including competitive market dynamics, escalating supply chain and operational expenses, distribution and wholesaler fees, as well as research and development costs. Additionally, pricing decisions are influenced by the limited size of patient populations for certain products.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000251	Actelion Pharmaceuticals US, Inc	04/28/2025	66215040201	VELETRI® (epoprostenol) Strength:1.5 MG Package Size:1 Form:Vial	01/28/2025	3.13	55.26	03/15/2027	Innovator Multiple Source Drug	None	None	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2025.
Rx0000459	AltaThera Pharmaceuticals LLC	01/02/2025	69724011210	Sotalol hydrochloride - Injection: 10-mL vial containing sotalol hydrochloride 150 mg	01/01/2025	327.00	3623.00	08/21/2039	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	At AltaThera, we are committed to upholding the highest standards of confidentiality and integrity. We want to emphasize that information related to our unit sales volume and cost increase factors is deemed nonpublic and proprietary. This includes, but is not limited to, detailed sales figures, production costs, and any associated sensitive data. We strictly prohibit the disclosure of such information to external parties without explicit authorization. This commitment is integral to maintaining a competitive edge in the market and safeguarding our business interests.
Rx0000231	American Health Packaging	04/04/2025	68084029121	Naltrexone HCl Oral Tablet 50 MG 30 tablets per box	02/07/2025	11.28	86.51	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000128	American Regent	04/28/2025	00517750425	ACETYLCYSTEINE SOLUTION 10%, 100MG/ML, 4ML Vial, PKG OF 25	02/01/2025	11.75	271.25	None	Non-innovator Multiple Source Drug	None	None	14113532	None	Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000128	American Regent	04/28/2025	00517760425	ACETYLCYSTEINE SOLUTION 20%, 4ML, PKG OF 25	02/01/2025	15.50	361.00	None	Non-innovator Multiple Source Drug	None	None	31571001	None	Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000128	American Regent	04/28/2025	00517250210	Caffeine & Sodium Benzoate, 250mg/ml 2mL SDV, 10pk	02/01/2025	24.60	365.10	None	Non-innovator Multiple Source Drug	None	None	3010067	None	Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000128	American Regent	04/29/2025	00517420125	HYDROXYZINE HCL, 25MG/ML, 1ML SDV, PKG. OF 25	02/01/2025	31.50	731.50	None	Non-innovator Multiple Source Drug	None	None	4160225	None	Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000128	American Regent	04/28/2025	00517560125	HYDROXYZINE HCL, 50MG/ML, 1ML SDV, PKG. OF 25	02/01/2025	34.75	806.50	None	Non-innovator Multiple Source Drug	None	None	7200522	None	Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000128	American Regent	04/29/2025	00517930225	MULTRYS (TRACE ELEMENTS INJECTION 4, (zinc 1,000 mcg, copper 60 mcg, manganese 3 mcg, and selenium 6mcg) 1ML Vial ,USP, PKG. OF 25	02/01/2025	26.75	623.00	07/01/2041	Single Source Drug	None	None	16424382	None	Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000128	American Regent	04/29/2025	00517930525	Tralement (TRACE ELEMENTS INJECTION 4 USP, (Zinc 3 mg, Copper 0.3 mg, Manganese 55 mcg, Selenium 60mcg), 1ML Vial, PKG. OF 25)	02/01/2025	29.00	674.50	07/01/2041	Single Source Drug	None	None	143985898	None	Our US Standards of Business Conduct (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://americanregent.com/media/br3lq3m3/3c3a9340-deb9-4172-95da-4704397f588d_us-standards-of-business-conduct_ver11_12feb2024.pdf) reflects that the Company is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	No change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	04/11/2025	64896066930	Emverm Oral Tablet Chewable 100 MG	01/20/2025	67.20	746.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	04/11/2025	64896040201	Opicapone 25 MG Capsule 30 EA	01/20/2025	66.36	736.71	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	04/11/2025	64896040301	Opicapone 50 MG Capsule 30 EA	01/20/2025	66.36	736.71	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	04/11/2025	64896069701	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 10 MG 100	01/20/2025	91.22	1012.64	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	04/11/2025	64896069713	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 10 MG 60	01/20/2025	54.73	607.59	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	04/11/2025	64896069801	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 15 MG 100	01/20/2025	126.50	1404.26	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	04/11/2025	64896069813	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 15 MG 60	01/20/2025	75.90	842.57	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	04/11/2025	64896069901	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG 100	01/20/2025	162.68	1805.93	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	04/11/2025	64896069913	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG 60	01/20/2025	97.07	1077.62	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	04/11/2025	64896070001	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 30 MG 100	01/20/2025	232.87	2585.09	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	04/11/2025	64896070013	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 30 MG 60	01/20/2025	139.72	1551.07	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	04/11/2025	64896070101	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG 100	01/20/2025	303.95	3374.18	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	04/11/2025	64896070113	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG 60	01/20/2025	182.37	2024.51	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	04/11/2025	64896069501	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 5 MG 100	01/20/2025	47.51	527.37	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	04/11/2025	64896069513	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 5 MG 60	01/20/2025	28.50	316.39	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	04/11/2025	64896069601	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 7.5 MG 100	01/20/2025	69.36	769.96	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	04/11/2025	64896069613	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 7.5 MG 60	01/20/2025	41.62	461.98	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000176	ANIP	03/20/2025	62559019016	METOCLOPRAMIDE HCL 5 mg/5 mL 473 SOLUTION, ORAL	02/03/2025	35.00	70.00	None	Non-innovator Multiple Source Drug	None	None	None	1	Due to market constraints and to avoid any supply disruptions of this important medicine, ANI has invested in increased production and manpower. Along with the increase in production there have been significant labor and material increases over previous years that ANI has absorbed rather than take a price increase. This increase allows ANI to continue to manufacture this product sustainably at this time.	None	There was no change or improvement to the product.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000132	Arbor Pharmaceuticals, LLC	04/29/2025	60631004030	EDARBI (azilsartan medoxomil) , 30 tablets , 40 mg	01/01/2025	21.39	259.09	03/26/2028	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000132	Arbor Pharmaceuticals, LLC	04/29/2025	60631008030	EDARBI (azilsartan medoxomil) , 30 tablets , 80 mg	01/01/2025	23.25	281.62	03/26/2028	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000132	Arbor Pharmaceuticals, LLC	04/29/2025	60631041230	EDARBYCLOR (azilsartan medoxomil / chlorthalidone) , 30 tablets , 40 mg / 12.5 mg	01/01/2025	21.95	265.81	07/01/2031	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000132	Arbor Pharmaceuticals, LLC	04/29/2025	60631042530	EDARBYCLOR (azilsartan medoxomil / chlorthalidone) , 30 tablets , 40 mg / 25 mg	01/01/2025	21.95	265.81	07/01/2031	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000132	Arbor Pharmaceuticals, LLC	04/29/2025	53451010301	HORIZANT (gabapentin enacarbil) extended-release tablet , 30 tablets , 300 mg	01/01/2025	46.41	562.11	06/10/2029	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000132	Arbor Pharmaceuticals, LLC	04/29/2025	53451010101	HORIZANT (gabapentin enacarbil) extended-release tablet , 30 tablets , 600 mg	01/01/2025	46.41	562.11	06/10/2029	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000141	Ascend Laboratories, LLC	04/23/2025	67877045860	Capecitabine Tablets 150MG 60 Count Bottle	02/09/2025	5.13	35.75	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	No Change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000141	Ascend Laboratories, LLC	04/23/2025	67877077258	Diclofenac Potassium Powder for solution 9 50MG Packets	02/09/2025	128.75	478.81	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	No Change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000141	Ascend Laboratories, LLC	04/23/2025	67877012420	Silver sulfadiazine cream 1% 20gm tube	03/24/2025	3.30	9.15	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	No Change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000141	Ascend Laboratories, LLC	04/23/2025	67877012425	Silver sulfadiazine cream 1% 25gm tube	03/24/2025	3.70	11.15	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	No Change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000141	Ascend Laboratories, LLC	04/23/2025	67877012440	Silver sulfadiazine cream 1% 400gm jar	03/24/2025	14.50	67.25	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	No Change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000141	Ascend Laboratories, LLC	04/23/2025	67877012450	Silver sulfadiazine cream 1% 50gm jar	03/24/2025	4.70	16.95	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	No Change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000141	Ascend Laboratories, LLC	04/23/2025	67877012405	Silver sulfadiazine cream 1% 50gm tube	03/24/2025	4.70	16.95	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	No Change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000141	Ascend Laboratories, LLC	04/23/2025	67877012485	Silver sulfadiazine cream 1% 85gm tube	03/24/2025	4.45	26.50	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	No Change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000015	AstraZeneca	04/23/2025	00310066812	Lynparza TAB 100MG 120 Count Bottle	01/01/2025	505.63	17360.06	10/25/2041	Single Source Drug	None	None	1713263269	None	When setting the price of medicines, AstraZeneca aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). AstraZeneca's pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.	None	No changes to report, product launched on 08/17/2017	None	None	None	None	None	None	None	None	None	None	None	Patent Expirate based on FDA Orange Book estimate; Gross Sales shared across brand
Rx0000015	AstraZeneca	04/23/2025	00310066860	Lynparza TAB 100MG 60 Count Bottle	01/01/2025	252.82	8680.03	10/25/2041	Single Source Drug	None	None	1713263269	None	When setting the price of medicines, AstraZeneca aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). AstraZeneca's pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.	None	No changes to report, product launched on 08/17/2017	None	None	None	None	None	None	None	None	None	None	None	Patent Expirate based on FDA Orange Book estimate; Gross Sales shared across brand
Rx0000015	AstraZeneca	04/23/2025	00310067912	Lynparza TAB 150MG 120 Count Bottle	01/01/2025	505.63	17360.06	10/25/2041	Single Source Drug	None	None	1713263269	None	When setting the price of medicines, AstraZeneca aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). AstraZeneca's pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.	None	No changes to report, product launched on 08/17/2017	None	None	None	None	None	None	None	None	None	None	None	Patent Expirate based on FDA Orange Book estimate; Gross Sales shared across brand
Rx0000015	AstraZeneca	04/23/2025	00310067960	Lynparza TAB 150MG 60 Count Bottle	01/01/2025	252.82	8680.03	10/25/2041	Single Source Drug	None	None	1713263269	None	When setting the price of medicines, AstraZeneca aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). AstraZeneca's pricing decisions are based on many factors that reflect our commitment to patients, global macroeconomic realities, and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value. Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.	None	No changes to report, product launched on 08/17/2017	None	None	None	None	None	None	None	None	None	None	None	Patent Expirate based on FDA Orange Book estimate; Gross Sales shared across brand
Rx0000354	AVEO Pharmaceuticals, Inc.	04/29/2025	45629008901	Fotivda Oral Capsule 0.89 mg, 21 count bottle	01/27/2025	1514.00	31796.00	11/05/2039	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, and overall research and development costs.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	As listed in the FDA Orange Book, the therapeutic use of tivozanib that has been approved by the FDA is presently protected by three granted United States patents. The latest to expire is US 11504365, which is scheduled to expire on November 5, 2039. Patent Data for Tivozanib [sourced from: FDA Orange Book] Product 001 TIVOZANIB HYDROCHLORIDE (FOTIVDA) CAPSULE Product No.: 001 Patent No.: 6821987 Patent Expiration: 04/26/2025 Drug Substance: DS Drug Product: DP Patent Use Code: U-3100 Delist Requested: Submission Date: 04/06/2021 Product No.: 001 Patent No: 7166722 Patent Expiration: 11/16/2028 Drug Substance: DS Drug Product: DP Patent Use Code: Delist Requested: Submission Date: 04/06/2021 Product No.: 001 Patent No.: 11504365 Patent Expiration: 11/05/2039 Drug Substance: Drug Product: Patent Use Code: U-3476 Submission Date: 12/01/2022 U-3100: A METHOD OF TREATING ADULTS WITH RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC THERAPIES BY INHIBITING THE ANGIOGENESIS OF BLOOD VESSELS WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR U-3476: TREATMENT OF ADULTS WITH MODERATE HEPATIC IMPAIRMENT AND RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC ANTI-CANCER THERAPIES WITH 1MG TIVOZANIB HCL ORALLY FOR 21 DAYS FOLLOWED BY NO DRUG FOR 7 DAYS Exclusivity Data Product No.: 001 Exclusivity Code: NCE Exclusivity Expiration: 03/10/2026
Rx0000354	AVEO Pharmaceuticals, Inc.	04/29/2025	45629013401	Fotivda Oral Capsule 1.34 mg, 21 count bottle	01/27/2025	1514.00	31796.00	11/05/2039	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, and overall research and development costs.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	As listed in the FDA Orange Book, the therapeutic use of tivozanib that has been approved by the FDA is presently protected by three granted United States patents. The latest to expire is US 11504365, which is scheduled to expire on November 5, 2039. Patent Data for Tivozanib [sourced from: FDA Orange Book] Product 001 TIVOZANIB HYDROCHLORIDE (FOTIVDA) CAPSULE Product No.: 001 Patent No.: 6821987 Patent Expiration: 04/26/2025 Drug Substance: DS Drug Product: DP Patent Use Code: U-3100 Delist Requested: Submission Date: 04/06/2021 Product No.: 001 Patent No: 7166722 Patent Expiration: 11/16/2028 Drug Substance: DS Drug Product: DP Patent Use Code: Delist Requested: Submission Date: 04/06/2021 Product No.: 001 Patent No.: 11504365 Patent Expiration: 11/05/2039 Drug Substance: Drug Product: Patent Use Code: U-3476 Submission Date: 12/01/2022 U-3100: A METHOD OF TREATING ADULTS WITH RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC THERAPIES BY INHIBITING THE ANGIOGENESIS OF BLOOD VESSELS WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR U-3476: TREATMENT OF ADULTS WITH MODERATE HEPATIC IMPAIRMENT AND RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC ANTI-CANCER THERAPIES WITH 1MG TIVOZANIB HCL ORALLY FOR 21 DAYS FOLLOWED BY NO DRUG FOR 7 DAYS Exclusivity Data Product No.: 001 Exclusivity Code: NCE Exclusivity Expiration: 03/10/2026
Rx0000108	AvKare	04/30/2025	42291045590	Eplerenone 50mg Tablet 90ct	02/19/2025	39.49	73.42	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000108	AvKare	04/30/2025	42291052201	Propranolol HCl ER 60mg Capsule 100ct	01/24/2025	6.07	41.24	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000108	AvKare	04/30/2025	42291052301	Propranolol HCl ER 80mg Capsule 100ct	01/24/2025	6.61	47.80	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000108	AvKare	04/30/2025	50268087228	Urea Cream 40% 1oz (28.35 grams) 1 tube	01/29/2025	8.91	43.31	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000580	Avyxa Pharma, LLC	04/22/2025	83831013401	Lutrate Depot (Leuprolide acetate for depot suspension) Injection 22.5 mg, 1 kit	03/26/2025	644.93	2000.00	None	Single Source Drug	None	None	None	1	Avyxa has recently acquired Lutrate Depot (leuprolide acetate for depot suspension), which is a gonadotropin-releasing hormone (GnRH) agonist indicated for palliative treatment of advanced prostatic cancer.  This product utilizes a microsphere drug delivery which is made out of biodegradable polymers that are known to pose no threat to the body and can hold a diverse array of drugs that can be delivered to the patient through a simple injection. Microspheres are historically known for being challenging and costly to manufacture.  Avyxa is committed to providing education materials to both health care professional and patients through the use of professional sales staff and will be establishing co-pay assistance programs for eligible patients.	None	No change or improvement necessitates the price increase.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000429	Axsome Therapeutics, Inc.	04/09/2025	81968035101	Sunosi - Tablet - 150mg - 30	01/01/2025	52.33	924.66	12/30/2042	Single Source Drug	None	None	None	1	None	1	None	1	05/09/2022	Jazz Pharmaceuticals	53000000	None	Axsome aquired Sunosi with a total upfront payment of $53 million a high single-digit royalty on Axsome's U.S. net sales of Sunosi in the current indication and a mid single-digit royalty on Axsome's U.S. net sales of Sunosi in future indications.	755.00	755.00	2019	660.00	None	The information contained in this report is subject to the following limitations and assumptions: Consistent with the relevant statutes and regulations. All information contained in this report is limited to that which Axsome believes is in the public domain or otherwise publicly available. Therefore Gross Sales Volume US Dollars Cost Increase Factors and Change Improvement Description have been left blank.
Rx0000429	Axsome Therapeutics, Inc.	04/09/2025	81968035001	Sunosi - Tablet - 75mg - 30	01/01/2025	52.33	924.66	12/30/2042	Single Source Drug	None	None	None	1	None	1	None	1	05/09/2022	Jazz Pharmaceuticals	53000000	None	Axsome aquired Sunosi with a total upfront payment of $53 million a high single-digit royalty on Axsome's U.S. net sales of Sunosi in the current indication and a mid single-digit royalty on Axsome's U.S. net sales of Sunosi in future indications.	755.00	755.00	2019	660.00	None	The information contained in this report is subject to the following limitations and assumptions: Consistent with the relevant statutes and regulations. All information contained in this report is limited to that which Axsome believes is in the public domain or otherwise publicly available. Therefore Gross Sales Volume US Dollars Cost Increase Factors and Change Improvement Description have been left blank.
Rx0000430	Azurity Pharmaceuticals	04/29/2025	52652400101	EPANED (enalapril maleate) Oral Solution , 150 mL , 1 mg / mL	01/01/2025	56.06	678.93	03/25/2036	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	52652900103	EPRONTIA (topiramate) Oral Solution , 120 mL , 25 mg / mL	01/01/2025	27.56	333.74	08/21/2040	Innovator Multiple Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	52652900102	EPRONTIA (topiramate) Oral Solution , 240 mL , 25 mg / mL	01/01/2025	51.44	622.97	08/21/2040	Innovator Multiple Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	65628020405	FIRVANQ (vancomycin) Oral Solution , 150 mL , 25 mg / 5 mL	01/01/2025	11.10	134.44	03/13/2035	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	65628020605	FIRVANQ (vancomycin) Oral Solution , 150 mL , 50 mg / 5 mL	01/01/2025	14.70	178.05	03/13/2035	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	65628020510	FIRVANQ (vancomycin) Oral Solution , 300 mL , 25 mg / 5 mL	01/01/2025	15.00	181.65	03/13/2035	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	65628020810	FIRVANQ (vancomycin) Oral Solution , 300 mL , 50 mg / 5 mL	01/01/2025	23.41	283.54	03/13/2035	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	52652600101	FLEQSUVY (baclofen) Oral Suspension , 120 mL , 5 mg / mL	01/01/2025	65.34	791.33	09/29/2037	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	24338005008	GLIADEL Sterile Wafers (carmustine implant) , 8 Wafers , 192.3 mg; 7.7 mg	01/01/2025	3487.70	42239.96	None	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	24338023030	NYMALIZE (nimodipine) ENFit PRE-FILLED ORAL SYRINGE , 12 x 5 mL , 30 mg / 5 mL	01/01/2025	52.92	640.95	04/16/2038	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	24338026008	NYMALIZE (nimodipine) oral solution , 237 mL , 60 mg / 10 mL	01/01/2025	214.57	2598.64	04/16/2038	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	24338026012	NYMALIZE (nimodipine) PRE-FILLED ORAL SYRINGE , 12 x 10 mL , 60 mg / 10 mL	01/01/2025	105.85	1281.95	04/16/2038	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	24338023012	NYMALIZE (nimodipine) PRE-FILLED ORAL SYRINGE, 30 mg / 5 mL, 12 x 5 mL	01/01/2025	52.92	640.95	04/16/2038	Non-innovator Multiple Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	52652300101	QBRELIS (lisinopril) Oral Solution , 150 mL , 1 mg / mL	01/01/2025	56.38	682.78	11/06/2035	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	24338053025	SOTYLIZE (sotalol hydrochloride) oral solution , 250 mL , 5 mg / mL	01/01/2025	48.55	588.04	08/31/2035	Innovator Multiple Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	24338053048	SOTYLIZE (sotalol hydrochloride) oral solution , 480 mL , 5 mg / mL	01/01/2025	93.23	1129.07	08/31/2035	Innovator Multiple Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	52652195002	THYQUIDITY (levothyroxine sodium) Oral Solution , 2 x 100 mL , 100 mcg / 5 mL	01/01/2025	23.85	288.80	08/06/2031	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	24338015020	TRIPTODUR (triptorelin) for extended release injectable suspension , 1 Unit , 22.5 mg	01/01/2025	1841.09	22297.67	06/30/2029	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	52652200101	Xatmep (methotrexate) Oral Solution , 120 mL , 2.5 mg / mL	01/01/2025	206.45	2500.39	01/02/2033	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	52652200106	Xatmep (methotrexate) Oral Solution , 60 mL , 2.5 mg / mL	01/01/2025	108.45	1313.49	01/02/2033	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	24338085303	ZENZEDI 10mg C-II (dextroamphetamine sulfate tablets, USP) , 30 tablets , 10 mg	01/01/2025	27.29	330.52	None	Non-innovator Multiple Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	24338085403	ZENZEDI 15mg C-II (dextroamphetamine sulfate tablets, USP) , 30 tablets , 15 mg	01/01/2025	27.29	330.52	None	Non-innovator Multiple Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	24338085003	ZENZEDI 2.5mg C-II (dextroamphetamine sulfate tablets, USP) , 30 tablets , 2.5 mg	01/01/2025	27.29	330.52	None	Non-innovator Multiple Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	24338085503	ZENZEDI 20mg C-II (dextroamphetamine sulfate tablets, USP) , 30 tablets , 20 mg	01/01/2025	27.29	330.52	None	Non-innovator Multiple Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	24338085603	ZENZEDI 30mg C-II (dextroamphetamine sulfate tablets, USP) , 30 tablets , 30 mg	01/01/2025	27.29	330.52	None	Non-innovator Multiple Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	24338085103	ZENZEDI 5mg C-II (dextroamphetamine sulfate tablets, USP) , 30 tablets , 5 mg	01/01/2025	27.29	330.52	None	Non-innovator Multiple Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	24338085203	ZENZEDI 7.5mg C-II (dextroamphetamine sulfate tablets, USP) , 30 tablets , 7.5 mg	01/01/2025	27.29	330.52	None	Non-innovator Multiple Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000430	Azurity Pharmaceuticals	04/29/2025	52652800101	ZONISADE (zonisamide) Oral Suspension , 150 mL , 100 mg / 5 mL	01/01/2025	34.64	419.55	08/18/2038	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC of a medication are determined with careful consideration of a number of factors, including commercial and government rebates, inflation and costs of goods, cost of administrative and commercial activities, market dynamics, manufacturing and supply considerations, patient support, therapeutic class and patient population, as well as patient needs and access.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000097	Bausch Health US, LLC	04/22/2025	00187581030	APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 174mg 30ct	01/01/2025	200.26	2223.10	06/27/2026	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187581130	APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 348mg 30ct	01/01/2025	263.99	2930.60	06/27/2026	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187581230	APLENZIN® (bupropion hydrobromide), Extended-Release Tablets, 522mg 30ct	01/01/2025	600.77	6669.18	06/27/2026	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187006410	ATIVAN® Tablets 1mg 1,000s	01/01/2025	3584.97	48397.06	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187006301	ATIVAN® Tablets .5mg 100s	01/01/2025	274.02	3699.21	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187006401	ATIVAN® Tablets 1mg 100s	01/01/2025	366.05	4941.61	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187006501	ATIVAN® Tablets 2mg 100s	01/01/2025	583.36	7875.36	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187301220	MESTINON 60mg /SYRUP (pyridostigmine bromide) 473mL 1 Bottle	01/01/2025	114.89	1756.26	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187301030	MESTINON 60mg TABLETS 100s (pyridostigmine bromide)	01/01/2025	141.46	2162.23	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187301330	MESTINON TIMESPAN 180mg TABLETS (pyridostigmine bromide) 30 CT	01/01/2025	80.49	1230.33	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187000402	SILIQ™ (brodalumab) Injection 210mg/1.5mL (1 box of 2 syringes)	01/01/2025	516.78	5736.81	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187073030	WELLBUTRIN® XL 150mg Tablets, 30ct	01/01/2025	197.72	2194.89	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187073090	WELLBUTRIN® XL 150mg Tablets, 90ct	01/01/2025	593.20	6585.07	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000097	Bausch Health US, LLC	04/22/2025	00187073130	WELLBUTRIN® XL 300mg Tablets, 30ct	01/01/2025	261.00	2897.35	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years. No patent expiration date listed.
Rx0000024	Bayer	01/06/2025	50419039501	Nubeqa 300 mg tab 120 count	01/01/2025	679.20	14253.60	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	01/06/2025	50419017105	Stivarga 40 mg tab 21 count bottle	01/01/2025	229.32	5960.85	07/09/2032	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	01/06/2025	50419017101	Stivarga 40 mg tab 28 count bottle	01/01/2025	305.76	7947.80	06/02/2030	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	01/06/2025	50419017103	Stivarga 40 mg tab 3x28 count bottle	01/01/2025	917.28	23843.40	06/02/2030	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	01/06/2025	50419017106	Stivarga 40 mg tab 4x21 count bottle	01/01/2025	917.28	23843.40	07/09/2032	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	01/06/2025	50419039101	VITRAKVI 100MG CAPS BT 1x60	01/01/2025	1559.40	40544.40	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	01/06/2025	50419039201	Vitrakvi 20 mg/mL oral solution	01/01/2025	693.00	18019.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000024	Bayer	01/06/2025	50419039001	VITRAKVI 25MG CAPS BT 1x60	01/01/2025	519.60	13514.40	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000103	Biocodex USA	01/27/2025	68418793906	Diacomit 250mg Capsule 60ct	01/27/2025	137.91	2108.05	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000103	Biocodex USA	01/27/2025	68418794106	Diacomit 250mg powder in packet 60ct	01/27/2025	137.91	2108.05	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000103	Biocodex USA	01/27/2025	68418794006	Diacomit 500mg Capsule 60ct	01/27/2025	275.82	4216.10	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000103	Biocodex USA	01/27/2025	68418794206	Diacomit 500mg powder in packet 60ct	01/27/2025	275.82	4216.10	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000261	BioMarin Pharmaceutical Inc	04/25/2025	68135081102	BRINEURA 150 mg/5 mL INJ, Kit (Two 5 mL vials (30mg/ml) (IEV)-one 5ml vial)	01/01/2025	1496.00	34754.00	05/05/2036	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000261	BioMarin Pharmaceutical Inc	04/25/2025	68135002001	NAGLAZYME 1MG/ML INJ, (5 mL vial)	01/01/2025	105.00	2451.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000261	BioMarin Pharmaceutical Inc	04/25/2025	68135075620	PALYNZIQ 10MG/0.5ML INJ,SYR,0.5MLsingle-dose prefilled syringe	01/01/2025	29.00	659.00	02/03/2031	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Inner NDC's for Palynziq: 68135005889, 68135067339, 68135075619
Rx0000261	BioMarin Pharmaceutical Inc	04/25/2025	68135005890	PALYNZIQ 2.5MG/0.5ML INJ,SYR,0.5ML single-dose prefilled syringe	01/01/2025	29.00	659.00	02/03/2031	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Inner NDC's for Palynziq: 68135005889, 68135067339, 68135075619
Rx0000261	BioMarin Pharmaceutical Inc	04/25/2025	68135067340	PALYNZIQ 20MG/ML INJ,SYR,1ML single-dose prefilled syringe	01/01/2025	29.00	659.00	02/03/2031	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Inner NDC's for Palynziq: 68135005889, 68135067339, 68135075619
Rx0000261	BioMarin Pharmaceutical Inc	04/25/2025	68135067345	PALYNZIQ 20MG/ML INJ,SYR,1ML Ten 1 mL single- dose prefilled syringes	01/01/2025	290.00	6590.00	02/03/2031	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Inner NDC's for Palynziq: 68135005889, 68135067339, 68135075619
Rx0000261	BioMarin Pharmaceutical Inc	04/25/2025	68135010001	VIMIZIM 1MG/ML INJ,SOLN,5ML vial	01/01/2025	64.00	1485.00	01/10/2032	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000261	BioMarin Pharmaceutical Inc	04/25/2025	68135011966	VOXZOGO .56MG/VIAL, Ten .56mg vial	01/01/2025	463.00	10746.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000261	BioMarin Pharmaceutical Inc	04/25/2025	68135008236	VOXZOGO 0.4MG/VIAL, Ten .4mg vial	01/01/2025	463.00	10746.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000261	BioMarin Pharmaceutical Inc	04/25/2025	68135018193	VOXZOGO 1.2MG/VIAL, Ten 1.2mg vial	01/01/2025	463.00	10746.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000078	Bristol Myers Squibb	04/15/2025	59572051502	ABECMA®, 300 to 460 × 106 CAR Positive Viable T Cells in 250 mL Bag for Intravenous Infusion	01/01/2025	29904.48	528312.43	02/09/2036	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	419500.00	419500.00	2021	419500.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572051503	ABECMA®, 300 to 460 × 106 CAR Positive Viable T Cells in 500 mL Bag for Intravenous Infusion	01/01/2025	29904.48	528312.43	02/09/2036	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	419500.00	419500.00	2021	419500.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572051501	ABECMA®, 300 to 460 x 106 CAR Positive T Cells in 50 mL Bag for Intravenous Infusion	01/01/2025	29904.48	528312.43	02/09/2036	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	419500.00	419500.00	2021	419500.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	73153090001	BREYANZI®, 50 to 110 × 106 CAR Positive Viable T Cells in Vials for Infusion	01/01/2025	43872.97	531350.40	08/20/2033	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	410310.00	410310.00	2021	410310.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	73625011311	CAMZYOS®, 10 mg capsule / 30 Count Bottle	01/01/2025	368.65	8560.93	06/19/2034	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/17/2020	Myokardia	13100000000	None	Bristol-Myers Squibb Company (BMS) acquired Myokardia in November 2020 for $13,100,000,000.	7356.16	7356.16	2022	7356.16	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	73625011411	CAMZYOS®, 15 mg capsule / 30 Count Bottle	01/01/2025	368.65	8560.93	06/19/2034	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/17/2020	Myokardia	13100000000	None	Bristol-Myers Squibb Company (BMS) acquired Myokardia in November 2020 for $13,100,000,000.	7356.16	7356.16	2022	7356.16	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	73625011111	CAMZYOS®, 2.5 mg capsule / 30 Count Bottle	01/01/2025	368.65	8560.93	06/19/2034	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/17/2020	Myokardia	13100000000	None	Bristol-Myers Squibb Company (BMS) acquired Myokardia in November 2020 for $13,100,000,000.	7356.16	7356.16	2022	7356.16	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	73625011211	CAMZYOS®, 5 mg capsule / 30 Count Bottle	01/01/2025	368.65	8560.93	06/19/2034	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/17/2020	Myokardia	13100000000	None	Bristol-Myers Squibb Company (BMS) acquired Myokardia in November 2020 for $13,100,000,000.	7356.16	7356.16	2022	7356.16	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572071030	IDHIFA®, 100MG tablet 30 count bottle	01/01/2025	2039.67	36034.17	09/16/2034	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	25742.52	24872.00	2017	24872.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572070530	IDHIFA®, 50MG tablet 30 count bottle	01/01/2025	2039.67	36034.17	09/16/2034	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	25742.52	24872.00	2017	24872.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572072012	INREBIC®, 100MG capsules 120 count bottle	01/01/2025	1188.50	27599.66	12/16/2026	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	21000.00	21000.00	2019	21000.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572073007	ONUREG®, 200MG tablets 7 count blister card	01/01/2025	381.96	13114.02	06/03/2030	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	10579.06	10579.06	2021	10579.06	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572074007	ONUREG®, 300MG tablets 7 count blister card	01/01/2025	381.96	13114.02	06/03/2030	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	10579.06	10579.06	2021	10579.06	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	00003218851	ORENCIA®, 125 mg/mL single-dose autoinjector, carton of 4	01/01/2025	256.29	5951.56	02/18/2028	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	00003218811	ORENCIA®, 125 mg/mL, single-dose prefilled syringe	01/01/2025	256.29	5951.56	02/18/2028	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	00003218713	ORENCIA®, 250 mg lyophilized powder	01/01/2025	51.19	1513.67	12/19/2026	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	00003281411	ORENCIA®, 50 mg/0.4mL, single dose prefilled syringe, 4 SYR	01/01/2025	256.29	5951.56	02/18/2028	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	00003281811	ORENCIA®, 87.5 mg/0.7 mL, single dose prefilled syringe, 4 SYR	01/01/2025	256.29	5951.56	02/18/2028	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	None	None	None	None	None	None	None	None	None	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572050100	POMALYST®, 1MG capsules 100 count	01/01/2025	4915.45	114147.61	12/21/2031	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	81936.32	79165.53	2013	49740.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572050121	POMALYST®, 1MG capsules 21 count	01/01/2025	1032.24	23971.00	12/21/2031	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	17206.63	16624.76	2013	10445.40	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572050200	POMALYST®, 2MG capsules 100 count	01/01/2025	4915.45	114147.61	12/21/2031	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	81936.32	79165.53	2013	49740.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572050221	POMALYST®, 2MG capsules 21 count	01/01/2025	1032.24	23971.00	12/21/2031	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	17206.63	16624.76	2013	10445.40	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572050300	POMALYST®, 3MG capsules 100 count	01/01/2025	4915.45	114147.61	12/21/2031	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	81936.32	79165.53	2013	49740.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572050321	POMALYST®, 3MG capsules 21 count	01/01/2025	1032.24	23971.00	12/21/2031	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	17206.63	16624.76	2013	10445.40	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572050400	POMALYST®, 4MG capsules 100 count	01/01/2025	4915.45	114147.61	12/21/2031	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	81936.32	79165.53	2013	49740.00	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572050421	POMALYST®, 4MG capsules 21 count	01/01/2025	1032.24	23971.00	12/21/2031	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000.	17206.63	16624.76	2013	10445.40	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572089028	ZEPOSIA®, 0.23,0.46,0.92MG 28CT KIT US	01/01/2025	373.37	8670.58	05/14/2029	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	7636.64	7636.64	2023	7636.64	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572081007	ZEPOSIA®, 0.23,0.46MG TITR STR PCK 7CT US (Wallet)	01/01/2025	93.34	2167.65	05/14/2029	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	1649.32	1649.32	2020	1649.32	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000078	Bristol Myers Squibb	04/15/2025	59572082030	ZEPOSIA®, 0.92MG CAP 30CT BTL US	01/01/2025	400.04	9289.90	05/14/2029	Single Source Drug	None	None	None	1	We consider multiple factors when setting a list price for a medicine, including: • The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. • Market and business considerations, including: o Ongoing research-investment costs; BMS invests more than 23% of its annual revenues in R&D, among the highest of any large company in any industry in the world; o Medical- and patient-service costs; this includes funding growing patient assistance programs; o Inflationary and capital-investment costs associated with manufacturing, storage and supply.	None	None	1	11/20/2019	Celgene	74000000000	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $74,000,000,000. Note that the product was acquired prior to commercialization, as a result of system limitations the WAC at Acquisition & WAC Amount Year Prior fields have been populated with the WAC at launch as a workaround.	7068.49	7068.49	2020	7068.49	None	Bristol-Myers Squibb Company (BMS) acquired Celgene Corporation (Celgene) in November 2019 for $ 74,000,000,000. This acquisition did not consist of costs for individual assets.
Rx0000392	Calliditas Therapeutics US Inc.	04/18/2025	81749000401	Tarpeyo Oral Capsule Delayed Release 4 MG 120 capsules	01/01/2025	1608.00	17850.00	01/23/2043	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000498	Catalyst Pharmaceuticals Inc	04/15/2025	69616021103	Firdapse 10mg Tablet 240/Bottle	01/01/2025	3337.78	58967.38	02/25/2037	Single Source Drug	None	None	None	1	response to recent economic conditions and inflation	None	None	1	None	None	None	None	None	None	None	None	None	None	Inner NDC's for Firdapse: 69616021104
Rx0000498	Catalyst Pharmaceuticals Inc	04/15/2025	69616021106	Firdapse Blister shelf pack of 120 - 10mg tablets	01/01/2025	1668.89	29483.69	02/25/2037	Single Source Drug	None	None	None	1	response to recent economic conditions and inflation	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000445	Cerona Therapeutics, Inc.	03/31/2025	81643927001	Floxuridine; for injection; sterile, nonpyrogenic, lyophilized powder for reconstitution; Each vial (packaged individually) contains 500 mg of floxuridine to be reconstituted with 5 mL of sterile water for injection.	01/03/2025	131.88	3899.91	None	Innovator Multiple Source Drug	None	None	None	1	JND Therapeutics, Inc., pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to the clinical value of the medicine, the economic value of the medicine, and market dynamics and competitor pricing.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000139	Chiesi USA	04/16/2025	10122051001	Curosurf® 1.5ml 80mg/mL 1 1.5mL vial - Suspension	01/01/2025	27.98	598.96	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chiesi USA believes is otherwise in the public domain or publicly available. (2) Columns N-V were intentionally left blank for this submission, as the drug was not acquired.
Rx0000139	Chiesi USA	04/16/2025	10122051003	Curosurf® 3.0ml 80mg/mL 1 3.0mL vial - Suspension	01/01/2025	55.17	1181.08	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Chiesi USA believes is otherwise in the public domain or publicly available. (2) Columns N-V were intentionally left blank for this submission, as the drug was not acquired.
Rx0000139	Chiesi USA	04/11/2025	10122010150	Ferriprox ORAL SOLUTION 100mg/1mL 1 bottle of 500 mL - Solution	01/04/2025	437.84	9194.81	10/26/2029	Single Source Drug	None	None	None	1	None	1	None	1	01/06/2020	ApoPharma Inc.	None	1	None	6363.07	5843.04	2015	4533.00	None	None
Rx0000139	Chiesi USA	04/11/2025	10122010401	Ferriprox TD 1000mg FILM COATED TABLETS 1000mg 1 carton of 5 blister packs - Tablet	01/04/2025	492.49	11436.77	10/25/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquired while in development. Approved while owned by Chiesi USA.
Rx0000139	Chiesi USA	04/16/2025	10122041028	Juxtapid Oral Capsule 10 MG 1 package of 28 capsules - Capsules	01/01/2025	2398.92	55708.37	08/19/2027	Single Source Drug	None	None	None	1	None	1	None	1	04/12/2023	Amryt Pharma Plc	None	1	None	50770.90	47897.18	2012	27535.00	None	5 Year History is all under new labeler code 10122 per communication from HCAI. Prior NDC is not listed due to submission errors.
Rx0000139	Chiesi USA	04/16/2025	10122042028	Juxtapid Oral Capsule 20 MG 1 package of 28 capsules - Capsules	01/01/2025	2398.92	55708.37	08/19/2027	Single Source Drug	None	None	None	1	None	1	None	1	04/12/2023	Amryt Pharma Plc	None	1	None	50770.90	47897.18	2012	27535.00	None	5 Year History is all under new labeler code 10122 per communication from HCAI. Prior NDC is not listed due to submission errors.
Rx0000139	Chiesi USA	04/16/2025	10122043028	Juxtapid Oral Capsule 30 MG 1 package of 28 capsules - Capsules	01/01/2025	2398.92	55708.37	08/19/2027	Single Source Drug	None	None	None	1	None	1	None	1	04/12/2023	Amryt Pharma Plc	None	1	None	50770.90	47897.18	2015	28885.00	None	5 Year History is all under new labeler code 10122 per communication from HCAI. Prior NDC is not listed due to submission errors.
Rx0000139	Chiesi USA	04/16/2025	10122040528	Juxtapid Oral Capsule 5 MG 1 package of 28 capsules - Capsules	01/01/2025	2398.92	55708.37	08/19/2027	Single Source Drug	None	None	None	1	None	1	None	1	04/12/2023	Amryt Pharma Plc	None	1	None	50770.90	47897.18	2012	27535.00	None	5 Year History is all under new labeler code 10122 per communication from HCAI. Prior NDC is not listed due to submission errors.
Rx0000139	Chiesi USA	04/16/2025	10122062010	Kengreal for injection 50mg/10ML 50mg 1 carton of 10 vials - Solution	01/01/2025	467.67	10011.98	07/10/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000139	Chiesi USA	04/11/2025	76431021001	Myalept Subcutaneous Soltution Reconsituted 11.3 MG - 1 vial. Weight based dosing.	01/01/2025	277.24	6438.14	None	Single Source Drug	None	None	None	1	None	1	None	1	04/12/2023	Amryt Pharma Plc	None	1	None	5867.52	5535.42	2014	3493.00	None	None
Rx0000139	Chiesi USA	04/11/2025	10122050201	Revcovi® (elapegademase-IvIr 1.6mg/ml) Injection 1 vial 2.4mg/1.5mL - Solution	01/04/2025	573.86	13326.36	None	Single Source Drug	None	None	None	1	None	1	None	1	11/24/2020	Leadiant Biosciences	None	1	None	10109.30	9856.00	2018	9856.00	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	59385002260	Belbuca (Buprenorphine HCl) 1 box of 60 Oral Buccal Film 150 MCG	01/01/2025	23.54	451.57	12/21/2032	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	03/22/2022	BioDelivery Sciences International, Inc	669431000	None	None	384.57	366.26	2015	255.60	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	59385002360	Belbuca (Buprenorphine HCl) 1 box of 60 Oral Buccal Film 300 MCG	01/01/2025	36.97	709.20	12/21/2032	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	03/22/2022	BioDelivery Sciences International, Inc	669431000	None	None	384.57	366.26	2015	255.60	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	59385002460	Belbuca (Buprenorphine HCl) 1 box of 60 Oral Buccal Film 450 MCG	01/01/2025	50.24	963.63	12/21/2032	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	03/22/2022	BioDelivery Sciences International, Inc	669431000	None	None	603.98	575.22	2015	401.40	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	59385002560	Belbuca (Buprenorphine HCl) 1 box of 60 Oral Buccal Film 600 MCG	01/01/2025	53.61	1028.27	12/21/2032	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	03/22/2022	BioDelivery Sciences International, Inc	669431000	None	None	820.66	781.58	2015	545.40	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	59385002160	Belbuca (Buprenorphine HCl) 1 box of 60 Oral Buccal Film 75 MCG	01/01/2025	23.54	451.57	12/21/2032	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	03/22/2022	BioDelivery Sciences International, Inc	669431000	None	None	875.70	834.00	2015	582.00	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	59385002660	Belbuca (Buprenorphine HCl) 1 box of 60 Oral Buccal Film 750 MCG	01/01/2025	56.37	1081.27	12/21/2032	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	03/22/2022	BioDelivery Sciences International, Inc	669431000	None	None	920.85	877.00	2015	612.00	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	59385002760	Belbuca (Buprenorphine HCl) 1 box of 60 Oral Buccal Film 900 MCG	01/01/2025	58.03	1113.08	12/21/2032	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	03/22/2022	BioDelivery Sciences International, Inc	669431000	None	None	947.93	902.79	2015	630.00	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	24510010010	Nucynta (Tapentadol Hydrochloride) 1 bottle of 100 Oral Tablets 100 MG	01/01/2025	247.24	1895.52	12/27/2025	Innovator Multiple Source Drug	None	None	181323520	None	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta’s manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	1088.71	990.64	2009	265.00	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	24510005010	Nucynta (Tapentadol Hydrochloride) 1 bottle of 100 Oral Tablets 50 MG	01/01/2025	158.77	1217.23	12/27/2025	Innovator Multiple Source Drug	None	None	181323520	None	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta’s manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	699.13	636.15	2009	170.00	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	24510007510	Nucynta (Tapentadol Hydrochloride) 1 bottle of 100 Oral Tablets 75 MG	01/01/2025	185.51	1422.23	12/27/2025	Innovator Multiple Source Drug	None	None	181323520	None	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta, and reinvestment in the product. Nucynta is an immediate-release formulation of tapentadol that is indicated for the management of acute adult pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional, general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta’s manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	816.86	743.28	2009	199.00	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	24510011660	Nucynta ER (Tapentadol Hydrochloride) 1 bottle of 60 Oral Tablets Extended Release 12 Hour 100 MG	01/01/2025	184.40	1413.72	03/22/2029	Innovator Multiple Source Drug	None	None	130108727	None	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta ER.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	835.46	760.20	2011	269.40	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	24510017460	Nucynta ER (Tapentadol Hydrochloride) 1 bottle of 60 Oral Tablets Extended Release 12 Hour 150 MG	01/01/2025	237.90	1823.93	03/22/2029	Innovator Multiple Source Drug	None	None	130108727	None	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta ER.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	1077.89	980.79	2011	346.80	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	24510023260	Nucynta ER (Tapentadol Hydrochloride) 1 bottle of 60 Oral Tablets Extended Release 12 Hour 200 MG	01/01/2025	302.01	2315.39	03/22/2029	Innovator Multiple Source Drug	None	None	130108727	None	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta ER.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	1368.32	1245.06	2011	441.60	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	24510029160	Nucynta ER (Tapentadol Hydrochloride) 1 bottle of 60 Oral Tablets Extended Release 12 Hour 250 MG	01/01/2025	377.84	2896.79	03/22/2029	Innovator Multiple Source Drug	None	None	130108727	None	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta ER.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	1711.91	1557.70	2011	441.60	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	24510005860	Nucynta ER (Tapentadol Hydrochloride) 1 bottle of 60 Oral Tablets Extended Release 12 Hour 50 MG	01/01/2025	99.71	764.41	03/22/2029	Innovator Multiple Source Drug	None	None	130108727	None	While Collegium's business pricing model is both proprietary and confidential, the decision to increase the WAC for Nucynta ER included a broad range of financial and non-financial factors including changing market dynamics, costs of labor and goods, post market requirements, support for the marketing and sales of Nucynta ER, and reinvestment in the product. Nucynta ER is an extended-release formulation of tapentadol that is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate. As such, it represents a valuable therapeutic treatment option. We have incurred substantial costs to obtain and maintain regulatory approval and continue to incur the substantial costs described above as well as the more traditional general and administrative costs associated with our operations, resulting in a deficit of over $200 Million since our inception. In addition, we continue to reinvest in Nucynta ER’s manufacturing infrastructure to maintain sufficient supply. These increases in costs were considered as part of this decision to permit the company to increase the wholesale acquisition cost of Nucynta ER.	None	None	1	02/14/2020	Assertio Therapeutics, Inc.	375000000	None	None	451.74	411.05	2011	145.80	None	None
Rx0000200	Collegium Pharmaceuticals	04/15/2025	59385004130	Symproic (Naldemedine Tosylate) 1 Bottle of 30 Oral Tablets 0.2 MG	01/01/2025	23.14	485.89	03/22/2029	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	03/22/2022	BioDelivery Sciences International, Inc	669431000	None	None	415.77	395.97	2017	313.95	None	None
Rx0000184	Cosette Pharmaceuticals, Inc.	04/03/2025	00713088509	Clomid Oral Tablet 50 MG 10 per box	02/03/2025	15.64	94.27	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000184	Cosette Pharmaceuticals, Inc.	04/03/2025	00713088530	Clomid Oral Tablet 50 MG 30 per box	02/03/2025	46.67	282.38	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000425	CSL Behring LLC	01/28/2025	63833082502	Berinert 500 units (500 IU / Solution / Pkg Size 1)	01/01/2025	203.41	4271.61	None	Single Source Drug	None	None	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	01/28/2025	63833082802	Haegarda 2000iu / 2000iu Solution / UOM EA = 1 vial	01/01/2025	93.10	2420.48	None	Single Source Drug	None	None	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000425	CSL Behring LLC	01/28/2025	63833082902	Haegarda 3000iu / 3000iu Solution / UOM EA = 1 vial	01/01/2025	139.64	3630.71	None	Single Source Drug	None	None	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	CSL Behring supports patient access to our lifesaving medicines which is reflected in our responsible approach to drug pricing consistent with the value our therapies deliver.
Rx0000081	Daiichi Sankyo, Inc.	04/15/2025	65597040601	Enhertu Intravenous Solution Reconstituted 100 MG 1 vial	01/01/2025	126.38	2934.75	12/20/2033	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000216	Deciphera Pharmaceuticals, LLC	04/25/2025	73207010130	Qinlock Oral Tablet 50 MG, 90 Each, Bottle	01/01/2025	1485.00	43470.00	10/06/2042	Single Source Drug	None	None	None	1	The establishment of price and associated price changes may take into consideration a number of factors such as current market dynamics, competitive environment, the clinical and economic value of therapy, therapeutic category, payer environment, government rebates, patient support, overall research and development costs, as well as business operational continuation needs. In our commitment to patients and ensuring patient access, we have a patient support program that provides reimbursement and financial assistance programs for eligible patients.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000492	Dynavax Technologies Corporation	02/21/2025	43528000305	HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant)] Adjuvanted 20 MCG / 0.5 ML PFS. 5 syringes/carton	01/15/2025	40.60	778.75	04/16/2032	Innovator Multiple Source Drug	None	None	392831796	None	Planned increase is due to increasing business costs and inflationary effects.	None	There is no change or improvement that necessitated the price increase.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000076	Eisai Inc.	04/17/2025	62856041030	DAYVIGO (lemborexant) 10mg Oral Tablet 30 count	01/23/2025	15.00	352.50	10/21/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Dayvigo (lemborexant) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on October 21, 2035.
Rx0000076	Eisai Inc.	04/17/2025	62856040530	DAYVIGO (lemborexant) 5mg Oral Tablet 30 count	01/23/2025	15.00	352.50	10/21/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Dayvigo (lemborexant) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on October 21, 2035.
Rx0000076	Eisai Inc.	04/17/2025	62856071405	Lenvatinib Mesylate 10 & 4 MG Capsule Therapy Pack 10 EA UU	01/23/2025	121.33	4163.83	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856071805	Lenvatinib Mesylate 10 MG & 2 x 4 MG Capsule Therapy Pack 15 EA UU	01/23/2025	121.33	4163.83	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856071005	Lenvatinib Mesylate 10 MG Capsule Therapy Pack 5 EA UU	01/23/2025	121.33	4163.83	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856072405	Lenvatinib Mesylate 2 x 10 MG & 4 MG Capsule Therapy Pack 15 EA UU	01/23/2025	121.33	4163.83	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856072005	Lenvatinib Mesylate 2 x 10 MG Capsule Therapy Pack 10 EA UU	01/23/2025	121.33	4163.83	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856070805	Lenvatinib Mesylate 2 x 4 MG Capsule Therapy Pack 10 EA UU	01/23/2025	121.33	4163.83	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856071205	Lenvatinib Mesylate 3 x 4 MG Capsule Therapy Pack 15 EA UU	01/23/2025	121.33	4163.83	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856071230	Lenvatinib Mesylate 3 x 4 MG Capsule Therapy Pack 90 EA UU	01/23/2025	728.00	24983.00	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856070430	Lenvatinib Mesylate 4 MG Capsule Therapy Pack 30 EA UU	01/23/2025	728.00	24983.00	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856070405	Lenvatinib Mesylate 4 MG Capsule Therapy Pack 5 EA UU	01/23/2025	121.33	4163.83	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856070830	LENVIMA (lenvatinib mesylate) 8 mg/day (4 mg x 2) 60 count	01/23/2025	728.00	24983.00	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856071030	LENVIMA (lenvatinib mesylate)10 mg/day (10 mg x 1) 30 count	01/23/2025	728.00	24983.00	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856071430	LENVIMA (lenvatinib mesylate)14 mg/day (10 mg x 1 and 4 mg x 1) 60 count	01/23/2025	728.00	24983.00	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856071830	LENVIMA (lenvatinib) 18 mg/day (10 mg x 1 and 4 mg x 2) 30 day supply	01/23/2025	728.00	24983.00	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856072030	LENVIMA (lenvatinib) 20 mg/day (10 mg x 2) 30 day supply	01/23/2025	728.00	24983.00	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000076	Eisai Inc.	04/17/2025	62856072430	LENVIMA (lenvatinib) 24 mg/day (10 mg x 2 and 4 mg x 1) 30 day supply	01/23/2025	728.00	24983.00	05/15/2038	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Lenvima (lenvatinib mesylate) is covered by a number of patents, including certain FDA Orange Book listed patents.  The last to expire of the FDA Orange Book listed patents will expire on May 15, 2038.
Rx0000114	Eli Lilly and Company	04/24/2025	00002481554	Verzenio Package Size: 14 Strength: 100 mg Dosage Form: TABLET	01/01/2025	231.09	4082.52	09/28/2031	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Lilly did not acquire the product in the previous 5 years. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is in the public domain or otherwise publicly available.
Rx0000114	Eli Lilly and Company	04/24/2025	00002533754	Verzenio Package Size: 14 Strength: 150 mg Dosage Form: TABLET	01/01/2025	231.09	4082.52	09/28/2031	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Lilly did not acquire the product in the previous 5 years. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is in the public domain or otherwise publicly available.
Rx0000114	Eli Lilly and Company	04/24/2025	00002621654	Verzenio Package Size: 14 Strength: 200 mg Dosage Form: TABLET	01/01/2025	231.09	4082.52	09/28/2031	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Lilly did not acquire the product in the previous 5 years. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is in the public domain or otherwise publicly available.
Rx0000114	Eli Lilly and Company	04/24/2025	00002448354	Verzenio Package Size: 14 Strength: 50 mg Dosage Form: TABLET	01/01/2025	231.09	4082.52	09/28/2031	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company (“Lilly”) to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. In determining the patent expiration date, Lilly evaluated compound patents that cover the products and/or method of use patents that, in isolation or in aggregate, cover all approved methods of using the products. Lilly did not consider pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of the products, e.g., their formulation and/or delivery devices (where applicable). Lilly did not acquire the product in the previous 5 years. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is in the public domain or otherwise publicly available.
Rx0000079	EMD Serono, Inc.	04/24/2025	44087122501	Cetrotide 0.25 mg Injection 1 Vial, 1 Pre-filled Syringe Sterile Water, & 2 Needles	01/29/2025	15.05	316.12	None	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087400006	Mavenclad 10 mg Tablet 1 x 2 and 4 x 1 Blister packs (6 count)	01/29/2025	2403.78	64839.06	11/23/2038	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087400007	Mavenclad 10 mg Tablet 2 x 2 and 3 x 1 Blister packs (7 count)	01/29/2025	2804.41	75645.57	11/23/2038	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087400008	Mavenclad 10 mg Tablet 3 x 2 and 2 x 1 Blister packs (8 count)	01/29/2025	3205.04	86452.08	11/23/2038	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087400004	Mavenclad 10 mg Tablet 4 x 1 Blister pack (4 count)	01/29/2025	1602.52	43226.04	11/23/2038	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087400009	Mavenclad 10 mg Tablet 4 x 2 and 1 x 1 Blister packs (9 count)	01/29/2025	3605.67	97258.59	11/23/2038	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087400005	Mavenclad 10 mg Tablet 5 x 1 Blister pack (5 count)	01/29/2025	2003.15	54032.55	11/23/2038	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087400000	Mavenclad 10 mg Tablet 5 x 2 Blister pack (10 count)	01/29/2025	4006.30	108065.10	11/23/2038	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087115001	Ovidrel 250 ug/0.5 mL Injection Single Dose Pre-filled Syringe	01/29/2025	17.57	251.84	None	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087002203	Rebif 22 mcg/0.5 mL Injection 12 Single Dose Pre-filled Syringe	01/29/2025	422.63	10988.32	None	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087004403	Rebif 44 mcg/0.5 mL Injection 12 Single Dose Pre-filled Syringe	01/29/2025	422.63	10988.32	None	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087882201	Rebif 6 Single Dose Pre-filled Syringe 8.8 mcg/0.2 mL and 6 Single Dose Pre-filled Syringe 22 mcg/0.5 mL	01/29/2025	422.63	10988.32	None	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087332201	Rebif Rebidose 22 mcg/0.5 mL Injection 12 Single-Use Autoinjectors	01/29/2025	422.63	10988.32	None	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087334401	Rebif Rebidose 44 mcg/0.5 mL Injection 12 Single-Use Autoinjectors	01/29/2025	422.63	10988.32	None	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087018801	Rebif Rebidose 6 Single Dose 8.8 mcg/0.2 mL Pre-filled Autoinjectors & 6 Single Dose 22 mcg/ 0.5 mL Pre-filled Autoinjectors	01/29/2025	422.63	10988.32	None	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087500003	Tepmetko 225 mg Tablet 3 x 10 Blister pack (30 count)	01/09/2025	671.70	12883.20	03/19/2030	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000079	EMD Serono, Inc.	04/24/2025	44087500006	Tepmetko 225 mg Tablet 6 x 10 Blister pack (60 count)	01/09/2025	1343.40	25766.40	03/19/2030	Single Source Drug	None	None	None	1	The change in price of the product is determined after careful consideration of a number of interdependent factors, including but not limited to, research and development, manufacturing costs, advertising and marketing, increased competitive value, increased rate of inflation and other economic dynamics, changes in market dynamics, supporting regulatory and safety commitments, operating patient assistance and educational programs, rebate increases and Medicaid, Medicare or 340B drug pricing program offsets.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000584	Endo USA, Inc.	04/30/2025	42023010501	BREVITAL SODIUM METHOHEXITAL SODIUM INJECTABLE 500MG/VIAL	02/24/2025	14.55	111.53	None	Single Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	92.36	85.92	1990	38.58	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	52244001002	Edex®, Alprostadil For Inj Kit 10 MCG, 2	01/01/2025	10.23	180.75	None	Innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	170.52	160.87	1998	78.00	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	52244001006	Edex®, Alprostadil For Inj Kit 10 MCG, 6	01/01/2025	30.70	542.32	None	Innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	511.62	482.66	1998	234.00	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	52244002002	Edex®, Alprostadil For Inj Kit 20 MCG, 2	01/01/2025	13.22	233.51	None	Innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	220.29	207.82	1998	100.75	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	52244002006	Edex®, Alprostadil For Inj Kit 20 MCG, 6	01/01/2025	39.65	700.49	None	Innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	660.84	623.43	1998	302.25	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	52244004002	Edex®, Alprostadil For Inj Kit 40 MCG, 2	01/01/2025	18.05	318.87	None	Innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	300.82	283.79	1998	137.60	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	52244004006	Edex®, Alprostadil For Inj Kit 40 MCG, 6	01/01/2025	54.15	956.57	None	Innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	902.42	851.34	1998	412.75	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	63481002509	FROVA®, Frovatriptan Succinate Tab 2.5 MG (Base Equivalent), 9	01/01/2025	127.03	1410.21	None	Innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	1283.18	1167.59	2002	135.30	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	63481062970	PERCOCET®, Oxycodone w/ Acetaminophen Tab 10-325 MG, 100	01/01/2025	371.73	4126.53	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	3754.80	3416.56	2001	131.65	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	63481062770	PERCOCET®, Oxycodone w/ Acetaminophen Tab 2.5-325 MG, 100	01/01/2025	188.01	2087.10	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	1899.09	1728.02	1999	44.45	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	63481062370	PERCOCET®, Oxycodone w/ Acetaminophen Tab 5-325 MG, 100	01/01/2025	263.14	2921.07	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	2657.93	2418.50	1999	72.35	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	63481062870	PERCOCET®, Oxycodone w/ Acetaminophen Tab 7.5-325 MG, 100	01/01/2025	284.28	3155.82	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	2871.54	2612.87	2001	100.70	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	52244010010	THEO-24®, Theophylline Cap ER 24HR 100 MG, 100	01/01/2025	34.85	386.91	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	352.06	320.35	2008	136.73	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	52244020010	THEO-24®, Theophylline Cap ER 24HR 200 MG, 100	01/01/2025	51.80	575.03	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	523.23	476.10	2008	203.21	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	52244030010	THEO-24®, Theophylline Cap ER 24HR 300 MG, 100	01/01/2025	63.67	706.76	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	643.09	585.16	2008	249.75	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	52244040010	THEO-24®, Theophylline Cap ER 24HR 400 MG, 100	01/01/2025	89.59	994.51	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	904.92	823.40	2008	351.43	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000584	Endo USA, Inc.	04/30/2025	42023011925	TIGAN TRIMETHOBENZAMIDE HYDROCHLORIDE INJECTABLE 100MG/ML, 25vl	02/24/2025	197.69	1515.63	None	Single Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	04/23/2024	Endo International plc	0	None	As of 4/23/2024, Endo, Inc. ("Endo"), a newly formed entity successfully completed the acquisition of substantially all of the assets of Endo International plc ("EIP"), as contemplated under EIP's plan of reorganization. As part Endo’s acquisition of EIP’s assets, Endo acquired this product. However, Endo is unable to provide the purchase price for this product since Endo does not have a methodology to allocate the purchase price of this product from EIP’s plan of reorganization. As a result, Endo has reported the “Acquisition Price” for this product as 0.	1255.18	1167.61	2006	164.78	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Endo believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/16/2025. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Endo has left the “Patent Expiration Date” field for this product blank. (3) Year Introduced: For this data element, Endo provided the market date for the product that Endo reports to the Centers for Medicare and Medicaid Services (“CMS”) under the Medicaid Drug Rebate Program. Consistent with CMS guidance, this date is the earliest date the product was first marketed under the application number by any labeler. (4) For the WAC at introduction Endo is reporting the earliest WAC reported to the drug pricing compendia under the product NDC.
Rx0000270	Eton Pharmaceuticals, Inc.	04/17/2025	71863010950	Alkindi Sprinkle (hydrocortisone) Oral Granules 0.5 MG, 50 Capsules, Bottle	01/10/2025	43.51	483.00	05/12/2034	Single Source Drug	None	None	None	1	Inflation and the rising costs of its development efforts, operations and support has impacted Eton’s business in recent years. The extended PBM processes to approve coverage and their unwillingness to approve prescribed drugs that are needed by patients also increases Eton’s cost of doing business.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000270	Eton Pharmaceuticals, Inc.	04/17/2025	71863011050	Alkindi Sprinkle (hydrocortisone) Oral Granules 1 MG, 50 Capsules, Bottle	01/10/2025	87.02	966.00	05/12/2034	Single Source Drug	None	None	None	1	Inflation and the rising costs of its development efforts, operations and support has impacted Eton’s business in recent years. The extended PBM processes to approve coverage and their unwillingness to approve prescribed drugs that are needed by patients also increases Eton’s cost of doing business.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000270	Eton Pharmaceuticals, Inc.	04/17/2025	71863011150	Alkindi Sprinkle (hydrocortisone) Oral Granules 2 MG, 50 Capsules, Bottle	01/10/2025	174.04	1932.00	05/12/2034	Single Source Drug	None	None	None	1	Inflation and the rising costs of its development efforts, operations and support has impacted Eton’s business in recent years. The extended PBM processes to approve coverage and their unwillingness to approve prescribed drugs that are needed by patients also increases Eton’s cost of doing business.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000270	Eton Pharmaceuticals, Inc.	04/17/2025	71863011250	Alkindi Sprinkle (hydrocortisone) Oral Granules 5 MG, 50 Capsules, Bottle	01/10/2025	435.09	4829.89	05/12/2034	Single Source Drug	None	None	None	1	Inflation and the rising costs of its development efforts, operations and support has impacted Eton’s business in recent years. The extended PBM processes to approve coverage and their unwillingness to approve prescribed drugs that are needed by patients also increases Eton’s cost of doing business.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000270	Eton Pharmaceuticals, Inc.	04/17/2025	15054104005	Increlex 40 mg/4 mL Subcutaneous Solution 4 mL MDV 1 carton	02/18/2025	8823.00	14705.00	None	Single Source Drug	None	None	None	1	Eton is investing significant additional resources into the product which we believe will be beneficial to patients. In particular, we are investing resources in an improved distribution model which we anticipate will make the product more accessible  for patients. Furthermore, we are integrating the product into a single hub system for improved and more streamlined access. Finally we are devoting additional resources to the sales and marketing of the product which we believe will improve both awareness and accessibility.	None	No change or improvement.	None	12/19/2024	Ipsen Biopharmaceuticals, Inc.	35000000	None	None	5882.00	5882.00	2006	450.00	None	None
Rx0000129	Fresenius Kabi USA LLC	04/24/2025	63323069310	Acetylcysteine Solution, USP 10% 100mg/mL 10mL Package Quantity 3	02/19/2025	6.36	51.84	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Price Increase Report is triggered based on 30-day course of therapy.
Rx0000129	Fresenius Kabi USA LLC	04/24/2025	63323069130	Acetylcysteine Solution, USP 10% 100mg/mL 30mL Package Quantity 3	02/19/2025	8.73	71.16	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Price Increase Report is triggered based on 30-day course of therapy.
Rx0000129	Fresenius Kabi USA LLC	04/24/2025	63323069504	Acetylcysteine Solution, USP 10% 100mg/mL 4mL Package Quantity 25	02/19/2025	44.75	364.00	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Price Increase Report is triggered based on 30-day course of therapy.
Rx0000129	Fresenius Kabi USA LLC	04/24/2025	63323069210	Acetylcysteine Solution, USP 20% 200mg/mL 10mL Package Quantity 3	02/19/2025	6.36	51.84	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Price Increase Report is triggered based on 30-day course of therapy.
Rx0000129	Fresenius Kabi USA LLC	04/24/2025	63323069030	Acetylcysteine Solution, USP 20% 200mg/mL 30mL Package Quantity 3	02/19/2025	10.92	88.95	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Price Increase Report is triggered based on 30-day course of therapy.
Rx0000129	Fresenius Kabi USA LLC	04/24/2025	63323036601	dimenhyDRINATE Injection Solution 50 MG/ML Package Quantity 25	02/19/2025	40.25	328.50	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Price Increase Report is triggered based on 30-day course of therapy.
Rx0000129	Fresenius Kabi USA LLC	04/24/2025	63323018410	Folic Acid 50mg 10mL MDV Package Quantity 1	02/19/2025	7.85	63.92	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Price Increase Report is triggered based on 30-day course of therapy.
Rx0000129	Fresenius Kabi USA LLC	04/24/2025	63323059613	Glucagon HCl (Diagnostic) Injection Solution Reconstituted 1 MG Package Quantity 10	02/19/2025	310.30	2526.80	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Price Increase Report is triggered based on 30-day course of therapy.
Rx0000129	Fresenius Kabi USA LLC	04/24/2025	63323051774	Heparin (Porcine) in NaCl Intravenous Solution 25000-0.45 UT/250ML-% Package Quantity 24	02/19/2025	31.92	260.64	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Price Increase Report is triggered based on 30-day course of therapy.
Rx0000129	Fresenius Kabi USA LLC	04/24/2025	63323052277	Heparin Sodium 25,000USP 500mL Freeflex Inj. in 5% Dextrose Package Quantity 24	02/19/2025	34.98	285.60	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Price Increase Report is triggered based on 30-day course of therapy.
Rx0000129	Fresenius Kabi USA LLC	04/24/2025	63323052374	Heparin Sodium 5% Dex 25,000USP 250mL Package Quantity 24	02/19/2025	31.59	257.04	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Price Increase Report is triggered based on 30-day course of therapy.
Rx0000129	Fresenius Kabi USA LLC	04/24/2025	63323034925	Imipenem-Cilastatin Intravenous Solution Reconstituted 250 MG Package Quantity 25	02/19/2025	52.50	427.25	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Price Increase Report is triggered based on 30-day course of therapy.
Rx0000129	Fresenius Kabi USA LLC	04/24/2025	63323072510	Remifentanil Hydrochloride for Inj. 5mg 10mL SDV Package Quantity 10	02/19/2025	280.70	3399.60	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Price Increase Report is triggered based on 30-day course of therapy.
Rx0000129	Fresenius Kabi USA LLC	04/24/2025	63323046817	Sensorcaine 0.25% 10mL SDV (MPF With Epinephrine) Package Quantity 25	02/19/2025	23.50	191.25	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Price Increase Report is triggered based on 30-day course of therapy.
Rx0000129	Fresenius Kabi USA LLC	04/24/2025	63323046417	Sensorcaine 0.25% 10mL SDV (Sterile Pack - MPF) Package Quantity 25	02/19/2025	14.75	178.75	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Price Increase Report is triggered based on 30-day course of therapy.
Rx0000129	Fresenius Kabi USA LLC	04/24/2025	63323046417	Sensorcaine 0.25% 10mL SDV (Sterile Pack - MPF) Package Quantity 25	02/19/2025	14.75	178.75	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Price Increase Report is triggered based on 30-day course of therapy.
Rx0000129	Fresenius Kabi USA LLC	04/24/2025	63323009330	Sodium Chloride 23.4% 120mEq 30mL SDV Package Quantity 25	02/19/2025	23.50	191.25	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Price Increase Report is triggered based on 30-day course of therapy.
Rx0000129	Fresenius Kabi USA LLC	04/24/2025	63323009561	Sodium Chloride 23.4% 400mEq 100mL PBP Package Quantity 20	02/19/2025	43.20	351.40	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Price Increase Report is triggered based on 30-day course of therapy.
Rx0000129	Fresenius Kabi USA LLC	04/24/2025	63323009020	Sodium Chloride Injection Solution 2.5 MEQ/ML Package Quantity 25	02/19/2025	16.00	129.50	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Price Increase Report is triggered based on 30-day course of therapy.
Rx0000497	Gamida Cell Inc.	03/26/2025	73441080004	Omisirge Cultured Fraction =8.0x10^8 TVNC and Non-Cultured Fraction =4.0x10^8 TVNC Intravenous, 1 each 1 KIT in 1 KIT (73441-800-04) * 80 mL in 1 BAG (73441-300-01) * 10 mL in 1 BAG (73441-200-01) * 40 mL in 1 BAG (73441-400-01) * 20 mL in 1 BAG (73441-1	01/31/2025	17470.00	512070.00	01/05/2039	Single Source Drug	None	None	None	1	Gamida Cell underwent a bankruptcy in May 2024 and, in that process we learned that the cost of bringing Omisirge to patients was much higher than we had originally anticipated.	None	No change or improvement was made.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000034	Genentech USA	03/20/2025	50242013001	ALECENSA® (alectinib) 150 mg capsule, bottle of 240. 150 mg hard capsules, white, with “ALE” printed in black ink on the cap and “150 mg” printed in black ink on the body.	01/01/2025	926.94	19465.83	None	Single Source Drug	None	None	None	1	We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn’t prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs.	None	We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000034	Genentech USA	03/20/2025	50242007001	GAZYVA® (obinutuzumab) 1,000 mg/40 mL vial. Injection: 1,000 mg/40 mL (25 mg/mL) clear, colorless to slightly brown solution in single-dose vial.	01/01/2025	370.88	8612.72	None	Single Source Drug	None	None	None	1	We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn’t prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs.	None	We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000034	Genentech USA	03/20/2025	50242010501	POLIVY® (polatuzumab vedotin-piiq) 140 mg vial. For injection: 140 mg/vial of polatuzumab vedotin-piiq as a white to grayish-white lyophilized powder in a single-dose vial for reconstitution and further dilution.	01/01/2025	542.08	18611.41	None	Single Source Drug	None	None	None	1	We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn’t prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs.	None	We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000034	Genentech USA	03/20/2025	50242010301	POLIVY® (polatuzumab vedotin-piiq) 30 mg vial. For injection: 30 mg/vial of polatuzumab vedotin-piiq as a white to grayish-white lyophilized powder in a single-dose vial for reconstitution and further dilution.	01/01/2025	116.16	3988.17	None	Single Source Drug	None	None	None	1	We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn’t prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs.	None	We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000034	Genentech USA	03/20/2025	50242012047	TNKase® (tenecteplase) 50 mg vial. For injection: 50 mg as a white to pale yellow lyophilized powder in a single-dose vial for reconstitution with co-packaged Sterile Water for Injection, USP (diluent).	01/01/2025	469.66	8297.26	None	Single Source Drug	None	None	None	1	We take decisions related to the prices of our medicines very seriously. Taking a carefully considered approach to the list price of our medicines is the best thing we as a manufacturer can do to enable broad access to patients. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn’t prevent our medicines from getting to people who need them. We strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs.	None	We continue to invest in significant and sustained research for each of our medicines after they first become available. We follow the science to determine how they might help people with other diseases who need new medicines and also how we might make even better medicines. When determining pricing for a new vial size or a new method of action, we take into consideration the price of the existing medicine.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000087	Gilead Sciences, Inc.	04/23/2025	61958250501	BIKTARVY bictegravir 30mg, emtricitabine 120mg, tenofovir alafenamide 15 mg tablets 30 ct	01/01/2025	234.89	4216.10	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	04/23/2025	61958250103	BIKTARVY bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg BLISTER PACK 30 ct	01/01/2025	234.89	4216.10	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	04/23/2025	61958250101	BIKTARVY bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, 30 ct	01/01/2025	234.89	4216.10	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	04/23/2025	61958090101	CAYSTON 75MG/VIAL KIT, 84mL	01/01/2025	706.97	12689.57	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	04/23/2025	61958110101	COMPLERA 200MG/25MG/300MG TABLETS, 30 ct	01/01/2025	213.77	3836.97	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	04/23/2025	61958190101	GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) 150/150/200/10MG TABLETS, 30 ct	01/01/2025	234.89	4216.10	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	04/23/2025	61958080205	LETAIRIS 10MG TABLETS 10 COUNT	01/01/2025	255.29	4582.12	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	04/23/2025	61958080201	LETAIRIS 10MG TABLETS 30 COUNT	01/01/2025	765.86	13746.43	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	04/23/2025	61958080105	LETAIRIS 5MG TABLETS 10 COUNT	01/01/2025	255.29	4582.12	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	04/23/2025	61958080101	LETAIRIS 5MG TABLETS 30 COUNT	01/01/2025	765.86	13746.43	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	04/23/2025	61958210101	ODEFSEY (emtricitabine, rilpivirine, and tenofovir alafenamide) 200/25/25MG TABLETS, 30 ct	01/01/2025	213.77	3836.97	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	04/23/2025	61958120101	STRIBILD (elvitegravir, cobicistat, emtricitabine, tenofobir) 150/150/200/300MG TABLETS, 30 ct	01/01/2025	246.41	4422.70	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	04/23/2025	61958140101	TYBOST (cobicistat) 150 MG TABLETS, 30 ct	01/01/2025	17.53	314.72	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	04/23/2025	61958290102	VEKLURY (remdesivir 100mg) for injection, 1 ct	01/01/2025	35.37	634.85	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	04/23/2025	61958230101	VEMLIDY (tenofovir alafenamide) 25MG TABLETS, 30 ct	01/01/2025	85.06	1526.65	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	04/23/2025	61958170101	ZYDELIG (idelalisib) 100MG TABLETS, 60 ct	01/01/2025	814.68	14622.87	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000087	Gilead Sciences, Inc.	04/23/2025	61958170201	ZYDELIG (idelalisib) 150MG TABLETS, 60 ct	01/01/2025	814.68	14622.87	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information provided in this report is subject to general limitations and assumptions Gilead has shared with OSHPD. The limitations and assumptions address gaps in guidance related to the definition and interpretation of various data elements within the WAC Increase Report. Additionally, consistent with the relevant statutes and regulations, the information provided in this report is limited to that which Gilead believes is in the public domain or otherwise publicly available. Lastly, Gilead has not provided a response to the drug acquisition related data fields for this drug product because Gilead did not acquire this drug product within the previous five years.
Rx0000029	GlaxoSmithKline	04/30/2025	49401008835	Benlysta Subcutaneous Solution Auto-injector 200 MG/ML CTN 4X1.0ML 1DS PF	01/01/2025	145.28	4987.78	None	Single Source Drug	None	None	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000029	GlaxoSmithKline	04/30/2025	49401008847	Benlysta Subcutaneous Solution Prefilled Syringe 200 MG/ML CTN 4X1.0ML 1DS PF	01/01/2025	145.28	4987.78	None	Single Source Drug	None	None	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000029	GlaxoSmithKline	04/30/2025	58160097620	Bexsero Intramuscular Suspension Prefilled Syringe 0.5ML PFS X10 10 PFS/CARTON	01/01/2025	133.80	2363.76	None	Single Source Drug	None	None	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000029	GlaxoSmithKline	04/30/2025	58160082311	Shingrix Intramuscular Suspension Reconstituted 50 MCG/0.5ML 0.5ML COMBO PK (20 VIALS)	01/01/2025	176.13	2155.08	None	Single Source Drug	None	None	None	1	None	1	The price increase listed is not related to any identified or claimed change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000287	Insmed Incorporated	03/18/2025	71558059028	Arikayce (Amikacin) Inhalation Suspension 590 MG/8.4ML 28 Kits	01/01/2025	765.43	16073.94	05/15/2035	Single Source Drug	None	None	254800000	None	Response to current economic circumstances	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000084	Ipsen Biopharmaceuticals, Inc.	02/14/2025	72607010000	Drug product name: Tazverik. Drug product strength: 200mg. Drug product dosage form: tablet. Drug product package size: 1 bottle (240 tablets).	02/15/2025	605.00	20775.00	05/03/2038	Single Source Drug	None	None	None	1	None	1	None	1	08/12/2022	Epizyme, Inc.	None	None	For purposes of 22 CCR § 96070(b)(12)(c) (requirement to report the purchase price of the relevant drug, if the drug was acquired by the manufacturer within the previous five years), Ipsen purchased Epizyme, Inc. in August 2022, including Tazverik. The purchase price of the drug product (as Ipsen understands that data element) is not in the public domain or otherwise publicly available. However, information regarding Ipsen’s purchase of Epizyme, Inc. is available on p. 82, Note 1.2 of section 3.2.5 of the Registration Document located at: https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/2023/04/06183729/EN_UNIVERSAL-REGISTRATION-DOCUMENT-2022-BD.pdf	17746.00	16585.00	2020	15500.00	None	The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book.
Rx0000248	Janssen Biotech, Inc.	04/28/2025	57894050301	DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj)Strength: 1800mg / 15 mL Package Size:1 Form:1 single vial	01/28/2025	549.24	10571.87	11/01/2036	Single Source Drug	None	None	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available.
Rx0000248	Janssen Biotech, Inc.	04/28/2025	57894050205	DARZALEX™ (daratumumab)Strength:100 mg 5 mL Package Size:1 Form:1 single vial	01/28/2025	40.30	775.63	09/25/2029	Single Source Drug	None	None	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available.
Rx0000253	Janssen Pharmaceuticals, Inc.	04/28/2025	50458002802	SPRAVATO™ Strength:56 mg Package Size:2 Form:Nasal Spray	01/28/2025	61.79	834.20	02/18/2040	Single Source Drug	None	None	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration data provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2025
Rx0000253	Janssen Pharmaceuticals, Inc.	04/28/2025	50458002803	SPRAVATO™ Strength:84 mg Package Size:3 Form:Nasal Spray	01/28/2025	92.69	1251.31	02/18/2040	Single Source Drug	None	None	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration data provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2025
Rx0000250	Janssen Products, LP	04/28/2025	59676003056	BALVERSA® (erdafitinib) Strength:3 MG Package Size:56 Form:Tablet	01/28/2025	1011.74	21246.54	02/02/2038	Single Source Drug	None	None	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2025.
Rx0000250	Janssen Products, LP	04/28/2025	59676003084	BALVERSA® (erdafitinib) Strength:3 MG Package Size:84 Form:Tablet	01/28/2025	1517.61	31869.81	02/02/2038	Single Source Drug	None	None	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2025.
Rx0000250	Janssen Products, LP	04/28/2025	59676004028	BALVERSA® (erdafitinib) Strength:4 MG Package Size:28 Form:Tablet	01/28/2025	674.49	14164.36	02/02/2038	Single Source Drug	None	None	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2025.
Rx0000250	Janssen Products, LP	04/28/2025	59676004056	BALVERSA® (erdafitinib) Strength:4 MG Package Size:56 Form:Tablet	01/28/2025	1348.99	28328.74	02/02/2038	Single Source Drug	None	None	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2025.
Rx0000250	Janssen Products, LP	04/28/2025	59676005028	BALVERSA® (erdafitinib) Strength:5 MG Package Size:28 Form:Tablet	01/28/2025	843.12	17705.46	02/02/2038	Single Source Drug	None	None	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2025.
Rx0000250	Janssen Products, LP	04/28/2025	59676061001	YONDELIS® (trabectedin) Strength:1 MG Package Size:1 Form:1 Single Vial	01/28/2025	241.36	3689.34	07/07/2028	Single Source Drug	None	None	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of April 15, 2025, and includes a 6 month pediatric extension.
Rx0000008	Jazz Pharmaceuticals, Inc.	04/28/2025	68727080002	Defitelio (Defibrotide Sodium) Injection 80mg/mL Carton of 10 2.5 mL Vials	01/14/2025	400.00	11780.00	06/22/2032	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The current patent expiration date, as defined under the California Code of Regulations § 96070, for Defitelio in the US corresponds to the last to expire of the patents listed in the Approved Products with Therapeutic Equivalence Evaluations (the “Orange Book) as published by the Federal Food and Drug Association as of April 25, 2025.   Unit Sales Volume and Change Improvement: Per CA Health & Safety Code Section 127681(c) Jazz Pharmaceuticals respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000008	Jazz Pharmaceuticals, Inc.	04/28/2025	68727074502	Vyxeos daunorubicin and cytarabine liposome for injection 100mg/20mL, 44 mg/20mL (2 20 mL vial carton)	01/14/2025	625.00	21535.00	10/15/2032	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The current patent expiration date, as defined under the California Code of Regulations § 96070, for Vyxeos in the US corresponds to the last to expire of the patents listed in the Approved Products with Therapeutic Equivalence Evaluations (the “Orange Book) as published by the Federal Food and Drug Association as of April 25, 2025.    Unit Sales Volume and Change Improvement: Per CA Health & Safety Code Section 127681(c) Jazz Pharmaceuticals respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000008	Jazz Pharmaceuticals, Inc.	04/28/2025	68727015001	Xywav (Calcium Oxybate, Magnesium Oxybate, Potassium Oxybate, Sodium Oxybate) 500 MG/ML Oral Solution 180 ml in 1 bottle	01/14/2025	310.00	6590.00	02/22/2041	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The current patent expiration date, as defined under the California Code of Regulations § 96070, for Xywav in the US corresponds to the last to expire of the patents listed in the Approved Products with Therapeutic Equivalence Evaluations (the “Orange Book) as published by the Federal Food and Drug Association as of April 25, 2025.    Unit Sales Volume and Change Improvement: Per CA Health & Safety Code Section 127681(c) Jazz Pharmaceuticals respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.
Rx0000127	Karyopharm Therapeutics Inc.	04/23/2025	72237010305	Xpovio (100 MG Once Weekly) Oral Tablet Therapy Pack 50 MG	01/01/2025	2117.00	32787.00	08/14/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000127	Karyopharm Therapeutics Inc.	04/23/2025	72237010207	Xpovio (40 MG Once Weekly) Oral Tablet Therapy Pack 40 MG	01/01/2025	2117.00	32787.00	08/14/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000127	Karyopharm Therapeutics Inc.	04/23/2025	72237010206	Xpovio (40 MG Twice Weekly) Oral Tablet Therapy Pack 40 MG	01/01/2025	2117.00	32787.00	08/14/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000127	Karyopharm Therapeutics Inc.	04/23/2025	72237010401	Xpovio (60 MG Once Weekly) Oral Tablet Therapy Pack 60 MG	01/01/2025	2117.00	32787.00	08/14/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000127	Karyopharm Therapeutics Inc.	04/23/2025	72237010103	Xpovio (60 MG Twice Weekly) Oral Tablet Therapy Pack 20 MG	01/01/2025	2117.00	32787.00	08/14/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000127	Karyopharm Therapeutics Inc.	04/23/2025	72237010202	Xpovio (80 MG Once Weekly) Oral Tablet Therapy Pack 40 MG	01/01/2025	2117.00	32787.00	08/14/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000127	Karyopharm Therapeutics Inc.	04/23/2025	72237010104	Xpovio (80 MG Twice Weekly) Oral Tablet Therapy Pack 20 MG	01/01/2025	2117.00	32787.00	08/14/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000264	Kedrion Biopharma Inc.	01/02/2025	76125090010	gammaked 10% carton w/ 1 x 100ml vial	01/01/2025	46.61	1027.92	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Kedrion’s price increase factors, costs, and revenue constitute trade secret information and are exempt from disclosure
Rx0000264	Kedrion Biopharma Inc.	01/02/2025	76125090001	gammaked 10% carton w/ 1 x 10ml vial	01/01/2025	9.32	205.58	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Kedrion’s price increase factors, costs, and revenue constitute trade secret information and are exempt from disclosure
Rx0000264	Kedrion Biopharma Inc.	01/02/2025	76125090020	gammaked 10% carton w/ 1 x 200ml vial	01/01/2025	93.22	2055.83	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Kedrion’s price increase factors, costs, and revenue constitute trade secret information and are exempt from disclosure
Rx0000264	Kedrion Biopharma Inc.	01/02/2025	76125090050	gammaked 10% carton w/ 1 x 50ml vial	01/01/2025	186.45	4111.68	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Kedrion’s price increase factors, costs, and revenue constitute trade secret information and are exempt from disclosure
Rx0000386	KVK Tech, Inc.	04/14/2025	10702000125	Lomaira Oral Tablet 8 MG 250ct	02/06/2025	29.12	149.95	None	Non-innovator Multiple Source Drug	None	None	650	None	Inflation based on the Consumer Price Index (CPI)	None	None	1	None	None	None	None	None	None	None	None	None	None	Drug was not acquired within the last 5 years
Rx0000386	KVK Tech, Inc.	04/14/2025	10702000109	Lomaira Oral Tablet 8 MG 90ct	01/01/2025	4.83	57.97	None	Non-innovator Multiple Source Drug	None	None	142000	None	Inflation based on the Consumer Price Index (CPI)	None	None	1	None	None	None	None	None	None	None	None	None	None	Drug was not acquired within the last 5 years
Rx0000386	KVK Tech, Inc.	02/19/2025	10702007106	Oxymorphone 10mg 60ct	02/17/2025	226.86	248.00	None	Non-innovator Multiple Source Drug	None	None	779424	None	The cost of raw material increases. The cost of DEA compliance/SOMS has also increased exponentially with the nationwide opioid litigation	None	None	1	None	None	None	None	None	None	None	None	None	None	Drug was not acquired within the last 5 years
Rx0000386	KVK Tech, Inc.	02/19/2025	10702007006	Oxymorphone 5mg 60ct	02/17/2025	80.27	101.00	None	Non-innovator Multiple Source Drug	None	None	1	None	The cost of raw material increases. The cost of DEA compliance/SOMS has also increased exponentially with the nationwide opioid litigation	None	None	1	None	None	None	None	None	None	None	None	None	None	Drug was not acquired within the last 5 years Also- we had $0 in sales for that NDC, and it was giving me an error, so I just plugged in $1
Rx0000521	La Jolla Pharmaceutical Company	04/29/2025	68547050102	Giapreza 2.5 mg/mL SDV Injection, Intravenous	01/02/2025	145.00	1765.00	01/06/2037	Single Source Drug	None	None	None	1	Our drugs target rare diseases and serve smaller patient populations, meaning that the costs of development and manufacturing must be spread over fewer patients, leading to the need for higher prices.  Our comprehensive evaluation included other similar drugs and we compared that analysis with pharmacoeconomics to make the decision to raise our price.	None	A change or improvement in the product does not necessitate the price increase.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000089	Lannett Company, Inc.	04/25/2025	54838050280	HydrOXYzine HCl, 10 mg/5 mL Solution, 473 mL bottle	01/21/2025	19.26	115.56	None	Non-innovator Multiple Source Drug	None	None	None	1	The change in WAC price reflects the increased cost to supply efficiently to patients due to recent API increase for this molecule incremental supply chain and manufacturing expense and marketing costs.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000009	Lantheus Medical Imaging, Inc.	04/08/2025	11994001116	DEFINITY US 16Vial KIT. INJECTION, SUSPENSION, 6.52 mg/mL. 16 VIAL, GLASS in 1 CARTON (11994-011-16) > 1.5 mL in 1 VIAL, GLASS	01/01/2025	348.76	5714.35	05/04/2037	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009	Lantheus Medical Imaging, Inc.	04/08/2025	11994001104	DEFINITY US 4Vial KIT. INJECTION, SUSPENSION, 6.52 mg/mL. 4 VIAL, GLASS in 1 CARTON (11994-011-04) > 1.5 mL in 1 VIAL, GLASS	01/01/2025	90.51	1483.01	05/04/2037	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009	Lantheus Medical Imaging, Inc.	04/08/2025	11994009136	LEU TechneLite® (Technetium Tc99m Generator) 1000 Ci 50 MIL/ML INJ 1 vial	01/01/2025	237.04	4187.72	07/01/2029	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009	Lantheus Medical Imaging, Inc.	04/08/2025	11994009109	LEU TechneLite® (Technetium Tc99m Generator) 10000 Ci 50 MIL/ML INJ 1 vial	01/01/2025	805.64	14232.95	07/01/2029	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009	Lantheus Medical Imaging, Inc.	04/08/2025	11994009110	LEU TechneLite® (Technetium Tc99m Generator) 12500 Ci 50 MIL/ML INJ 1 vial	01/01/2025	947.22	16734.19	07/01/2029	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009	Lantheus Medical Imaging, Inc.	04/08/2025	11994009111	LEU TechneLite® (Technetium Tc99m Generator) 15000 Ci 50 MIL/ML INJ 1 vial	01/01/2025	1165.08	20583.07	07/01/2029	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009	Lantheus Medical Imaging, Inc.	04/08/2025	11994009112	LEU TechneLite® (Technetium Tc99m Generator) 18000 Ci 50 MIL/ML INJ 1 vial	01/01/2025	1433.04	25317.12	07/01/2029	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009	Lantheus Medical Imaging, Inc.	04/08/2025	11994009173	LEU TechneLite® (Technetium Tc99m Generator) 2000 Ci 50 MIL/ML INJ 1 vial	01/01/2025	299.08	5283.81	07/01/2029	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009	Lantheus Medical Imaging, Inc.	04/08/2025	11994009192	LEU TechneLite® (Technetium Tc99m Generator) 2500 Ci 50 MIL/ML INJ 1 vial	01/01/2025	328.79	5808.70	07/01/2029	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009	Lantheus Medical Imaging, Inc.	04/08/2025	11994009101	LEU TechneLite® (Technetium Tc99m Generator) 3000 Ci 50 MIL/ML INJ 1 vial	01/01/2025	368.33	6507.20	07/01/2029	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009	Lantheus Medical Imaging, Inc.	04/08/2025	11994009103	LEU TechneLite® (Technetium Tc99m Generator) 4000 Ci 50 MIL/ML INJ 1 vial	01/01/2025	430.32	7602.35	07/01/2029	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009	Lantheus Medical Imaging, Inc.	04/08/2025	11994009104	LEU TechneLite® (Technetium Tc99m Generator) 4500 Ci 50 MIL/ML INJ 1 vial	01/01/2025	464.67	8209.16	07/01/2029	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009	Lantheus Medical Imaging, Inc.	04/08/2025	11994009105	LEU TechneLite® (Technetium Tc99m Generator) 5000 Ci 50 MIL/ML INJ 1 vial	01/01/2025	500.32	8839.05	07/01/2029	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009	Lantheus Medical Imaging, Inc.	04/08/2025	11994009106	LEU TechneLite® (Technetium Tc99m Generator) 6000 Ci 50 MIL/ML INJ 1 vial	01/01/2025	565.11	9983.60	07/01/2029	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009	Lantheus Medical Imaging, Inc.	04/08/2025	11994009107	LEU TechneLite® (Technetium Tc99m Generator) 7500 Ci 50 MIL/ML INJ 1 vial	01/01/2025	662.05	11696.22	07/01/2029	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000009	Lantheus Medical Imaging, Inc.	04/08/2025	11994000602	NEUROLITE® (Kit for the Preparation of Technetium Tc99m Bicisate for Injection)	01/01/2025	213.57	7332.65	11/23/2008	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000413	Leadiant Biosciences, Inc.	04/03/2025	54482002002	Cystaran Ophthalmic Solution 0.44 %, 15ML, Unit-of-Use, Single Bottle	01/01/2025	424.64	2597.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000413	Leadiant Biosciences, Inc.	04/03/2025	54482005401	Matulane Oral Capsule 50 MG, 100 Each, Single Bottle	01/01/2025	1925.36	14852.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000276	LEO Pharma Inc.	04/18/2025	50222034604	Adbry (tralokinumab-ldrm) solution injection, 150 mg/mL, 2 cartons in 1 multipack > 2 syringes in 1 carton > 1 mL in 1 syringe	01/01/2025	230.34	4069.37	01/09/2027	Single Source Drug	None	None	None	1	LEO increased the price due to increasing competition and a growing utilization of our product in once monthly dosing. This is additionally supported by the new major market competitor with a similar clinical mechanism of action in IL 13 at once monthly maintenance dosing, which is priced significantly higher. LEO Pharma’s Adbry syringe still continues to be the lowest net cost price product in the Atopic Dermatitis category.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	LEO Pharma A/S, the Danish parent company of LEO Pharma, entered into a license and royalty agreement with AstraZeneca on June 30, 2016 for the exclusive, global rights to tralokinumab in atopic dermatitis and any future dermatology indications.
Rx0000276	LEO Pharma Inc.	04/18/2025	50222034602	Adbry (tralokinumab-ldrm) solution injection, 150 mg/mL, 2 syringes in 1 carton > 1 mL in 1 syringe	01/01/2025	115.17	2034.69	01/09/2027	Single Source Drug	None	None	None	1	LEO increased the price due to increasing competition and a growing utilization of our product in once monthly dosing. This is additionally supported by the new major market competitor with a similar clinical mechanism of action in IL 13 at once monthly maintenance dosing, which is priced significantly higher. LEO Pharma’s Adbry syringe still continues to be the lowest net cost price product in the Atopic Dermatitis category.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	LEO Pharma A/S, the Danish parent company of LEO Pharma, entered into a license and royalty agreement with AstraZeneca on June 30, 2016 for the exclusive, global rights to tralokinumab in atopic dermatitis and any future dermatology indications.
Rx0000025	Lundbeck LLC	04/29/2025	67386031401	Onfi 10mg. 100 Tablets	01/02/2025	149.08	3130.68	None	Innovator Multiple Source Drug	None	None	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000025	Lundbeck LLC	04/29/2025	67386031501	Onfi 20mg. 100 Tablets	01/02/2025	298.16	6261.30	None	Innovator Multiple Source Drug	None	None	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000025	Lundbeck LLC	04/29/2025	67386013051	Vyepti 100mg/ml single dose vial	01/02/2025	60.32	1888.15	None	Single Source Drug	None	None	None	1	"Brain health is Lundbeck’s sole focus and there is a high cost and high risk to developing and bringing therapies for brain diseases to market. As we price our therapies, we carefully balance the high-risk nature of this work with the needs of patients who depend on us to continue seeking new ways to improve their quality of life. Our pricing practices reflect these realities and focus on the value that our treatments bring to patients and society, the need to invest in continued innovation, and our commitment to affordability – offering patient assistance programs that can help ensure patients who rely on our medicines have access to our therapies."	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000072	Mayne Pharma Inc	04/11/2025	51862076530	Rhofade 1 g/100 g cream 30 g tube	02/01/2025	60.74	735.58	06/11/2035	Single Source Drug	None	None	None	1	Recent changes in market dynamics and heightened competition have led us to adapt our approach to ensure continued growth and success strategically. As the competitive landscape evolves, we have focused on enhancing our offerings, improving efficiency, and investing in innovation to better meet customer needs and expectations. These adjustments are essential for maintaining our position in the market and delivering exceptional value, ensuring that we remain well-positioned to thrive in an increasingly competitive environment.	None	No change or improvement.	None	09/04/2023	EPI Health LLC	8000000	None	None	568.00	568.00	2024	674.84	None	Mayne Pharma Commercial LLC (“Mayne Pharma”) previously notified CA of an NDC change for Rhofade (""the Product"") from 71403000330 to 51862076530. The qualifying WAC increase went into effect on the same day the new NDC (51862076530) went into effect. For clarity, no changes to the Product or Product formulation have occurred, and no changes are anticipated at this time. Accordingly, the initial decision by Mayne Pharma to increase the WAC for the Product was in no way based on, or related to, any change or improvement in the Product. Rather the decision to increase the WAC was based on other factors including, but not limited to, the value of the treatment and market dynamics related to the Product. Please see the 5-year WAC increase history under the prior NDC (71403000330). WAC Effective Date: 06/01/2024, WAC Increase Amount 55.72, WAC After Increase 674.84; WAC Effective Date: 9/20/2023, WAC Increase Amount 51.12, WAC After Increase 619.12; WAC Effective Date: 04/01/2022, WAC Increase Amount 24.46, WAC After Increase 568.00; WAC Effective Date: 1/19/2021, WAC of 543.54
Rx0000138	Merck Sharp & Dohme LLC	04/16/2025	00006542312	BRIDION 10 200 mg/2 mL VIAL (ML)	01/06/2025	64.80	1361.40	07/27/2026	Single Source Drug	None	None	None	1	Merck periodically increases the list prices of our medicines and vaccines to: 1) recognize the value they provide to patients and healthcare systems, 2) recoup the cost of inflation, 3) adapt to changing market conditions and address market considerations, 4) fund research and development to bring forward new medicines and 5) fund capital investments. We have funded a range of important investments, such as: Capital investments in the U.S. of more than $7 billion in the last three years, with planned investment of more than $11 billion in the U.S. between 2024 and 2028 including to increase manufacturing capacity. Investments in research and development that last year alone totaled nearly $18 billion ($177 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular diseases, metabolic diseases, infectious diseases, neurosciences, immunology, ophthalmology, respiratory diseases, and vaccines.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	PATENT_EXPIRATION_DATE: The list of Recent Lost Patents reflects the expiration of the key patent or exclusivity period for the pharmaceutical product, which often results in a loss of market exclusivity. The key patent(s) for a product typically covers the product’s active pharmaceutical ingredient. Later-expiring patents directed to other innovations associated with the product, including for example, formulations, manufacturing processes or uses of the product, may provide additional commercial benefits and/or varying degrees of additional protection. Regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and, in some cases, may provide more effective or longer lasting marketing exclusivity than a product’s patent portfolio. In the U.S., the data protection term generally runs five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication, and twelve years from first marketing approval of a biological product.
Rx0000138	Merck Sharp & Dohme LLC	04/16/2025	00006542515	BRIDION 10 500 mg/5 mL VIAL (ML)	01/06/2025	118.50	2493.50	07/27/2026	Single Source Drug	None	None	None	1	Merck periodically increases the list prices of our medicines and vaccines to: 1) recognize the value they provide to patients and healthcare systems, 2) recoup the cost of inflation, 3) adapt to changing market conditions and address market considerations, 4) fund research and development to bring forward new medicines and 5) fund capital investments. We have funded a range of important investments, such as: Capital investments in the U.S. of more than $7 billion in the last three years, with planned investment of more than $11 billion in the U.S. between 2024 and 2028 including to increase manufacturing capacity. Investments in research and development that last year alone totaled nearly $18 billion ($177 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular diseases, metabolic diseases, infectious diseases, neurosciences, immunology, ophthalmology, respiratory diseases, and vaccines.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	PATENT_EXPIRATION_DATE: The list of Recent Lost Patents reflects the expiration of the key patent or exclusivity period for the pharmaceutical product, which often results in a loss of market exclusivity. The key patent(s) for a product typically covers the product’s active pharmaceutical ingredient. Later-expiring patents directed to other innovations associated with the product, including for example, formulations, manufacturing processes or uses of the product, may provide additional commercial benefits and/or varying degrees of additional protection. Regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and, in some cases, may provide more effective or longer lasting marketing exclusivity than a product’s patent portfolio. In the U.S., the data protection term generally runs five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication, and twelve years from first marketing approval of a biological product.
Rx0000138	Merck Sharp & Dohme LLC	04/16/2025	52015008001	DIFICD 20 200 mg Tablets	01/06/2025	224.20	5205.00	01/15/2024	Single Source Drug	None	None	None	1	Merck periodically increases the list prices of our medicines and vaccines to: 1) recognize the value they provide to patients and healthcare systems, 2) recoup the cost of inflation, 3) adapt to changing market conditions and address market considerations, 4) fund research and development to bring forward new medicines and 5) fund capital investments. We have funded a range of important investments, such as: Capital investments in the U.S. of more than $7 billion in the last three years, with planned investment of more than $11 billion in the U.S. between 2024 and 2028 including to increase manufacturing capacity. Investments in research and development that last year alone totaled nearly $18 billion ($177 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular diseases, metabolic diseases, infectious diseases, neurosciences, immunology, ophthalmology, respiratory diseases, and vaccines.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	PATENT_EXPIRATION_DATE: The list of Recent Lost Patents reflects the expiration of the key patent or exclusivity period for the pharmaceutical product, which often results in a loss of market exclusivity. The key patent(s) for a product typically covers the product’s active pharmaceutical ingredient. Later-expiring patents directed to other innovations associated with the product, including for example, formulations, manufacturing processes or uses of the product, may provide additional commercial benefits and/or varying degrees of additional protection. Regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and, in some cases, may provide more effective or longer lasting marketing exclusivity than a product’s patent portfolio. In the U.S., the data protection term generally runs five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication, and twelve years from first marketing approval of a biological product.
Rx0000138	Merck Sharp & Dohme LLC	04/16/2025	52015070022	DIFICID 1 packet granules (40mg/mL final concentration) Suspension-Reconsitituted-Oral (EA)	01/06/2025	224.20	5205.00	01/15/2024	Single Source Drug	None	None	None	1	Merck periodically increases the list prices of our medicines and vaccines to: 1) recognize the value they provide to patients and healthcare systems, 2) recoup the cost of inflation, 3) adapt to changing market conditions and address market considerations, 4) fund research and development to bring forward new medicines and 5) fund capital investments. We have funded a range of important investments, such as: Capital investments in the U.S. of more than $7 billion in the last three years, with planned investment of more than $11 billion in the U.S. between 2024 and 2028 including to increase manufacturing capacity. Investments in research and development that last year alone totaled nearly $18 billion ($177 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular diseases, metabolic diseases, infectious diseases, neurosciences, immunology, ophthalmology, respiratory diseases, and vaccines.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	PATENT_EXPIRATION_DATE: The list of Recent Lost Patents reflects the expiration of the key patent or exclusivity period for the pharmaceutical product, which often results in a loss of market exclusivity. The key patent(s) for a product typically covers the product’s active pharmaceutical ingredient. Later-expiring patents directed to other innovations associated with the product, including for example, formulations, manufacturing processes or uses of the product, may provide additional commercial benefits and/or varying degrees of additional protection. Regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and, in some cases, may provide more effective or longer lasting marketing exclusivity than a product’s patent portfolio. In the U.S., the data protection term generally runs five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication, and twelve years from first marketing approval of a biological product.
Rx0000138	Merck Sharp & Dohme LLC	04/16/2025	67919003001	ZERBAXA 10 1.5 gram VIAL (EA)	01/06/2025	157.10	1743.60	05/15/2028	Single Source Drug	None	None	None	1	Merck periodically increases the list prices of our medicines and vaccines to: 1) recognize the value they provide to patients and healthcare systems, 2) recoup the cost of inflation, 3) adapt to changing market conditions and address market considerations, 4) fund research and development to bring forward new medicines and 5) fund capital investments. We have funded a range of important investments, such as: Capital investments in the U.S. of more than $7 billion in the last three years, with planned investment of more than $11 billion in the U.S. between 2024 and 2028 including to increase manufacturing capacity. Investments in research and development that last year alone totaled nearly $18 billion ($177 billion since 2010), on a GAAP basis, focused on cancer, cardiovascular diseases, metabolic diseases, infectious diseases, neurosciences, immunology, ophthalmology, respiratory diseases, and vaccines.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	PATENT_EXPIRATION_DATE: The list of Recent Lost Patents reflects the expiration of the key patent or exclusivity period for the pharmaceutical product, which often results in a loss of market exclusivity. The key patent(s) for a product typically covers the product’s active pharmaceutical ingredient. Later-expiring patents directed to other innovations associated with the product, including for example, formulations, manufacturing processes or uses of the product, may provide additional commercial benefits and/or varying degrees of additional protection. Regulatory exclusivity tied to the protection of clinical data is complementary to patent protection and, in some cases, may provide more effective or longer lasting marketing exclusivity than a product’s patent portfolio. In the U.S., the data protection term generally runs five years from first marketing approval of a new chemical entity, extended to seven years for an orphan drug indication, and twelve years from first marketing approval of a biological product.
Rx0000603	Merz Pharmaceuticals, LLC	04/21/2025	10144042760	Ampyra Oral Tablet Extended Release 12 Hour 10 MG Package Quantity 1 Bottle of 60 Tablets	01/01/2025	212.85	4469.76	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	07/10/2024	Acorda Therapeutics	None	1	None	4256.91	3869.92	2010	1056.16	None	None
Rx0000603	Merz Pharmaceuticals, LLC	04/21/2025	10144034260	Inbrija Inhalation Capsule 42 MG Package Quantity 1 Bottle of 60 Tablets	01/01/2025	61.06	1282.30	11/16/2032	Single Source Drug	None	None	None	1	None	1	None	1	07/10/2024	Acorda Therapeutics	None	1	None	1221.24	1152.12	2019	950.00	None	None
Rx0000051	MILLICENT U.S., INC.	04/28/2025	72495020105	Femring Vaginal Ring 1 pouch in 1 carton; 1 ring in 1 pouch (0.05 mg/day)	01/09/2025	70.80	832.12	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000051	MILLICENT U.S., INC.	04/28/2025	72495020210	Femring Vaginal Ring 1 pouch in 1 carton; 1 ring in 1 pouch (0.1 mg/day)	01/09/2025	75.45	886.73	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000051	MILLICENT U.S., INC.	04/28/2025	72495040128	Intrarosa Vaginal Insert 28 blister pack in 1 box; 1 insert in 1 blister Pack (6.5 mg insert)	01/09/2025	24.08	294.63	03/19/2031	Single Source Drug	None	None	None	1	None	1	None	1	05/01/2020	AMAG	125000000	None	None	212.30	202.00	2017	175.00	None	None
Rx0000397	Mirum Pharmaceuticals	04/30/2025	68974087640	CHENODAL TABLETS 1 PACK 100 TABS 250 MG	01/01/2025	4783.14	57929.14	None	Single Source Drug	None	None	None	1	Mirum's pricing strategy reflects a careful evaluation of multiple elements, such as competitive market conditions, increasing supply chain and operational costs, distribution and wholesaler fees, along with research and development expenditures. Small patient popuations reflect pricing of products.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000476	Neurelis	04/22/2025	72252051002	Valtoco 10 MG Dose Nasal Liquid 10 MG/0.1ML 2 per box	01/01/2025	34.85	731.87	03/27/2029	Single Source Drug	None	None	None	1	None	1	No Change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000476	Neurelis	04/22/2025	72252051504	Valtoco 15 MG Dose Nasal Liquid Therapy Pack 7.5 MG/0.1ML 2 per box	01/01/2025	34.85	731.87	03/27/2029	Single Source Drug	None	None	None	1	None	1	No Change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000476	Neurelis	04/22/2025	72252052004	Valtoco 20 MG Dose Nasal Liquid Therapy Pack 10 MG/0.1ML 2 per box	01/01/2025	34.85	731.87	03/27/2029	Single Source Drug	None	None	None	1	None	1	No Change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000476	Neurelis	04/22/2025	72252050502	Valtoco 5 MG Dose Nasal Liquid 5 MG/0.1ML 2 per box	01/01/2025	34.85	731.87	03/27/2029	Single Source Drug	None	None	None	1	None	1	No Change or Improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000420	Nielsen BioSciences, Inc.	01/02/2025	59584013801	Candin Injection Solution/1U in 0.1mL Intradermally/1mL Vial	01/01/2025	26.00	322.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Nielsen Biosciences price increase factors, costs and revenue constitute trade secret information and are exempt from disclosure.
Rx0000420	Nielsen BioSciences, Inc.	01/02/2025	59584014001	Spherusol Injection Solution/Coccidioides immitis Spherule-Derived Skin Test Antigen - 1.27mcg/0.1mL/1mL Vial/0.1mL Intradermally/1ml multidose vial	01/01/2025	102.00	1252.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Nielsen Biosciences price increase factors, costs and revenue constitute trade secret information and are exempt from disclosure.
Rx0000204	Noden Pharma USA, Inc.	04/30/2025	70839015030	TEKTURNA TABLETS 1 PACK 30 TABS 150 MG	01/01/2025	28.51	345.30	08/19/2026	Single Source Drug	None	None	None	1	LXO evaluates numerous elements, such as competitive market conditions, rising supply chain and operational costs, distributor and wholesaler fees, and research and development expenditures. Furthermore, the strategy takes into account the restricted size of patient populations for certain products when making pricing decisions.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000204	Noden Pharma USA, Inc.	04/30/2025	70839030030	TEKTURNA TABLETS 1 PACK 30 TABS 300 MG	01/01/2025	35.97	435.64	08/19/2026	Single Source Drug	None	None	None	1	LXO evaluates numerous elements, such as competitive market conditions, rising supply chain and operational costs, distributor and wholesaler fees, and research and development expenditures. Furthermore, the strategy takes into account the restricted size of patient populations for certain products when making pricing decisions.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000073	Novartis	04/29/2025	00078062651	AFINITOR DISPERZ TABLET FOR SUSPENSION 2 mg 28	01/14/2025	443.97	18202.78	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078062751	AFINITOR DISPERZ TABLET FOR SUSPENSION 3 mg 28	01/14/2025	448.42	18385.12	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078062851	AFINITOR DISPERZ TABLET FOR SUSPENSION 5 mg 28	01/14/2025	466.71	19135.21	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078056751	AFINITOR TABLET 10 mg 28	01/14/2025	466.71	19135.21	07/01/2028	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078059451	AFINITOR TABLET 2.5 mg 28	01/14/2025	446.20	18294.01	07/01/2028	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078056651	AFINITOR TABLET 5 mg 28	01/14/2025	466.71	19135.21	07/01/2028	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078062051	AFINITOR TABLET 7.5 mg 28	01/14/2025	466.71	19135.21	07/01/2028	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078072910	BETOPTIC S SUSPENSION, DROPS(FINAL DOSAGE FORM)(ML) 0.25 % 10	01/14/2025	36.54	405.63	None	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078072915	BETOPTIC S SUSPENSION, DROPS(FINAL DOSAGE FORM)(ML) 0.25 % 15	01/14/2025	54.81	608.40	None	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078063998	COSENTYX (2 SYRINGES) SYRINGE (ML) 150 mg/mL 1	01/14/2025	222.27	7631.23	12/21/2035	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078063941	COSENTYX SENSOREADY (2 PENS) PEN INJECTOR (ML) 150 mg/mL 1	01/14/2025	222.27	7631.23	12/21/2035	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078063968	COSENTYX SENSOREADY PEN PEN INJECTOR (ML) 150 mg/mL 1	01/14/2025	222.27	7631.23	12/21/2035	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078063997	COSENTYX SYRINGE SYRINGE (ML) 150 mg/mL 1	01/14/2025	222.27	7631.23	12/21/2035	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078105697	COSENTYX SYRINGE SYRINGE (ML) 75 mg/0.5 mL 0.5	01/14/2025	111.13	3815.61	12/21/2035	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078056115	EXFORGE HCT TABLET 10 mg-160 mg-12.5 mg 30	01/14/2025	8.96	367.48	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078056215	EXFORGE HCT TABLET 10 mg-160 mg-25 mg 30	01/14/2025	8.96	367.48	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078056315	EXFORGE HCT TABLET 10 mg-320 mg-25 mg 30	01/14/2025	11.38	466.53	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078055915	EXFORGE HCT TABLET 5 mg-160 mg-12.5 mg 30	01/14/2025	7.90	323.96	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078056015	EXFORGE HCT TABLET 5 mg-160 mg-25 mg 30	01/14/2025	7.90	323.96	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078048915	EXFORGE TABLET 10 mg-160 mg 30	01/14/2025	8.96	367.48	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078049115	EXFORGE TABLET 10 mg-320 mg 30	01/14/2025	11.38	466.53	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078048815	EXFORGE TABLET 5 mg-160 mg 30	01/14/2025	7.90	323.96	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078049015	EXFORGE TABLET 5 mg-320 mg 30	01/14/2025	10.02	410.90	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078046815	EXJADE TABLET, DISPERSIBLE 125 mg 30	01/14/2025	37.64	1543.38	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078046915	EXJADE TABLET, DISPERSIBLE 250 mg 30	01/14/2025	75.29	3086.70	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078047015	EXJADE TABLET, DISPERSIBLE 500 mg 30	01/14/2025	150.57	6173.29	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078060715	GILENYA CAPSULE 0.5 mg 30	01/14/2025	1052.51	11683.96	12/25/2027	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078073461	ILARIS VIAL (ML) 150 mg/mL 1	01/14/2025	777.75	20221.61	12/09/2029	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078071315	JADENU SPRINKLE GRANULES IN PACKET (EA) 180 mg 30	01/14/2025	298.13	3309.54	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078072015	JADENU SPRINKLE GRANULES IN PACKET (EA) 360 mg 30	01/14/2025	596.25	6618.97	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078072715	JADENU SPRINKLE GRANULES IN PACKET (EA) 90 mg 30	01/14/2025	149.07	1654.81	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078065515	JADENU TABLET 180 mg 30	01/14/2025	298.13	3309.54	11/21/2034	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078065615	JADENU TABLET 360 mg 30	01/14/2025	596.25	6618.97	11/21/2034	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078065415	JADENU TABLET 90 mg 30	01/14/2025	149.07	1654.81	11/21/2034	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078100768	KESIMPTA PEN PEN INJECTOR (ML) 20 mg/0.4 mL 0.4	01/14/2025	611.49	9347.07	12/30/2037	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078086001	KISQALI TABLET 200 mg/day (200 mg x 1) 21	01/14/2025	565.93	7640.05	04/14/2036	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078086742	KISQALI TABLET 400 mg/day (200 mg x 2) 42	01/14/2025	1131.86	15280.15	04/14/2036	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078087463	KISQALI TABLET 600 mg/day (200 mg x 3) 63	01/14/2025	1414.83	19100.20	04/14/2036	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078116147	MEKINIST SOLUTION, RECONSTITUTED, ORAL 0.05 mg/mL 90	01/14/2025	133.83	1806.73	10/15/2030	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078110515	MEKINIST TABLET 0.5 mg 30	01/14/2025	371.76	5018.74	03/02/2034	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078111215	MEKINIST TABLET 2 mg 30	01/14/2025	1265.28	17081.33	03/02/2034	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078038566	MYFORTIC TABLET, DELAYED RELEASE (ENTERIC COATED) 180 mg 120	01/14/2025	80.62	894.94	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078038666	MYFORTIC TABLET, DELAYED RELEASE (ENTERIC COATED) 360 mg 120	01/14/2025	161.23	1789.85	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078024815	NEORAL CAPSULE 100 mg 30	01/14/2025	31.78	352.78	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078024615	NEORAL CAPSULE 25 mg 30	01/14/2025	7.95	88.28	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078027422	NEORAL SOLUTION, ORAL 100 mg/mL 50	01/14/2025	57.74	640.93	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078070184	PIQRAY TABLET 200 mg/day (200 mg x 1) 28	01/14/2025	1763.16	23802.68	04/29/2033	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078071502	PIQRAY TABLET 250 mg/day (200 mg x 1 and 50 mg x 1) 56	01/14/2025	1763.16	23802.68	04/29/2033	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078070802	PIQRAY TABLET 300 mg/day (150 mg x 2) 56	01/14/2025	1763.16	23802.68	04/29/2033	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078097261	PROMACTA POWDER IN PACKET (EA) 12.5 mg 30	01/14/2025	579.73	7826.37	01/13/2026	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078069761	PROMACTA POWDER IN PACKET (EA) 25 mg 30	01/14/2025	579.76	7826.79	01/13/2026	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078068415	PROMACTA TABLET 12.5 mg 30	01/14/2025	579.73	7826.37	02/01/2028	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078068515	PROMACTA TABLET 25 mg 30	01/14/2025	579.73	7826.37	02/01/2028	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078068655	PROMACTA TABLET 50 mg 14	01/14/2025	489.59	6609.51	02/01/2028	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078068615	PROMACTA TABLET 50 mg 30	01/14/2025	1049.13	14163.26	02/01/2028	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078068715	PROMACTA TABLET 75 mg 30	01/14/2025	1573.70	21244.90	02/01/2028	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078069819	RYDAPT CAPSULE 25 mg 112	01/14/2025	2198.59	24406.60	12/02/2030	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078069899	RYDAPT CAPSULE 25 mg 56	01/14/2025	1099.30	12203.31	12/02/2030	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078109120	SCEMBLIX TABLET 20 mg 60	01/14/2025	651.41	22365.11	05/14/2040	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078109820	SCEMBLIX TABLET 40 mg 60	01/14/2025	651.41	22365.11	05/14/2040	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078070956	TABRECTA TABLET 150 mg 56	01/14/2025	284.55	11666.47	07/22/2035	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078071656	TABRECTA TABLET 200 mg 56	01/14/2025	284.55	11666.47	07/22/2035	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078068266	TAFINLAR CAPSULE 50 mg 120	01/14/2025	904.27	12207.68	03/02/2034	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078068166	TAFINLAR CAPSULE 75 mg 120	01/14/2025	1165.38	15732.65	03/02/2034	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078115421	TAFINLAR TABLET FOR SUSPENSION 10 mg 210	01/14/2025	316.51	4272.84	06/29/2038	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078059287	TASIGNA CAPSULE 150 mg 28	01/14/2025	1603.32	21644.84	10/07/2032	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078052687	TASIGNA CAPSULE 200 mg 28	01/14/2025	1603.32	21644.84	10/07/2032	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078095166	TASIGNA CAPSULE 50 mg 120	01/14/2025	1717.84	23190.81	10/07/2032	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078050883	TEGRETOL SUSPENSION, ORAL (FINAL DOSE FORM) 100 mg/5 mL 450	01/14/2025	4.85	198.82	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078050905	TEGRETOL TABLET 200 mg 100	01/14/2025	7.53	308.69	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078051005	TEGRETOL XR TABLET, EXTENDED RELEASE 12 HR 100 mg 100	01/14/2025	4.03	165.24	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078051105	TEGRETOL XR TABLET, EXTENDED RELEASE 12 HR 200 mg 100	01/14/2025	8.04	329.79	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078051205	TEGRETOL XR TABLET, EXTENDED RELEASE 12 HR 400 mg 100	01/14/2025	16.07	659.06	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078087601	TOBRADEX OINTMENT (GRAM) 0.3 %-0.1 % 3.5	01/14/2025	26.85	298.09	None	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078081301	TOBREX OINTMENT (GRAM) 0.3 % 3.5	01/14/2025	25.22	280.00	None	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078035752	TRILEPTAL SUSPENSION, ORAL (FINAL DOSE FORM) 300 mg/5 mL (60 mg/mL) 250	01/14/2025	11.95	489.75	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078045605	TRILEPTAL TABLET 150 mg 100	01/14/2025	14.20	582.14	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078033705	TRILEPTAL TABLET 300 mg 100	01/14/2025	25.93	1063.21	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078045705	TRILEPTAL TABLET 600 mg 100	01/14/2025	47.66	1954.09	None	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078067119	TYKERB TABLET 250 mg 150	01/14/2025	248.21	10176.70	09/18/2029	Innovator Multiple Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078107766	VOTRIENT TABLET 200 mg 120	01/14/2025	434.60	17818.65	None	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000073	Novartis	04/29/2025	00078069484	ZYKADIA TABLET 150 mg 84	01/14/2025	1241.67	13783.76	02/02/2032	Single Source Drug	None	None	None	1	Novartis sets prices for its products based on the value they deliver to patients, healthcare systems and society. We believe this incentivizes health systems to focus on interventions that deliver the most effective, efficient, and sustainable outcomes. We also work to advocate for policies that support a sustainable ecosystem for innovative medicines. We experience significant pressure on the pricing of our medicines. These have many sources, including increasing healthcare costs, funding restrictions and policy changes that affect pricing decision throughout a drug’s lifecycle. A worldwide slowdown in economic growth and the onset of war in certain parts of the world has led to increased strain on budgets in many major economies. Legislative and regulatory developments may create further pressures on pricing and the availability of our products. We take a holistic approach across our portfolio of innovative medicines when making pricing decisions.	None	Not applicable	None	None	None	None	None	None	None	None	None	None	None	Novartis provides this report consistent with its understanding and interpretation of California SB 17 Chapter 603 Chapter 9 § 127681 and its provisions. In providing this report, Novartis does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California SB 17 Chapter 603 Chapter 9 § 127681 as it may relate to Novartis or any of its affiliates now or in the future. Novartis, on behalf of itself and affiliates, expressly reserves all such rights. When any of this information is requested, whether under the California Public Records Act (Government Code Section 6250 et seq.) or otherwise, we request that Novartis is notified of the request and afforded the opportunity to submit objections to disclosure.
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/24/2025	59148008213	Jynarque 15mg tablets, 30 count bottle	01/01/2025	755.99	11555.86	04/07/2030	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/24/2025	59148007928	Jynarque 15mg/15mg Kit	01/01/2025	1411.18	21570.93	04/07/2030	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/24/2025	59148008313	Jynarque 30mg tablets, 30 count bottle	01/01/2025	755.99	11555.86	04/07/2030	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/24/2025	59148008028	Jynarque 30mg/15mg Kit	01/01/2025	1411.18	21570.93	04/07/2030	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/24/2025	59148008728	Jynarque 45mg/15mg 4x Kit	01/01/2025	1411.18	21570.93	04/07/2030	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/24/2025	59148008828	Jynarque 60mg/30mg 4x Kit	01/01/2025	1411.18	21570.93	04/07/2030	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000067	Otsuka America Pharmaceutical, Inc.	03/24/2025	59148008928	Jynarque 90mg/30mg 4x Kit	01/01/2025	1411.18	21570.93	04/07/2030	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000622	Otsuka ICU Medical	04/29/2025	00990793819	DEXTROSE 10% INJ USP 1000ML 500ML FILL CS of 12	01/01/2025	285.84	66.36	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990793519	DEXTROSE 20% INJ USP 1000ML 500ML FILL CS of 12	01/01/2025	35.28	136.92	None	Innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990792323	DEXTROSE 5% INJ USP LIFECARE 100ML CS of 48	01/01/2025	78.24	103.68	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990792337	DEXTROSE 5% INJ USP LIFECARE 100ML CS of 80	01/01/2025	78.40	168.00	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990792320	DEXTROSE 5% INJ USP LIFECARE 25ML QUAD/PK CS of 48	01/01/2025	343.68	107.04	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990792255	DEXTROSE 5% INJ USP LIFECARE 500ML 2-PT CS of 18	01/01/2025	66.96	99.54	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990792313	DEXTROSE 5% INJ USP LIFECARE 50ML CS of 48	01/01/2025	75.84	107.04	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990792336	DEXTROSE 5% INJ USP LIFECARE 50ML CS of 80	01/01/2025	68.00	170.40	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990792409	DEXTROSE 5%/0.225% SODIUM CL INJ USP LC 1000 ML CS of 12	01/01/2025	12.60	66.36	None	Single Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990792403	DEXTROSE 5%/0.225% SODIUM CL INJ USP LC 500 ML CS of 24	01/01/2025	24.24	132.72	None	Single Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990792509	DEXTROSE 5%/0.3% SODIUM CL INJ USP LC 1000 ML CS of 12	01/01/2025	237.12	66.36	None	Innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990792503	DEXTROSE 5%/0.3% SODIUM CL INJ USP LC 500 ML CS of 24	01/01/2025	38.16	132.72	None	Innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990737262	IONOSOL MB AND 5% DEXTROSE INJ LIFECARE 250ML CS of 24	01/01/2025	102.96	132.24	None	Single Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990796509	NORMOSOL-M/5% DEXTROSE INJ LIFECARE 1000 ML CS of 12	01/01/2025	31.92	66.36	None	Single Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990796809	NORMOSOL-R/5% DEXTROSE INJ LIFECARE 1000 ML CS of 12	01/01/2025	92.40	66.36	None	Single Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990711109	POTASSIUM CL 20MEQ 5% DEX/LACT RINGERS 1000ML CS of 12	01/01/2025	25.92	110.64	None	Innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990797205	SODIUM CL 0.9% IRRIGATION USP LIFECARE 1000ML CS of 12	01/01/2025	48.60	51.72	None	Innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990797207	SODIUM CL 0.9% IRRIGATION USP LIFECARE 2000ML CS of 6	01/01/2025	24.66	41.94	None	Innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990797208	SODIUM CL 0.9% IRRIGATION USP LIFECARE 3000ML CS of 4	01/01/2025	11.52	34.48	None	Innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990773037	SODIUM CL INJ USP 0.45% 100 ML CS of 80	01/01/2025	105.60	189.60	None	Innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990773036	SODIUM CL INJ USP 0.45% 50 ML CS of 80	01/01/2025	259.20	228.00	None	Innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990798423	SODIUM CL INJ USP 0.9% 100 ML FLEXIBLE CONTAINER CS of 48	01/01/2025	70.56	111.84	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990798413	SODIUM CL INJ USP 0.9% 50 ML FLEXIBLE CONTAINER CS of 48	01/01/2025	64.32	118.08	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990798437	SODIUM CL INJ USP 0.9% LIFECARE 100ML CS of 80	01/01/2025	89.60	153.60	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990798436	SODIUM CL INJ USP 0.9% LIFECARE 50 ML CS of 80	01/01/2025	121.60	116.00	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990798355	SODIUM CL INJ USP 0.9% LIFECARE 500 ML 2-PT CS of 18	01/01/2025	34.38	99.54	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990798420	SODIUM CL INJ USP 0.9% LIFECARE QUAD/PK 25 ML CS of 48	01/01/2025	58.08	106.56	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000622	Otsuka ICU Medical	04/29/2025	00990797305	STERILE WATER FOR IRRIG FLEX CONTAINER 1000 ML CS of 12	01/01/2025	49.20	51.36	None	Innovator Multiple Source Drug	None	None	None	1	None	1	No improvement.	None	None	None	None	None	None	None	None	None	None	None	WAC submitted at CASE price.
Rx0000484	Pacira Pharmaceuticals, Inc.	04/24/2025	65250013309	EXPAREL (bupivacaine liposome injectable suspension) 133mg/10mL 10 vials in one carton	01/01/2025	136.58	2412.90	02/02/2043	Single Source Drug	None	None	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000484	Pacira Pharmaceuticals, Inc.	04/24/2025	65250013304	EXPAREL (bupivacaine liposome injectable suspension) 133mg/10mL 4 vials in one carton	01/01/2025	54.63	965.15	02/02/2043	Single Source Drug	None	None	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000006	Pfizer	04/30/2025	51144005001	ADCETRIS, 50mg, single-dose vial, packaged singly	01/01/2025	458.00	12200.00	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	12/14/2023	Seagen	43000000000	None	On December 14, 2023 we acquired Seagen Inc., a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.	10878.00	10078.00	2011	4500.00	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409592101	Aminophylline Injection Rx, 250 mg/10 mL, VIAL (ML), 10	01/01/2025	41.31	454.41	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00008042303	Antivenin (micrurus fulvius equine origin), 10mL, VIAL (ML), 1	01/01/2025	381.13	8003.79	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009722402	ATGAM (lymphocyte immune globulin,antithymocyte (equine)), 50 mg/mL, Ampul(ML), 5	01/01/2025	3143.67	24101.48	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409963005	ATROPINE SULFATE (atropine sulfate), 0.05 mg/mL, SYRINGE (ML), 1	01/01/2025	24.65	271.19	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	58394063503	BeneFIX® (coagulation factor IX (recombinant)) Lyophilized Powder for Reconstitution Rx, 1000 unit, VIAL (EA), 1	01/01/2025	47.60	1747.60	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	58394063603	BeneFIX® (coagulation factor IX (recombinant)) Lyophilized Powder for Reconstitution Rx, 2000 unit, VIAL (EA), 1	01/01/2025	95.20	3495.20	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	58394063303	BeneFIX® (coagulation factor IX (recombinant)) Lyophilized Powder for Reconstitution Rx, 250 unit, VIAL (EA), 1	01/01/2025	11.90	436.90	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	58394063703	BeneFIX® (coagulation factor IX (recombinant)) Lyophilized Powder for Reconstitution Rx, 3000 unit, VIAL (EA), 1	01/01/2025	142.80	5242.80	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	58394063403	BeneFIX® (coagulation factor IX (recombinant)) Lyophilized Powder for Reconstitution Rx, 500 unit, VIAL (EA), 1	01/01/2025	23.80	873.80	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	60793070110	BICILLIN L-A (penicillin G benzathine), 1.2 million unit/2 mL, SYRINGE (ML), 1	01/01/2025	304.99	3354.87	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	60793070210	BICILLIN L-A (penicillin G benzathine), 2.4 million unit/4 mL, SYRINGE (ML), 1	01/01/2025	624.97	6874.69	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	60793070010	BICILLIN L-A (penicillin G benzathine), 600,000 unit/mL, SYRINGE (ML), 1	01/01/2025	176.10	1937.05	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069013501	BOSULIF (bosutinib), 100 mg, TABLET, 1	01/01/2025	601.92	20669.00	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069019301	BOSULIF (bosutinib), 400 mg, TABLET, 1	01/01/2025	601.92	20669.00	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069013601	BOSULIF (bosutinib), 500 mg, TABLET, 1	01/01/2025	601.92	20669.00	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	70255002503	BRAFTOVI (encorafenib), 75 mg, CAPSULE, 120	01/01/2025	477.11	16385.00	08/27/2030	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	70255002501	BRAFTOVI (encorafenib), 75 mg, CAPSULE, 180	01/01/2025	477.11	16385.00	08/27/2030	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409162301	Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 1 mg/mL (1 mg/mL) Single Dose Glass Fliptop Vial, 10	01/01/2025	7.42	81.60	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409162601	Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 2 mg/mL (2 mg/mL) Single Dose Glass Fliptop Vial, 10	01/01/2025	9.07	99.81	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409162602	Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 2 mg/mL (4 mg/2 mL) Single Dose Glass Fliptop Vial, 10	01/01/2025	12.78	140.53	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069033530	Cibinqo™ (abrocitinib) Tablet Rx, 100 mg, Tablet, 30	01/01/2025	278.37	5845.69	02/19/2034	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069043530	Cibinqo™ (abrocitinib) Tablet Rx, 200 mg, Tablet, 30	01/01/2025	278.37	5845.69	02/19/2034	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069023530	Cibinqo™ (abrocitinib) Tablet Rx, 50 mg, Tablet, 30	01/01/2025	278.37	5845.69	02/19/2034	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409330024	CIPROFLOXACIN, 400 MG/200 ML , INTRAVENOUS SOLUTION (ML), 24	01/01/2025	8.68	95.45	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009379422	CORVERT (ibutilide fumarate), 0.1 mg/mL, VIAL (ML), 10	01/01/2025	10.98	559.83	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009379401	CORVERT (ibutilide fumarate), 1 mg/10 mL, VIAL (ML), 10	01/01/2025	10.98	559.83	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409233725	Deferoxamine Mesylate Injection Rx, 2 g, Single Dose Glass Fliptop Vial, 4	01/01/2025	14.10	155.14	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409118130	Demerol™ (meperidine hydrochloride) Injection - Controlled Substance - SCHEDULE II Rx, 50 mg/mL (1,500 mg/30 mL) Multiple Dose Glass Fliptop Vial, 1	01/01/2025	12.49	137.41	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009027101	DEPO-ESTRADIOL (estradiol cypionate), 5 mg/mL, VIAL (ML), 1	01/01/2025	20.30	223.33	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409741903	Dextran (dextran) Injection Rx, 500 mL (10% LMD in 0.9% Sodium Chloride), Intravenous solution, 12	01/01/2025	48.22	530.44	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409741803	Dextran (dextran) Injection Rx, 500 mL (10% LMD in 5% Dextrose), Intravenous solution, 12	01/01/2025	46.85	515.31	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409321312	Diazepam Injection - Controlled Substance - SCHEDULE IV Rx, 5 mg/mL, VIAL (ML), 10	01/01/2025	50.11	551.17	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409234632	Dobutamine Hydrochloride, 1mg/ml, Vial, 12	01/01/2025	24.17	145.03	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409234732	Dobutamine Hydrochloride, 2mg/ml, Vial, 12	01/01/2025	66.43	250.96	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409372432	Dobutamine Hydrochloride, 4mg/ml, Vial, 12	01/01/2025	14.59	257.78	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409781022	Dopamine Hydrochloride in 5% Dextrose Injection Rx, 1,600 mcg/mL (400 mg/250 mL), Flexible Container, 12	01/01/2025	24.71	271.81	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409780922	Dopamine Hydrochloride in 5% Dextrose Injection Rx, 1,600 mcg/mL (800 mg/500 mL), Flexible Container, 12	01/01/2025	24.84	190.47	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409780924	Dopamine Hydrochloride in 5% Dextrose Injection Rx, 3,200 mcg/mL (800 mg/250 mL), Flexible Container, 12	01/01/2025	22.87	251.55	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409493301	Epinephrine Injection Rx, 1mg/10mL (0.1 mg/mL) ABBOJECT Single-dose syringe, 10	01/01/2025	9.28	102.08	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409648201	Erythrocin™ (lactobionate) IV Rx, 500 mg, Single Dose Glass Fliptop Vial, 10	01/01/2025	45.44	954.28	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	55724021121	Eucrisa® (crisaborole) ointment, 2% for topical use Rx, 20 mg/gm (100 gm), Tube, 1	01/01/2025	30.52	793.41	12/29/2029	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	55724021111	Eucrisa® (crisaborole) ointment, 2% for topical use Rx, 20 mg/gm (60 gm), Tube, 1	01/01/2025	42.91	1115.68	12/29/2029	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409909422	FENTANYL CITRATE (fentanyl citrate), 50 mcg/mL, VIAL (ML), 2	01/01/2025	9.24	47.74	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069021702	Fragmin® (dalteparin sodium) Injection Rx, 10,000 IU/1 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	01/01/2025	60.38	1268.05	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069022002	Fragmin® (dalteparin sodium) Injection Rx, 12,500 IU/0.5 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	01/01/2025	75.49	1585.19	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069022302	Fragmin® (dalteparin sodium) Injection Rx, 15,000 IU/0.6 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	01/01/2025	90.58	1902.10	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069022802	Fragmin® (dalteparin sodium) Injection Rx, 18,000 IU/0.72 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards test potency, 10	01/01/2025	108.69	2282.52	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069019502	Fragmin® (dalteparin sodium) Injection Rx, 2,500 IU/0.2 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	01/01/2025	18.61	390.80	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069019602	Fragmin® (dalteparin sodium) Injection Rx, 5,000 IU/0.2 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	01/01/2025	30.19	634.02	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069020602	Fragmin® (dalteparin sodium) Injection Rx, 7,500 IU/0.3 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	01/01/2025	45.29	951.14	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069023201	Fragmin® (dalteparin sodium) Injection Rx, 95,000 IU/3.8 mL Multidose Vial, 1	01/01/2025	51.90	1089.95	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409120703	Gentamicin Sulfate Injection Rx, 40 mg/mL (80 mg/2 mL) Single Dose Glass Fliptop Vial, 25	01/01/2025	2.58	88.53	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409001230	Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 12500 unit/250 mL, INTRAVENOUS SOLUTION, 250	01/01/2025	36.92	406.07	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409765030	Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 25000 unit/250 mL (100 unit/mL), INTRAVENOUS SOLUTION, 250	01/01/2025	21.34	448.11	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409724803	HEXTEND (hetastarch/electrolyte solution,lactated), 500mL, Vial, 12	01/01/2025	65.82	340.07	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409155554	HEXTEND LACTATED ELECTROLYTE (hetastarch/electrolyte solution,lactated), 500mL, Vial, 12	01/01/2025	115.04	1265.40	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409128337	HYDROMORPHONE HCL (hydromorphone HCl), 1 mg/mL, SYRINGE (ML), 10	01/01/2025	4.90	53.93	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409263401	HYDROMORPHONE HCL (hydromorphone HCl), 10 mg/mL, VIAL (ML), 1	01/01/2025	38.15	81.01	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409131236	HYDROMORPHONE HCL (hydromorphone HCl), 2 mg/mL, SYRINGE (ML), 10	01/01/2025	6.57	72.27	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409336510	HYDROMORPHONE HCL (hydromorphone HCl), 2 mg/mL, VIAL (ML), 1	01/01/2025	1.81	20.97	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069018821	IBRANCE (palbociclib), 100 mg, CAPSULE, 1	01/01/2025	479.61	16462.00	03/05/2027	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069048603	IBRANCE (palbociclib), 100 mg, TABLET, 21	01/01/2025	479.61	16462.00	03/05/2027	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069018921	IBRANCE (palbociclib), 125 mg, CAPSULE, 1	01/01/2025	479.61	16462.00	03/05/2027	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069068803	IBRANCE (palbociclib), 125 mg, TABLET, 21	01/01/2025	479.61	16462.00	03/05/2027	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069018721	IBRANCE (palbociclib), 75 mg, CAPSULE, 1	01/01/2025	479.61	16462.00	03/05/2027	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069028403	IBRANCE (palbociclib), 75 mg, TABLET, 21	01/01/2025	479.61	16462.00	03/05/2027	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069014501	INLYTA (axitinib), 1 mg, TABLET, 1	01/01/2025	616.33	21162.00	10/29/2025	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069015111	INLYTA (axitinib), 5 mg, TABLET, 1	01/01/2025	616.33	21162.00	10/29/2025	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409175410	MAGNESIUM SULFATE (magnesium sulfate), 4 mEq/mL (50 %), SYRINGE (ML), 1	01/01/2025	33.68	370.46	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	70255001002	MEKTOVI (binimetinib), 15 mg, TABLET, 180	01/01/2025	468.23	16075.97	03/13/2026	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409189323	MORPHINE SULFATE (morphine sulfate), 10 mg/mL, SYRINGE (ML), 10	01/01/2025	5.08	55.86	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409189023	MORPHINE SULFATE (morphine sulfate), 2 mg/mL, SYRINGE (ML), 10	01/01/2025	4.29	47.15	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409189123	MORPHINE SULFATE (morphine sulfate), 4 mg/mL, SYRINGE (ML), 10	01/01/2025	4.32	47.52	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	61703032518	Pamidronate Disodium, 6MG/ML, Vial, 10	01/01/2025	4.13	45.39	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00046257512	Premphase® (conjugated estrogens/medroxy progesterone acetate) Tablets Rx, 0.625 mg/5 mg, Tablet, 28	01/01/2025	5.80	247.61	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00046110511	Prempro® (conjugated estrogens/medroxy progesterone acetate) Tablets Rx, 0.3 mg-1.5 mg, TABLET, 28	01/01/2025	5.80	247.61	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00046110611	Prempro® (conjugated estrogens/medroxy progesterone acetate) Tablets Rx, 0.45 mg/1.5 mg, Tablet, 28	01/01/2025	5.80	247.61	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00046110711	Prempro® (conjugated estrogens/medroxy progesterone acetate) Tablets Rx, 0.625 mg/2.5 mg Tablet, 28	01/01/2025	5.80	247.61	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00046110811	Prempro® (conjugated estrogens/medroxy progesterone acetate) Tablets Rx, 0.625 mg/5 mg, Tablet, 28	01/01/2025	5.80	247.61	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409190201	Procainamide Hydrochloride Injection Rx, 100 mg/mL (1,000 mg/10 mL) Multiple Dose Glass Fliptop Vial, 25	01/01/2025	1035.73	3337.35	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009316906	PROSTIN VR (alprostadil), 500 mcg/1ML,Ampoule, 5	01/01/2025	38.40	806.40	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009021505	PROSTIN VR (alprostadil), 500 mcg/ML, Ampul, 5	01/01/2025	38.40	806.40	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409553414	Sodium Bicarbonate Injection Rx, 4.2% (5mEq/10mL) per glass Abboject® syringe, 10	01/01/2025	20.11	221.21	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409491614	Sodium Bicarbonate Injection Rx, 7.5% (44/6 mEq/50mL) per glass Abboject® syringe, 10	01/01/2025	26.05	286.52	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409490014	Sodium Bicarbonate Injection Rx, 8.4% (10mEq/10mL) per glass vial Abboject® syringe, 10	01/01/2025	25.97	285.68	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409663714	Sodium Bicarbonate Injection Rx, 8.4% (50mEq/50mL) per glass Abbotject® syringe, 10	01/01/2025	19.18	210.99	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009001612	SOLU-CORTEF (hydrocortisone sodium succinate) 500 mg/4 mL, VIAL (EA), 1	01/01/2025	3.97	83.28	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009082501	SOLU-CORTEF (hydrocortisone sodium succinate), 100 mg, VIAL (EA), 1	01/01/2025	2.38	18.24	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009001103	SOLU-CORTEF (hydrocortisone sodium succinate), 100 mg/2 mL, VIAL EA, 1	01/01/2025	1.50	22.92	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009001305	SOLU-CORTEF (hydrocortisone sodium succinate), 250 mg/2 mL VIAL (EA), 1	01/01/2025	2.77	42.41	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009001104	SOLU-CORTEF hydrocortisone sodium succinate), 100 mg/2 mL, VIAL (EA), 1	01/01/2025	26.79	562.50	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009001306	SOLU-CORTEF hydrocortisone sodium succinate), 250 mg/2 mL, VIAL (EA) 1	01/01/2025	49.54	1040.43	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009000501	SOLU-CORTEF(hydrocortisone sodium succinate), 1000 mg/8 mL, VIAL EA 1	01/01/2025	7.93	166.50	None	Innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009716601	Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 10 mg, VIAL (EA), 1	01/01/2025	24.11	291.95	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009716630	Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 10 mg/1 mL Syringe, 30	01/01/2025	723.16	8758.27	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009716801	Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 15 mg, VIAL (EA), 1	01/01/2025	36.16	437.95	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009716830	Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 15 mg/1 mL Syringe, 30	01/01/2025	1084.83	13138.55	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009718801	Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 20 mg, VIAL (EA), 1	01/01/2025	48.21	583.89	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009718830	Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 20 mg/ 1 mL Syringe, 30	01/01/2025	1446.35	17516.93	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009719901	Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 25 mg, VIAL (EA), 1	01/01/2025	60.26	729.86	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009719930	Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 25mg/1 mL Syringe, 30	01/01/2025	1807.93	21896.06	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009720001	Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 30 mg, VIAL (EA), 1	01/01/2025	72.32	875.84	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00009720030	Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 30 mg/1 mL Syringe, 30	01/01/2025	2169.51	26275.20	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409338221	SUFENTANIL CITRATE (sufentanil citrate), 50 mcg/mL, VIAL (ML), 1	01/01/2025	8.58	94.36	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069029630	Talzenna® (talazoparib) Rx, 0.25MG CAP, 30	01/01/2025	300.83	6314.00	10/19/2029	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069150130	Talzenna® (talazoparib) Rx, 0.5MG CAP, 30	01/01/2025	901.51	18941.00	10/19/2029	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069175130	Talzenna® (talazoparib) Rx, 0.75MG CAPSULE, 30	01/01/2025	901.51	18941.00	10/19/2029	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069119530	Talzenna® (talazoparib) Rx, 1MG CAP, 30	01/01/2025	901.51	18941.00	10/19/2029	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409159304	THAM (tromethamine), 36 mg/mL (0.3 M), INTRAVENOUS SOLUTION, 6	01/01/2025	214.14	2355.50	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00005010010	Trumenba® (meningococcal group B vaccine) Injection Rx, 0.5 mL Pre-filled Syringe, 10	02/01/2025	170.56	2065.68	10/29/2026	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00005010005	Trumenba® (meningococcal group B vaccine) Injection Rx, 0.5 mL Pre-filled Syringe, 5	02/01/2025	85.28	1032.84	10/29/2026	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00409963305	Verapamil Hydrochloride Injection Rx, 2.5 mg/mL (10 mg/4 mL) Ansyr™ Plastic Syringe, 10	01/01/2025	89.38	983.19	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069814120	XALKORI (crizotinib), 200 mg, CAPSULE, 1	01/01/2025	1345.65	23773.10	10/08/2029	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069814020	XALKORI (crizotinib), 250 mg, CAPSULE, 1	01/01/2025	1345.65	23773.10	10/08/2029	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069100201	XELJANZ (tofacitinib citrate), 10 mg, TABLET, 1	01/01/2025	289.20	6073.14	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069100101	XELJANZ (tofacitinib citrate), 5 mg, TABLET, 1	01/01/2025	289.20	6073.14	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069050130	XELJANZ XR (tofacitinib citrate), 11 mg, TABLET, EXTENDED RELEASE 24 HR, 1	01/01/2025	289.20	6073.14	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069050230	XELJANZ XR (tofacitinib citrate), 22 mg, TABLET, EXTENDED RELEASE 24 HR, 30	01/01/2025	289.20	6073.14	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	00069102902	Xeljanz® (tofacitinib ) Oral Solution Rx, 1 mg/mL, SOLUTION ORAL, 240	01/01/2025	231.36	4858.51	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	58394002403	Xyntha Solofuse® (antihemophilic factor (recombinant), plasma/albumin-free) For Intravenous Use, Freeze-Dried Powder in Prefilled Dual-Chamber Syringe Rx, 1,000 IU (nominal) Single Use Prefilled Dual-chamber Syringe, 1	01/01/2025	91.00	1911.00	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	58394002503	Xyntha Solofuse® (antihemophilic factor (recombinant), plasma/albumin-free) For Intravenous Use, Freeze-Dried Powder in Prefilled Dual-Chamber Syringe Rx, 2,000 IU (nominal) Single Use Prefilled Dual-chamber Syringe, 1	01/01/2025	182.00	3822.00	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	58394002203	Xyntha Solofuse® (antihemophilic factor (recombinant), plasma/albumin-free) For Intravenous Use, Freeze-Dried Powder in Prefilled Dual-Chamber Syringe Rx, 250 IU (nonimal) Single Use Prefilled Dual-chamber Syringe, 1	01/01/2025	22.75	477.75	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	58394001603	Xyntha Solofuse® (antihemophilic factor (recombinant), plasma/albumin-free) For Intravenous Use, Freeze-Dried Powder in Prefilled Dual-Chamber Syringe Rx, 3,000 IU (nominal) Single Use Prefilled Dual-chamber Syringe, 1	01/01/2025	273.00	5733.00	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	58394002303	Xyntha Solofuse® (antihemophilic factor (recombinant), plasma/albumin-free) For Intravenous Use, Freeze-Dried Powder in Prefilled Dual-Chamber Syringe Rx, 500 IU (nominal) Single Use Prefilled Dual-chamber Syringe, 1	01/01/2025	45.50	955.50	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	58394001401	Xyntha® (antihemophilic factor (recombinant), plasma/albumin-free ) For Intravenous Use, Freeze-Dried Powder Rx, 1,000 IU per Vial (nominal) Single Use Vial, 1	01/01/2025	91.00	1911.00	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	58394001501	Xyntha® (antihemophilic factor (recombinant), plasma/albumin-free ) For Intravenous Use, Freeze-Dried Powder Rx, 2,000 IU per Vial (nominal) Single Use Vial, 1	01/01/2025	182.00	3822.00	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	58394001201	Xyntha® (antihemophilic factor (recombinant), plasma/albumin-free ) For Intravenous Use, Freeze-Dried Powder Rx, 250 IU per Vial (nominal) Single Use Vial, 1	01/01/2025	22.75	477.75	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000006	Pfizer	04/30/2025	58394001301	Xyntha® (antihemophilic factor (recombinant), plasma/albumin-free ) For Intravenous Use, Freeze-Dried Powder Rx, 500 IU per Vial (nominal) Single Use Vial, 1	01/01/2025	45.50	955.50	None	Single Source Drug	None	None	None	1	A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121064610	AMANTADINE HYDROCHLORIDE (AMANTADINE HYDROCHLORIDE) 50mg/5mL Oral Solution, 10mL Cup [Qty: 100]	01/02/2025	35.58	394.93	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121202410	LACOSAMIDE (LACOSAMIDE) 10mg/mL Oral Solution, 10mL Cup [Qty: 1]	01/02/2025	4.85	53.88	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121202495	LACOSAMIDE (LACOSAMIDE) 10mg/mL Oral Solution, 10mL Cup [Qty: 10]	01/02/2025	48.53	538.78	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121303615	LACOSAMIDE (LACOSAMIDE) 10mg/mL Oral Solution, 15mL Cup [Qty: 1]	01/02/2025	7.28	80.82	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121303695	LACOSAMIDE (LACOSAMIDE) 10mg/mL Oral Solution, 15mL Cup [Qty: 10]	01/02/2025	72.80	808.18	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121404874	LACOSAMIDE (LACOSAMIDE) 10mg/mL Oral Solution, 20mL Cup [Qty: 1]	01/02/2025	9.71	107.76	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121404895	LACOSAMIDE (LACOSAMIDE) 10mg/mL Oral Solution, 20mL Cup [Qty: 10]	01/02/2025	97.07	1077.57	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121101205	LACOSAMIDE (LACOSAMIDE) 10mg/mL Oral Solution, 5mL Cup [Qty: 1]	01/02/2025	2.43	26.94	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121101295	LACOSAMIDE(LACOSAMIDE) 10mg/mL Oral Solution, 5mL Cup [Qty: 10]	01/02/2025	24.27	269.40	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121115440	LACTULOSE (LACTULOSE) - 10g/15mL Oral Solution, 30mL Cup [Qty: 40]	01/02/2025	13.10	78.62	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121457715	LACTULOSE (LACTULOSE) 10g/15mL Oral Solution, 15mL Cup [Qty: 1]	01/02/2025	0.29	1.75	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121457740	LACTULOSE (LACTULOSE) 10g/15mL Oral Solution, 15mL Cup [Qty: 40]	01/02/2025	11.66	69.98	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121115430	LACTULOSE (LACTULOSE) 10g/15mL Oral Solution, 30mL Cup [Qty: 1]	01/02/2025	0.33	1.97	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121115400	LACTULOSE (LACTULOSE) 10g/15mL Oral Solution, 30mL Cup [Qty: 100]	01/02/2025	30.25	181.50	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	03/03/2025	00121077001	LORAZEPAM 2mg/mL Oral Concentrate, 30mL bottle [Qty: 1]	03/03/2025	16.53	31.55	None	Non-innovator Multiple Source Drug	None	None	None	1	The generic Lorazepam oral liquid market currently has 3 suppliers in the US. This market has recently experienced a supply disruption which is putting significant strain on PAI Pharma. PAI Pharma’s supply position is constrained and can’t take on the additional customer request without investments (API, components, resources, etc.) and managing long lead time materials. PAI Pharma is raising WAC to improve supply position and offset the add complexity.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121135010	VALPROIC ACID (VALPROIC ACID) 250mg/5mL Oral Solution, 10mL Cup [Qty: 1]	01/02/2025	0.23	2.47	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121135000	VALPROIC ACID (VALPROIC ACID) 250mg/5mL Oral Solution, 10mL Cup [Qty: 100]	01/02/2025	22.22	246.70	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121467505	VALPROIC ACID (VALPROIC ACID) 250mg/5mL Oral Solution, 5mL Cup [Qty: 1]	01/02/2025	0.12	1.37	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121467500	VALPROIC ACID (VALPROIC ACID) 250mg/5mL Oral Solution, 5mL Cup [Qty: 100]	01/02/2025	12.35	137.14	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121467540	VALPROIC ACID (VALPROIC ACID) 250mg/5mL Oral Solution, 5mL Cup [Qty: 40]	01/02/2025	7.79	86.44	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000410	PharmaEssentia USA Corporation	04/14/2025	73536050001	Besremi Subcutaneous Solution Prefilled Syringe 500 MCG/ML	01/17/2025	505.00	8923.00	02/26/2034	Single Source Drug	None	None	None	1	PharmaEssentia USA Corporation prices BESREMi using a variety of inforamtion and factors that are not public in nature and are related to confidential costs incurred coupled with expected drug utilization in a limited therapeutic class. Some factors that led to this increase in price include incremental costs of doing business, higher inflation of cost of goods, and increased participation and levels of discounting arrangements to government programs.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000469	Pharming Healthcare Inc	02/19/2025	71274035002	Ruconest 2100 U; Injection; Powder for Solution; 1 Carton	01/01/2025	450.00	8075.00	10/07/2026	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000469	Pharming Healthcare Inc	02/19/2025	71274035001	Ruconest C1 Esterase Inhibitor (Recombinant) 2100 UNIT Solution Reconstituted 1 EA UD	01/01/2025	450.00	8075.00	10/07/2026	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000118	Progenics Pharmaceuticals, Inc.	04/14/2025	71258002201	Pylarify PIFLUFOLASTAT F-18 50 mL in 1 VIAL, MULTI-DOSE INJECTION	02/01/2025	312.84	5535.52	06/09/2037	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000536	Protega Pharmaceuticals, Inc.	04/03/2025	81140010210	RoxyBond Oral Tablet Abuse-Deterrent 15 MG 100 tablets per bottle	02/05/2025	170.99	1898.16	08/12/2028	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000536	Protega Pharmaceuticals, Inc.	04/03/2025	81140010310	RoxyBond Oral Tablet Abuse-Deterrent 30 MG 100 tablets per bottle	02/05/2025	230.44	2558.14	08/12/2028	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000536	Protega Pharmaceuticals, Inc.	04/03/2025	81140010110	RoxyBond Oral Tablet Abuse-Deterrent 5 MG 100 tablets per bottle	02/05/2025	138.65	1539.13	08/12/2028	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000220	Puma Biotechnology, Inc.	03/02/2025	70437024033	Nerlynx Oral Tablet 40 mg, 133 tablet package	02/03/2025	1145.00	17510.00	07/18/2031	Single Source Drug	None	None	12130000	None	Inflation has driven up costs in almost all areas of operations.	None	There was no change or improvement that necessitated the price increase.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000220	Puma Biotechnology, Inc.	03/02/2025	70437024018	Nerlynx Oral Tablet 40 mg, 180 tablet package	02/03/2025	1550.00	23700.00	07/18/2031	Single Source Drug	None	None	230470000	None	Inflation has driven up costs in almost all areas of operations.	None	There was no change or improvement that necessitated the price increase.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000056	Purdue Pharma LP	03/03/2025	59011027660	HYSINGLA ER 100MG TABLETS 60S	01/01/2025	211.17	3589.87	12/21/2031	Single Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011027160	HYSINGLA ER 20MG TABLETS 60S	01/01/2025	45.21	768.51	12/21/2031	Single Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011027260	HYSINGLA ER 30MG TABLETS 60S	01/01/2025	65.99	1121.77	12/21/2031	Single Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011027360	HYSINGLA ER 40MG TABLETS 60S	01/01/2025	88.90	1511.28	12/21/2031	Single Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011027460	HYSINGLA ER 60MG TABLETS 60S	01/01/2025	123.10	2092.64	12/21/2031	Single Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011027560	HYSINGLA ER 80MG TABLETS 60S	01/01/2025	165.96	2821.37	12/21/2031	Single Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011041010	OXYCONTIN 10MG TABLETS 100S	01/01/2025	33.33	566.56	03/29/2030	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011041020	OXYCONTIN 10MG TABLETS HUD 20S	01/01/2025	6.84	116.33	03/29/2030	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011041510	OXYCONTIN 15MG TABLETS 100S	01/01/2025	49.06	834.05	03/29/2030	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011041520	OXYCONTIN 15MG TABLETS HUD 20S	01/01/2025	10.07	171.13	03/29/2030	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011042010	OXYCONTIN 20MG TABLETS 100S	01/01/2025	62.15	1056.59	03/29/2030	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011042020	OXYCONTIN 20MG TABLETS HUD 20S	01/01/2025	12.75	216.73	03/29/2030	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011043010	OXYCONTIN 30MG TABLETS 100S	01/01/2025	86.44	1469.44	03/29/2030	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011043020	OXYCONTIN 30MG TABLETS HUD 20S	01/01/2025	17.74	301.50	03/29/2030	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011044010	OXYCONTIN 40MG TABLETS 100S	01/01/2025	106.44	1809.51	08/24/2027	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011044020	OXYCONTIN 40MG TABLETS HUD 20S	01/01/2025	21.83	371.04	08/24/2027	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011046010	OXYCONTIN 60MG TABLETS 100S	01/01/2025	150.71	2561.99	08/24/2027	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011046020	OXYCONTIN 60MG TABLETS HUD 20S	01/01/2025	30.92	525.61	08/24/2027	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011048010	OXYCONTIN 80MG TABLETS 100S	01/01/2025	185.74	3157.54	08/24/2027	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011048020	OXYCONTIN 80MG TABLETS HUD 20S	01/01/2025	38.10	647.72	08/24/2027	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000342	PureTek Corporation	04/02/2025	59088000381	Bruselix, Vitamin C, Zinc, Arnica Montana Extract, Bromelain, Diosmin, Rutin, Citrus Bioflavonoids, Hesperidin Methyl Chalcone, tablets (14ct)	04/01/2025	776.00	1604.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000342	PureTek Corporation	04/02/2025	59088016254	Diatrol Multivitamin (30ct), caplets, Vita A 900mcg, Vit C 50mg, Vit D3 18.75 mcg, Vit E 13.5mg, Vit K1 90 mcg, Thiamin 4mg, Vit B2 4mg, Niacin 24mg, Vit B6 8mg, Folate 1700mcg, Vit B12 8,cg, Biotin 30mcg, Panthothenic Acid 8mg, Chromium 200mcg	04/01/2025	818.42	1646.42	None	Single Source Drug	None	None	None	1	Raw material, component and manufacturing costs. New or stricter regulatory requirements increase testing, validation, and documentation costs as well as stability studies, batch testing, and third-party certifications. Rising fuel prices, import/export duties, or increased warehousing expenses. Rising costs of goods and services in general.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000342	PureTek Corporation	04/02/2025	59088000854	Finazol, Vit A, Vit C, Vit D3, Vitamin E, Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Biotin, Pantothenic Acid, Calcium, Iron, Iodine, Magnesium, Zinc, Selenium, Copper, Manganese, Chromium, Molybdenum, Potassium, Boron, caplets, 30ct	04/01/2025	776.00	1604.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000342	PureTek Corporation	04/02/2025	59088001554	Flotrex 0.5mg, Vitamin A, Vitamin C, Vitamin D3, Vitamin E, Thiamin, Vitamin E, Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Fluoride, chewable tablets (30ct)	04/01/2025	776.00	1604.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000342	PureTek Corporation	04/02/2025	59088020407	Lidotral 5% Gel, Lidocaine HCI 5%, (3oz)	04/01/2025	818.42	1646.42	None	Single Source Drug	None	None	None	1	Raw material, component and manufacturing costs. New or stricter regulatory requirements increase testing, validation, and documentation costs as well as stability studies, batch testing, and third-party certifications. Rising fuel prices, import/export duties, or increased warehousing expenses. Rising costs of goods and services in general.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000342	PureTek Corporation	04/02/2025	59088035003	Lidotral 5% Spray, Lidocaine HCI 5%, (1fl oz)	04/01/2025	818.42	1646.42	None	Single Source Drug	None	None	None	1	Raw material, component and manufacturing costs. New or stricter regulatory requirements increase testing, validation, and documentation costs as well as stability studies, batch testing, and third-party certifications. Rising fuel prices, import/export duties, or increased warehousing expenses. Rising costs of goods and services in general.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000342	PureTek Corporation	04/02/2025	59088022700	Salycim Cream, Salicylic Acid 6%, (2oz)	04/01/2025	818.42	1646.42	None	Single Source Drug	None	None	None	1	Raw material, component and manufacturing costs. New or stricter regulatory requirements increase testing, validation, and documentation costs as well as stability studies, batch testing, and third-party certifications. Rising fuel prices, import/export duties, or increased warehousing expenses. Rising costs of goods and services in general.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000342	PureTek Corporation	04/02/2025	59088032607	Scartrate Cream, Dimethicone 5% + Allantoin 2.25%, (3oz)	04/01/2025	818.42	1646.42	None	Single Source Drug	None	None	None	1	Raw material, component and manufacturing costs. New or stricter regulatory requirements increase testing, validation, and documentation costs as well as stability studies, batch testing, and third-party certifications. Rising fuel prices, import/export duties, or increased warehousing expenses. Rising costs of goods and services in general.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000356	Radius Health, Inc.	01/31/2025	70539000102	TYMLOS 80 MCG Pen / Carton Injection: 3120 mcg/1.56 mL (2000 mcg/mL) in a single-patient-use prefilled pen. The prefilled pen delivers 30 daily doses of 80 mcg abaloparatide in 40 mcL of sterile, clear, colorless solution.	01/01/2025	160.02	2827.02	01/10/2040	Single Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Radius believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 10/26/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Radius Health, Inc. did not acquire this product from another manufacturer within the previous five years. As a result, Radius Health has left columns N-U blank because they are not applicable to this product.
Rx0000356	Radius Health, Inc.	01/31/2025	70539000101	TYMLOS 80 MCG Pen. Injection: 3120 mcg/1.56 mL (2000 mcg/mL) in a single-patient-use prefilled pen. The prefilled pen delivers 30 daily doses of 80 mcg abaloparatide in 40 mcL of sterile, clear, colorless solution.	01/01/2025	160.02	2827.02	01/10/2040	Single Source Drug	None	None	None	1	None	1	The price increase was not necessitated by a change or improvement in the drug.	None	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Radius believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 10/26/2023. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Radius Health, Inc. did not acquire this product from another manufacturer within the previous five years. As a result, Radius Health has left columns N-U blank because they are not applicable to this product.
Rx0000363	Recordati Rare Diseases, inc.	04/15/2025	55292041005	Cystadrops Ophthalmic Solution 0.37 % 1 5ml bottle	01/01/2025	115.46	2424.65	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	04/15/2025	55292032060	Isturisa Oral Tablet 1 MG 60 tablets	01/01/2025	944.10	10881.98	10/12/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	04/15/2025	55292032160	Isturisa Oral Tablet 5 MG 60 tablets	01/01/2025	4720.49	54409.87	10/12/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	04/15/2025	55292070255	Panhematin Intravenous Solution Reconstituted 350 MG 1 vial	01/01/2025	245.97	10940.49	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	04/15/2025	55292013901	Signifor LAR Intramuscular Suspension Reconstituted ER 10 MG 1 vial	01/01/2025	953.38	20021.07	05/23/2028	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	04/15/2025	55292014001	Signifor LAR Intramuscular Suspension Reconstituted ER 20 MG 1 vial	01/01/2025	953.38	20021.07	05/23/2028	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	04/15/2025	55292014101	Signifor LAR Intramuscular Suspension Reconstituted ER 30 MG 1 vial	01/01/2025	953.38	20021.07	05/23/2028	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	04/15/2025	55292014201	Signifor LAR Intramuscular Suspension Reconstituted ER 40 MG 1 vial	01/01/2025	953.38	20021.07	05/23/2028	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	04/15/2025	55292014301	Signifor LAR Intramuscular Suspension Reconstituted ER 60 MG 1 vial	01/01/2025	953.38	20021.07	05/23/2028	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	04/15/2025	55292013160	Signifor Subcutaneous Solution 0.3 MG/ML 60 Ampules	01/01/2025	1004.34	21091.07	12/14/2026	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	04/15/2025	55292013260	Signifor Subcutaneous Solution 0.6 MG/ML 60 Ampules	01/01/2025	1004.34	21091.07	12/14/2026	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000363	Recordati Rare Diseases, inc.	04/15/2025	55292013360	Signifor Subcutaneous Solution 0.9 MG/ML 60 Ampules	01/01/2025	1004.34	21091.07	12/14/2026	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000166	Redhill Biopharma, Inc.	04/17/2025	57841115002	Talicia Oral Capsule Delayed Release 250-12.5-10 MG 2 Bottles of 84 Capsules	01/01/2025	24.34	835.73	02/12/2034	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000239	Rigel Pharmaceuticals, Inc.	03/31/2025	71332000660	GAVRETO 100MG 60 CAPS	01/03/2025	667.42	11812.00	11/01/2036	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	02/22/2024	BluePrint Medicines Corporation	15000000	None	None	11144.58	10613.89	2020	9621.60	None	None
Rx0000239	Rigel Pharmaceuticals, Inc.	03/31/2025	71332000690	GAVRETO 100MG 90 CAPS	01/03/2025	1001.15	17718.00	11/01/2036	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	02/22/2024	BluePrint Medicines Corporation	15000000	None	None	16716.85	15920.81	2020	14432.40	None	None
Rx0000239	Rigel Pharmaceuticals, Inc.	03/31/2025	71332000101	TAVALISSE TAB 100MG 60 TABS	01/03/2025	730.00	15530.00	07/27/2032	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000239	Rigel Pharmaceuticals, Inc.	03/31/2025	71332000201	TAVALISSE Tab 150MG 60 TABS	01/03/2025	730.00	15530.00	07/27/2032	Single Source Drug	None	None	None	1	Pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000095	Salix Pharmaceuticals, Inc.	04/22/2025	65649055102	RELISTOR® (methylnaltrexone bromide) 12mg/0.6mL, vial	01/01/2025	9.62	169.93	12/31/2030	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000095	Salix Pharmaceuticals, Inc.	04/22/2025	65649055103	RELISTOR® (methylnaltrexone bromide) PFS 12 mg/0.6mL, 7ct	01/01/2025	67.33	1189.50	12/31/2030	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000095	Salix Pharmaceuticals, Inc.	04/22/2025	65649055107	RELISTOR® (methylnaltrexone bromide) PFS 12 mg/0.6mL, vial	01/01/2025	9.62	169.93	12/31/2030	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000095	Salix Pharmaceuticals, Inc.	04/22/2025	65649055204	RELISTOR® (methylnaltrexone bromide) PFS 8 mg/0.4mL, 7ct	01/01/2025	67.33	1189.50	12/31/2030	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000095	Salix Pharmaceuticals, Inc.	04/22/2025	65649030103	XIFAXAN® (rifaximin) 200 mg Tablets, 30 ct	01/01/2025	19.07	336.78	07/24/2029	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000095	Salix Pharmaceuticals, Inc.	04/22/2025	65649030303	XIFAXAN® (rifaximin) 550mg Tablets HUD 6 cards of 10, 60ct Card	01/01/2025	196.03	3463.26	10/02/2029	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000095	Salix Pharmaceuticals, Inc.	04/22/2025	65649030302	XIFAXAN® (rifaximin) 550mg Tablets, 60ct	01/01/2025	196.03	3463.26	10/02/2029	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
Rx0000011	Sanofi	04/30/2025	00024591902	DUPIXENT® (dupilumab) injection200 mg/1.14 mL (1.14 mL/pen) - 2 pens	01/03/2025	190.16	3993.36	03/28/2031	Single Source Drug	None	None	None	1	Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation. Our US prescription medicine pricing principles focus on three key areas: clear rationale for pricing at the time of launch of a new medicine; reporting of pricing actions for our medicines in the United States over time; and continued transparency around our pricing decisions. You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	04/30/2025	00024591801	DUPIXENT® (dupilumab) injection200 mg/1.14 mL (1.14 mL/syringe) - 2 syringes	01/03/2025	190.16	3993.36	03/28/2031	Single Source Drug	None	None	None	1	Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation. Our US prescription medicine pricing principles focus on three key areas: clear rationale for pricing at the time of launch of a new medicine; reporting of pricing actions for our medicines in the United States over time; and continued transparency around our pricing decisions. You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	04/30/2025	00024591502	DUPIXENT® (dupilumab) injection300 mg/2 mL (2 mL/pen) - 2 pens	01/03/2025	190.16	3993.36	03/28/2031	Single Source Drug	None	None	None	1	Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation. Our US prescription medicine pricing principles focus on three key areas: clear rationale for pricing at the time of launch of a new medicine; reporting of pricing actions for our medicines in the United States over time; and continued transparency around our pricing decisions. You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	04/30/2025	00024591401	DUPIXENT® (dupilumab) injection300 mg/2 mL (2 mL/syringe) - 2 syringes	01/03/2025	190.16	3993.36	03/28/2031	Single Source Drug	None	None	None	1	Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation. Our US prescription medicine pricing principles focus on three key areas: clear rationale for pricing at the time of launch of a new medicine; reporting of pricing actions for our medicines in the United States over time; and continued transparency around our pricing decisions. You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	04/30/2025	00024590801	KEVZARA® (sarilumab) injection 150 mg/1.14 mL (1.14 mL syringe) - 2 syringes	01/03/2025	260.59	4603.71	09/19/2031	Single Source Drug	None	None	None	1	Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation. Our US prescription medicine pricing principles focus on three key areas: clear rationale for pricing at the time of launch of a new medicine; reporting of pricing actions for our medicines in the United States over time; and continued transparency around our pricing decisions. You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	04/30/2025	00024592001	KEVZARA® (sarilumab) injection 150 mg/1.14 mL (1.14 mL/pen) - 2 pens	01/03/2025	260.59	4603.71	09/19/2031	Single Source Drug	None	None	None	1	Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation. Our US prescription medicine pricing principles focus on three key areas: clear rationale for pricing at the time of launch of a new medicine; reporting of pricing actions for our medicines in the United States over time; and continued transparency around our pricing decisions. You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	04/30/2025	00024592201	KEVZARA® (sarilumab) injection 200 mg/1.14 mL (1.14 mL/pen) - 2 pens	01/03/2025	260.59	4603.71	09/19/2031	Single Source Drug	None	None	None	1	Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation. Our US prescription medicine pricing principles focus on three key areas: clear rationale for pricing at the time of launch of a new medicine; reporting of pricing actions for our medicines in the United States over time; and continued transparency around our pricing decisions. You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	04/30/2025	00024591001	KEVZARA® (sarilumab) injection 200 mg/1.14 mL (1.14 mL/syringe) - 2 syringes	01/03/2025	260.59	4603.71	09/19/2031	Single Source Drug	None	None	None	1	Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation. Our US prescription medicine pricing principles focus on three key areas: clear rationale for pricing at the time of launch of a new medicine; reporting of pricing actions for our medicines in the United States over time; and continued transparency around our pricing decisions. You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	04/30/2025	00024065401	SARCLISA® (isatuximab-irfc) injection100 mg/5 mL (20 mg/mL) (5 mL/vial) - 1 vial	01/03/2025	51.45	842.94	10/19/2032	Single Source Drug	None	None	None	1	Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation. Our US prescription medicine pricing principles focus on three key areas: clear rationale for pricing at the time of launch of a new medicine; reporting of pricing actions for our medicines in the United States over time; and continued transparency around our pricing decisions. You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	04/30/2025	00024065601	SARCLISA® (isatuximab-irfc) injection500 mg/25 mL (20 mg/mL) (25 mL/vial) - 1 vial	01/03/2025	257.24	4214.72	10/19/2032	Single Source Drug	None	None	None	1	Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation. Our US prescription medicine pricing principles focus on three key areas: clear rationale for pricing at the time of launch of a new medicine; reporting of pricing actions for our medicines in the United States over time; and continued transparency around our pricing decisions. You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	04/30/2025	49281075221	TUBERSOL®(Tuberculin tests) 5 tub. unit/0.1 mL, 1VIAL (ML)	01/01/2025	9.10	110.23	None	Single Source Drug	None	None	None	1	Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation. Our US prescription medicine pricing principles focus on three key areas: clear rationale for pricing at the time of launch of a new medicine; reporting of pricing actions for our medicines in the United States over time; and continued transparency around our pricing decisions. You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	04/30/2025	49281075222	TUBERSOL®(Tuberculin tests) 5 tub. unit/0.1 mL, 5 VIAL (ML)	01/01/2025	35.46	429.50	None	Single Source Drug	None	None	None	1	Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation. Our US prescription medicine pricing principles focus on three key areas: clear rationale for pricing at the time of launch of a new medicine; reporting of pricing actions for our medicines in the United States over time; and continued transparency around our pricing decisions. You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	04/30/2025	49281079051	Typhim Vi® (Typhoid vaccine) 0.5 mL (1-dose) syringe	01/01/2025	6.98	146.57	None	Single Source Drug	None	None	None	1	Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation. Our US prescription medicine pricing principles focus on three key areas: clear rationale for pricing at the time of launch of a new medicine; reporting of pricing actions for our medicines in the United States over time; and continued transparency around our pricing decisions. You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	04/30/2025	49281079020	Typhim Vi® (Typhoid vaccine) 10 mL (0.5 mL dose) vial	01/01/2025	96.49	2026.30	None	Single Source Drug	None	None	None	1	Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation. Our US prescription medicine pricing principles focus on three key areas: clear rationale for pricing at the time of launch of a new medicine; reporting of pricing actions for our medicines in the United States over time; and continued transparency around our pricing decisions. You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000011	Sanofi	04/30/2025	49281091501	YF-VAX (yellow fever vaccine live/PF) 10 exp4.74 unit/0.5 mL, 1 VIAL (EA)	01/01/2025	92.46	1119.83	None	Single Source Drug	None	None	None	1	Sanofi is an industry leader in responsible pricing, and we acknowledge our role in preserving a sustainable health care system and limiting our contribution to U.S. health care spending growth. To maintain an environment that will continue to bring new healthcare solutions to patients, we must encourage a transition to a value-driven healthcare system that provides incentives for the highest-quality care. This evolution will enable both affordable access to treatments and continued investment in medical innovation. Our US prescription medicine pricing principles focus on three key areas: clear rationale for pricing at the time of launch of a new medicine; reporting of pricing actions for our medicines in the United States over time; and continued transparency around our pricing decisions. You can learn more about our Pricing Principles and read our latest report here: https://www.sanofi.us/en/our-company/social-impact/responsible-business-values/pricing-principles	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000028	Servier Pharmaceuticals LLC	04/30/2025	72694095401	ONCASPAR INJECTION 1 VIAL 5 ML 3750 IU	01/01/2025	1276.91	26815.15	None	Single Source Drug	None	None	None	1	Servier's pricing strategy is the result of a comprehensive assessment of various factors, including competitive market dynamics, escalating supply chain and operational expenses, distribution and wholesaler fees, as well as research and development investments. The pricing of products also accounts for the unique challenges posed by small patient populations.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000004	Shionogi Inc.	04/30/2025	59630026610	FETROJA, for injection, 1 gram of cefiderocol, 2 grams of FETROJA for injection every 8 hours, 10 single-dose vials per pack	01/01/2025	131.80	2328.40	09/03/2035	Single Source Drug	None	None	None	1	Pricing decisions are made based on careful consideration of many factors including, but not limited to, therapeutic area, business costs, research and development costs, and market dynamics.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000074	Sigmapharm Laboratories, LLC	01/29/2025	42794002808	Disulfiram 250mg tablet 30ct bottle	03/29/2025	98.50	170.00	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000175	Sobi Inc	04/16/2025	66658023407	Kineret Subcutaneous Solution Prefilled Syringe 100 MG/0.67ML - 7 prefilled syringes	01/01/2025	96.48	1474.79	07/20/2026	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Inner NDC's for Kineret: 66658023401
Rx0000245	Solco Healthcare US, LLC	05/12/2025	43547060210	PKGS LISDEX CAPSULES 10MG C2 100 CT	05/19/2025	126.14	200.00	None	Non-innovator Multiple Source Drug	None	None	1733790	None	Due to current limited product availability in the market, some customers are willing to pay a higher price (higher than old WAC) to secure additional supply.	None	No change or improvement to the drug.	None	None	None	None	None	None	None	None	None	None	None	The recommended dosage is 1 capsule per day. So the new WAC cost for a 30-day treatment is $60.00
Rx0000245	Solco Healthcare US, LLC	05/12/2025	43547060310	PKGS LISDEX CAPSULES 20MG C2 100 CT	05/19/2025	126.14	200.00	None	Non-innovator Multiple Source Drug	None	None	1976629	None	Due to current limited product availability in the market, some customers are willing to pay a higher price (higher than old WAC) to secure additional supply.	None	No change or improvement to the drug.	None	None	None	None	None	None	None	None	None	None	None	The recommended dosage is 1 capsule per day. So the new WAC cost for a 30-day treatment is $60.00
Rx0000245	Solco Healthcare US, LLC	05/12/2025	43547060410	PKGS LISDEX CAPSULES 30MG C2 100 CT	05/19/2025	126.14	200.00	None	Non-innovator Multiple Source Drug	None	None	5286437	None	Due to current limited product availability in the market, some customers are willing to pay a higher price (higher than old WAC) to secure additional supply.	None	No change or improvement to the drug.	None	None	None	None	None	None	None	None	None	None	None	The recommended dosage is 1 capsule per day. So the new WAC cost for a 30-day treatment is $60.00
Rx0000245	Solco Healthcare US, LLC	05/12/2025	43547060510	PKGS LISDEX CAPSULES 40MG C2 100 CT	05/19/2025	126.14	200.00	None	Non-innovator Multiple Source Drug	None	None	3597728	None	Due to current limited product availability in the market, some customers are willing to pay a higher price (higher than old WAC) to secure additional supply.	None	No change or improvement to the drug.	None	None	None	None	None	None	None	None	None	None	None	The recommended dosage is 1 capsule per day. So the new WAC cost for a 30-day treatment is $60.00
Rx0000245	Solco Healthcare US, LLC	05/12/2025	43547060610	PKGS LISDEX CAPSULES 50MG C2 100 CT	05/19/2025	126.14	200.00	None	Non-innovator Multiple Source Drug	None	None	1747303	None	Due to current limited product availability in the market, some customers are willing to pay a higher price (higher than old WAC) to secure additional supply.	None	No change or improvement to the drug.	None	None	None	None	None	None	None	None	None	None	None	The recommended dosage is 1 capsule per day. So the new WAC cost for a 30-day treatment is $60.00
Rx0000245	Solco Healthcare US, LLC	05/12/2025	43547060710	PKGS LISDEX CAPSULES 60MG C2 100 CT	05/19/2025	126.14	200.00	None	Non-innovator Multiple Source Drug	None	None	0	1	Due to current limited product availability in the market, some customers are willing to pay a higher price (higher than old WAC) to secure additional supply.	None	No change or improvement to the drug.	None	None	None	None	None	None	None	None	None	None	None	The recommended dosage is 1 capsule per day. So the new WAC cost for a 30-day treatment is $60.00
Rx0000245	Solco Healthcare US, LLC	05/12/2025	43547060810	PKGS LISDEX CAPSULES 70MG C2 100 CT	05/19/2025	116.00	200.00	None	Non-innovator Multiple Source Drug	None	None	0	1	Due to current limited product availability in the market, some customers are willing to pay a higher price (higher than old WAC) to secure additional supply.	None	No change or improvement to the drug.	None	None	None	None	None	None	None	None	None	None	None	The recommended dosage is 1 capsule per day. So the new WAC cost for a 30-day treatment is $60.00
Rx0000575	Stallergenes Greer USA	04/09/2025	22840010730	PALFORZIA 120MG, (15) 20mg capsules and (15) 100mg capsules	03/03/2025	319.88	959.64	12/31/2025	Innovator Multiple Source Drug	None	None	None	1	1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age. 2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx. 3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers. 4. Significant cost increases to the REMS program that is required for this drug. 5. Significant cost increases to the manufacturing and packaging of the product. 6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy.	None	There was no change/improvement to this NDC.	None	09/04/2023	Nestle Health Science	None	1	Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia.	584.26	533.57	2020	445.00	None	None
Rx0000575	Stallergenes Greer USA	04/09/2025	22840010345	PALFORZIA 12MG, (30) 1mg capsules and (15) 10 mg capsules	03/03/2025	319.88	959.64	12/31/2025	Innovator Multiple Source Drug	None	None	None	1	1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age. 2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx. 3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers. 4. Significant cost increases to the REMS program that is required for this drug. 5. Significant cost increases to the manufacturing and packaging of the product. 6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy.	None	There was no change/improvement to this NDC.	None	09/04/2023	Nestle Health Science	None	1	Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia.	584.26	533.57	2020	445.00	None	None
Rx0000575	Stallergenes Greer USA	04/09/2025	22840010860	PALFORZIA 160MG, (45) 20mg capsules and (15) 100mg capsules	03/03/2025	319.88	959.64	12/31/2025	Innovator Multiple Source Drug	None	None	None	1	1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age. 2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx. 3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers. 4. Significant cost increases to the REMS program that is required for this drug. 5. Significant cost increases to the manufacturing and packaging of the product. 6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy.	None	There was no change/improvement to this NDC.	None	09/04/2023	Nestle Health Science	None	1	Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia.	584.26	533.57	2020	445.00	None	None
Rx0000575	Stallergenes Greer USA	04/09/2025	22840010930	PALFORZIA 200MG, (30) 100mg capsules	03/03/2025	319.88	959.64	12/31/2025	Innovator Multiple Source Drug	None	None	None	1	1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age. 2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx. 3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers. 4. Significant cost increases to the REMS program that is required for this drug. 5. Significant cost increases to the manufacturing and packaging of the product. 6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy.	None	There was no change/improvement to this NDC.	None	09/04/2023	Nestle Health Science	None	1	Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia.	584.26	533.57	2020	445.00	None	None
Rx0000575	Stallergenes Greer USA	04/09/2025	22840010415	PALFORZIA 20MG, (15) 20mg capsules	03/03/2025	319.88	959.64	12/31/2025	Innovator Multiple Source Drug	None	None	None	1	1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age. 2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx. 3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers. 4. Significant cost increases to the REMS program that is required for this drug. 5. Significant cost increases to the manufacturing and packaging of the product. 6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy.	None	There was no change/improvement to this NDC.	None	09/04/2023	Nestle Health Science	None	1	Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia.	584.26	533.57	2020	445.00	None	None
Rx0000575	Stallergenes Greer USA	04/09/2025	22840011060	PALFORZIA 240MG, (30) 20mg capsules and (30) 100mg capsules	03/03/2025	319.88	959.64	12/31/2025	Innovator Multiple Source Drug	None	None	None	1	1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age. 2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx. 3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers. 4. Significant cost increases to the REMS program that is required for this drug. 5. Significant cost increases to the manufacturing and packaging of the product. 6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy.	None	There was no change/improvement to this NDC.	None	09/04/2023	Nestle Health Science	None	1	Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia.	584.26	533.57	2020	445.00	None	None
Rx0000575	Stallergenes Greer USA	04/09/2025	22840011115	PALFORZIA 300MG 15/Count	03/03/2025	319.88	959.64	12/31/2025	Innovator Multiple Source Drug	None	None	None	1	1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age. 2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx. 3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers. 4. Significant cost increases to the REMS program that is required for this drug. 5. Significant cost increases to the manufacturing and packaging of the product. 6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy.	None	There was no change/improvement to this NDC.	None	09/04/2023	Nestle Health Science	None	1	Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia.	584.26	533.57	2020	445.00	None	None
Rx0000575	Stallergenes Greer USA	04/09/2025	22840011130	PALFORZIA 300MG 30/Count	03/03/2025	639.75	1919.28	12/31/2025	Innovator Multiple Source Drug	None	None	None	1	1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age. 2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx. 3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers. 4. Significant cost increases to the REMS program that is required for this drug. 5. Significant cost increases to the manufacturing and packaging of the product. 6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy.	None	There was no change/improvement to this NDC.	None	09/04/2023	Nestle Health Science	None	1	Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia.	1168.42	1067.14	2020	890.00	None	None
Rx0000575	Stallergenes Greer USA	04/09/2025	22840012745	PALFORZIA 3MG, (45) 1 mg capsules in one blister pack	03/03/2025	319.88	959.64	12/31/2025	Innovator Multiple Source Drug	None	None	None	1	1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age. 2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx. 3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers. 4. Significant cost increases to the REMS program that is required for this drug. 5. Significant cost increases to the manufacturing and packaging of the product. 6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy.	None	There was no change/improvement to this NDC.	None	09/04/2023	Nestle Health Science	None	1	Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia.	584.26	533.57	2020	445.00	None	None
Rx0000575	Stallergenes Greer USA	04/09/2025	22840010530	PALFORZIA 40MG (30), 20mg capsules	03/03/2025	319.88	959.64	12/31/2025	Innovator Multiple Source Drug	None	None	None	1	1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age. 2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx. 3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers. 4. Significant cost increases to the REMS program that is required for this drug. 5. Significant cost increases to the manufacturing and packaging of the product. 6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy.	None	There was no change/improvement to this NDC.	None	09/04/2023	Nestle Health Science	None	1	Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia.	584.26	533.57	2020	445.00	None	None
Rx0000575	Stallergenes Greer USA	04/09/2025	22840010290	PALFORZIA 6MG, (90) 1 mg capsules in one blister pack	03/03/2025	319.88	959.64	12/31/2025	Innovator Multiple Source Drug	None	None	None	1	1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age. 2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx. 3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers. 4. Significant cost increases to the REMS program that is required for this drug. 5. Significant cost increases to the manufacturing and packaging of the product. 6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy.	None	There was no change/improvement to this NDC.	None	09/04/2023	Nestle Health Science	None	1	Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia.	584.26	533.57	2020	445.00	None	None
Rx0000575	Stallergenes Greer USA	04/09/2025	22840010660	PALFORZIA 80MG, (60) 20mg capsules	03/03/2025	319.88	959.64	12/31/2025	Innovator Multiple Source Drug	None	None	None	1	1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age. 2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx. 3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers. 4. Significant cost increases to the REMS program that is required for this drug. 5. Significant cost increases to the manufacturing and packaging of the product. 6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy.	None	There was no change/improvement to this NDC.	None	09/04/2023	Nestle Health Science	None	1	Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia.	584.26	533.57	2020	445.00	None	None
Rx0000575	Stallergenes Greer USA	04/09/2025	22840011313	PALFORZIA INITIAL DOSE PACK contains (1) 0.5mg capsule; (1) 1mg capsule; (1) 0.5mg capsule and (1) 1mg capsule; (3) 1mg capsules; (6) 1mg capsules	03/03/2025	916.51	959.64	12/31/2025	Innovator Multiple Source Drug	None	None	None	1	1. Significant investment into securing FDA approval to expand indication to include patients 1 to 3 years of age. 2. Significant investment in and expansion of our Co-Pay Savings Program for patients to limit out of pocket costs to approximately $20 per Rx. 3. Significant investment in and expansion of the services that our Specialty Pharmacy and Hub provide to both patients and providers. 4. Significant cost increases to the REMS program that is required for this drug. 5. Significant cost increases to the manufacturing and packaging of the product. 6. Without this price increase, the sustainability of keeping the product on the market would be in jeopardy.	None	There was no change/improvement to this NDC.	None	09/04/2023	Nestle Health Science	None	1	Stallergenes Greer will pay undisclosed milestone payments and ongoing royalties to Nestle for the acquisition of Palforzia.	39.39	35.97	2020	30.00	None	None
Rx0000005	Sumitomo Pharma America, Inc.	04/16/2025	63402020230	Aptiom 200 mg tablet 30 count bottle	01/01/2025	76.24	1347.04	08/24/2032	Single Source Drug	None	None	None	1	SMPA has made the decision to increase the WAC price of the applicable product effective January 1, 2025. This price change is due to increases in the cost of business operations related to the product.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000005	Sumitomo Pharma America, Inc.	04/16/2025	63402020430	Aptiom 400 mg tablet 30 count bottle	01/01/2025	76.24	1347.04	08/24/2032	Single Source Drug	None	None	None	1	SMPA has made the decision to increase the WAC price of the applicable product effective January 1, 2025. This price change is due to increases in the cost of business operations related to the product.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000005	Sumitomo Pharma America, Inc.	04/16/2025	63402020660	Aptiom 600 mg tablet 60 count bottle	01/01/2025	152.48	2694.08	08/24/2032	Single Source Drug	None	None	None	1	SMPA has made the decision to increase the WAC price of the applicable product effective January 1, 2025. This price change is due to increases in the cost of business operations related to the product.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000005	Sumitomo Pharma America, Inc.	04/16/2025	63402020830	Aptiom 800 mg tablet 30 count bottle	01/01/2025	76.24	1347.04	08/24/2032	Single Source Drug	None	None	None	1	SMPA has made the decision to increase the WAC price of the applicable product effective January 1, 2025. This price change is due to increases in the cost of business operations related to the product.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	04/21/2025	17772013130	Qelbree Oral Capsule Extended Release 24 Hour 100 MG Package Quantity 1 Bottle of 30 Capsules	01/01/2025	21.37	377.49	04/02/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	04/21/2025	17772013230	Qelbree Oral Capsule Extended Release 24 Hour 150 MG Package Quantity 1 Bottle of 30 Capsules	01/01/2025	21.37	377.49	04/02/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	04/21/2025	17772013330	Qelbree Oral Capsule Extended Release 24 Hour 200 MG Package Quantity 1 Bottle of 30 Capsules	01/01/2025	21.37	377.49	04/02/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000165	Supernus Pharmaceuticals, Inc.	04/21/2025	17772013360	Qelbree Oral Capsule Extended Release 24 Hour 200 MG Package Quantity 1 Bottle of 60 Capsules	01/01/2025	42.74	754.98	04/02/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020018030	ALUNBRIG 180 MG TABLET * 30 PACK	01/06/2025	606.00	20793.00	11/10/2035	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020011330	ALUNBRIG 30 MG TABLET * 30 PACK	01/06/2025	202.00	6934.00	11/10/2035	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020009030	ALUNBRIG 90 MG TABLET * 30 PACK	01/06/2025	606.00	20793.00	11/10/2035	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020009007	ALUNBRIG 90 MG TABLET * 7 PACK	01/06/2025	142.00	4855.00	11/10/2035	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020019830	ALUNBRIG INITIATION PACK - 7 CT 90 MG TABLET and 23 CT 180 MG TABLET - PER PACK	01/06/2025	606.00	20793.00	11/10/2035	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/28/2025	64764030020	Entyvio Intravenous Solution Reconstituted 300 MG	01/01/2025	693.33	9359.91	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired in the last 5 years. Please note that Patent Expiration Date is not publicly available for Entyvio. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020053630	ICLUSIG 10 MG TABLET * 30 PACK	01/06/2025	871.00	22640.00	12/12/2033	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020053530	ICLUSIG 15 MG TABLET * 30 PACK	01/06/2025	871.00	22640.00	12/12/2033	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020053330	ICLUSIG 30 MG TABLET * 30 PACK	01/06/2025	871.00	22640.00	12/12/2033	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020053430	ICLUSIG 45 MG TABLET * 30 PACK	01/06/2025	871.00	22640.00	12/12/2033	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020023002	NINLARO 2.3 MG CAPSULE * 3 PACK	01/06/2025	390.00	13364.00	11/20/2029	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020023001	NINLARO 2.3 MG CAPSULE * SINGLE PACK	01/06/2025	130.00	4458.00	11/20/2029	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020039002	NINLARO 3.0 MG CAPSULE * 3 PACK	01/06/2025	390.00	13364.00	11/20/2029	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020039001	NINLARO 3.0 MG CAPSULE * SINGLE PACK	01/06/2025	130.00	4458.00	11/20/2029	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020040002	NINLARO 4.0 MG CAPSULE * 3 PACK	01/06/2025	390.00	13364.00	11/20/2029	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	04/16/2025	63020040001	NINLARO 4.0 MG CAPSULE * SINGLE PACK	01/06/2025	130.00	4458.00	11/20/2029	Single Source Drug	None	None	None	1	None	1	NA	None	None	None	None	None	None	None	None	None	None	None	Acquisition information was left blank as the NDC/Product was not acquired within the last 5 years. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/who-we-are/takeda-pricing-philosophy/
Rx0000232	TerSera Therapeutics LLC	04/16/2025	74527002202	Margenza Intravenous Solution 250 MG/10ML (25 MG/ML), 10 ML, Unit-Dose, 1 Vial	02/01/2025	233.84	2595.81	12/02/2041	Single Source Drug	None	None	None	1	None	1	None	1	11/12/2024	MacroGenics, Inc.	40000000	None	None	2361.97	2248.16	2021	2077.00	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000232	TerSera Therapeutics LLC	04/16/2025	74527002203	Margenza Intravenous Solution 250 MG/10ML, (25 MG/ML), 10 ML, Unit-Dose, 4 Vials	02/01/2025	935.34	10383.22	12/02/2041	Single Source Drug	None	None	None	1	None	1	None	1	11/12/2024	MacroGenics, Inc.	40000000	None	None	9447.88	8992.64	2021	8308.00	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000232	TerSera Therapeutics LLC	04/16/2025	70720072010	Prialt Intrathecal Solution 100 MCG/1 ML, Unit-Dose, 1 Vial	01/01/2025	54.56	1167.92	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000232	TerSera Therapeutics LLC	04/16/2025	70720072310	Prialt Intrathecal Solution 500 MCG/20ML (25 MCG/ML), 20 ML, Unit-Dose, 1 Vial	01/01/2025	258.88	5542.14	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000232	TerSera Therapeutics LLC	04/16/2025	70720072210	Prialt Intrathecal Solution 500 MCG/5ML, 5 ML, Unit-Dose, 1 Vial	01/01/2025	258.88	5542.14	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000232	TerSera Therapeutics LLC	04/16/2025	70720010025	Quzyttir Intravenous Solution 10 MG/ML, 1 ML, Unit-Dose, 25 Vials	01/01/2025	404.00	8646.50	02/28/2030	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000232	TerSera Therapeutics LLC	04/16/2025	70720010010	Quzyttir Intravenous Solution 10 MG/ML, 1 ML, Unit-Dose, Vial	01/01/2025	16.69	357.38	02/28/2030	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000232	TerSera Therapeutics LLC	04/16/2025	70720012585	Xermelo Oral Tablet 250 MG, 84 Each, Unit-of-Use, 1 Box	01/01/2025	948.46	10528.82	02/28/2031	Single Source Drug	None	None	None	1	None	1	None	1	09/08/2020	Lexicon Pharmaceuticals, Inc.	159000000	None	None	6559.00	6253.00	2017	5164.00	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000232	TerSera Therapeutics LLC	04/16/2025	70720095130	Zoladex Subcutaneous Implant 10.8 MG, 1 Each, Unit-of-Use, 1 Box	01/01/2025	136.39	2920.02	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000232	TerSera Therapeutics LLC	04/16/2025	70720095036	Zoladex Subcutaneous Implant 3.6 MG, 1 Each, Unit-Dose, 1 Syringe	01/01/2025	58.58	1051.40	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000302	Tetraphase Pharmaceuticals	04/29/2025	71773010012	Xerava 12 (10 mL) SDVs 100 mg Injection, Powder, Lyophilized, for Solution	01/02/2025	80.00	1400.00	10/19/2037	Single Source Drug	None	None	None	1	Our drugs target rare diseases and serve smaller patient populations, meaning that the costs of development and manufacturing must be spread over fewer patients, leading to the need for higher prices.  Our comprehensive evaluation included other similar drugs and we compared that analysis with pharmacoeconomics to make the decision to raise our price.	None	A change or improvement in the product does not necessitate the price increase.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000302	Tetraphase Pharmaceuticals	04/29/2025	71773005012	Xerava 12 (10 mL) SDVs 50 mg Injection, Powder, Lyophilized, for Solution	01/02/2025	67.00	805.00	10/19/2037	Single Source Drug	None	None	None	1	Our drugs target rare diseases and serve smaller patient populations, meaning that the costs of development and manufacturing must be spread over fewer patients, leading to the need for higher prices.  Our comprehensive evaluation included other similar drugs and we compared that analysis with pharmacoeconomics to make the decision to raise our price.	None	A change or improvement in the product does not necessitate the price increase.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000217	Teva Neuroscience, Inc.	04/29/2025	68546014256	AZILECT 0.5MG TABLET 30 EACH	01/01/2025	107.50	1251.10	08/27/2027	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000217	Teva Neuroscience, Inc.	04/29/2025	68546022956	AZILECT 1MG TABLET 30 EACH	01/01/2025	107.50	1251.10	08/27/2027	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	57844011001	ADDERALL 10MG TABLET 100EA	01/01/2025	100.80	1173.10	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	57844011201	ADDERALL 12.5MG TABLET 100EA	01/01/2025	100.80	1173.10	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	57844011501	ADDERALL 15MG TABLET 100EA	01/01/2025	100.80	1173.10	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	57844012001	ADDERALL 20MG TABLET 100EA	01/01/2025	100.80	1173.10	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	57844013001	ADDERALL 30MG TABLET 100EA	01/01/2025	100.80	1173.10	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	57844010501	ADDERALL 5MG TABLET 100EA	01/01/2025	100.80	1173.10	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	57844011701	ADDERALL 7.5MG TABLET 100EA	01/01/2025	100.80	1173.10	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	57844014001	ADIPEX-P TABLETS 100 EA	01/01/2025	25.60	297.96	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	57844014056	ADIPEX-P TABLETS 30 EA	01/01/2025	5.95	69.22	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	63459070060	AMRIX 15 MG XR CAPSULE 60EA	01/01/2025	327.30	3809.70	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	63459070160	AMRIX 30 MG XR CAPSULE 60EA	01/01/2025	327.30	3809.70	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	52544008001	FIORICET ORAL CAPS 50/300/40 MG 100 EA	01/01/2025	72.30	841.90	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	52544008201	FIORICET ORAL CAPs 50/300/40/30 MG 100 EA	01/01/2025	151.50	1762.70	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	57844021552	GALZIN 25 MG CAPSULE 250 EA	01/01/2025	53.30	620.80	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	57844020852	GALZIN 50 MG CAPSULE 250 EA	01/01/2025	88.90	1034.60	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	00575620030	PROGLYCEM ORAL SUS 50MG/ML 30ML	01/01/2025	41.80	486.60	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	63459010130	PROVIGIL 100MG 30 EA	01/01/2025	143.80	1674.10	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	63459020130	PROVIGIL 200MG 30 EA	01/01/2025	217.30	2529.50	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000019	Teva Pharmaceuticals USA	04/29/2025	63459060106	TRISENOX VIAL 2 MG/ML 6 ML 10 VIAL	01/01/2025	1096.60	12762.80	None	Innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	04/29/2025	51285013197	LOESTRIN 21 1.0MG/20MCG TABLET 105 EA	01/01/2025	93.40	1087.40	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	04/29/2025	51285012797	LOESTRIN 21 1.5MG/30MCG TABLET 105 EA	01/01/2025	93.40	1087.40	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	04/29/2025	51285012870	LOESTRIN FE 28 1.5MG/30MCG TABLET 140 EA	01/01/2025	93.40	1087.40	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	04/29/2025	51285012570	LOESTRIN FE 28 1MG/20MCG TABLET 140 EA	01/01/2025	93.40	1087.40	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	04/29/2025	51285036801	TREXALL 10 MG TABLET 30EA	01/01/2025	118.90	1383.80	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	04/29/2025	51285036901	TREXALL 15 MG TABLET 30EA	01/01/2025	178.40	2075.80	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	04/29/2025	51285036601	TREXALL 5 MG TABLET 30EA	01/01/2025	59.50	692.10	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000219	Teva Women's Health, Inc.	04/29/2025	51285036701	TREXALL 7.5 MG TABLET 30EA	01/01/2025	89.20	1037.90	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	No patent expiration date listed - no patents ever listed Acquisition fields left blank; product was not acquired within the previous five years.
Rx0000573	The Harvard Drug Group, L.L.C. dba Major Pharmaceuticals	04/08/2025	00904714461	Dronabinol 2.5mg Cap Unit Dose 10X10	04/01/2025	377.25	849.60	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000573	The Harvard Drug Group, L.L.C. dba Major Pharmaceuticals	04/08/2025	00904714504	Dronabinol 5mg Cap Unit Dose 3X10	04/01/2025	226.52	515.77	None	Non-innovator Multiple Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000395	Travere Therapeutics, Inc.	04/09/2025	68974020030	Filspari 200 mg Tablet 30 count Bottle	02/10/2025	692.64	12432.27	03/29/2030	Single Source Drug	None	None	None	1	Travere routinely assesses the prices of its medicines to determine if they remain appropriate, taking into account the value delivered, the price of other medicines available and increases in our costs. As part of our overall approach to pricing medicine, we also work with payers and patient organizations to ensure that any price adjustment does not present a barrier to access.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000395	Travere Therapeutics, Inc.	04/09/2025	68974040030	Filspari 400 mg Tablet 30 count Bottle	02/10/2025	692.64	12432.27	03/29/2030	Single Source Drug	None	None	None	1	Travere routinely assesses the prices of its medicines to determine if they remain appropriate, taking into account the value delivered, the price of other medicines available and increases in our costs. As part of our overall approach to pricing medicine, we also work with payers and patient organizations to ensure that any price adjustment does not present a barrier to access.	None	No change or improvement.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000618	Trifluent Pharma LLC	04/29/2025	73352045501	HYDROCORTISONE TOPICAL SOLUTION 2.5% 30ML	01/06/2025	253.50	1238.00	None	Non-innovator Multiple Source Drug	None	None	635434	None	Very shortly after we launched two products, we discovered an issue in our systems that led to a pricing error. We immediately filed a pricing correction on 1/6 for both products.	None	n/a	None	12/16/2024	Mission Pharmacal	None	1	None	204.23	204.23	2011	204.23	None	None
Rx0000618	Trifluent Pharma LLC	04/29/2025	73352084530	TRIDACAINE XL LIDOCAINE 5% PATCH 30CT	01/06/2025	744.00	1540.00	None	Non-innovator Multiple Source Drug	None	None	16601	None	Very shortly after we launched two products, we discovered an issue in our systems that led to a pricing error. We immediately filed a pricing correction on 1/6 for both products.	None	n/a	None	12/01/2024	Yaral	None	1	None	85.50	85.50	2023	85.50	None	This product was a repackaged product.
Rx0000090	UCB, Inc	04/28/2025	50474070062	CIMZIA LYOPHOLIZED POWDER FOR INJECTION, 2 X 200 MG VIALS	01/01/2025	280.24	5999.43	None	Single Source Drug	None	None	1394698000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family.
Rx0000090	UCB, Inc	04/28/2025	50474071079	CIMZIA PRE-FILLED SYRINGE KIT, 2 X 200 MG/ML PRE-FILLED SYRINGES	01/01/2025	280.24	5999.43	None	Single Source Drug	None	None	1394698000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family.
Rx0000090	UCB, Inc	04/28/2025	50474071081	CIMZIA PRE-FILLED SYRINGE STARTER KIT, 6 X 200 MG/ML PRE-FILLED SYRINGES	01/01/2025	840.72	17998.30	None	Single Source Drug	None	None	1394698000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years. Our Public Gross Sales Volumes are rolled up to the Product level and not NDC specific. Amount supplied represents the whole Product family.
Rx0000036	United Therapeutics	04/24/2025	66302030001	ORENITRAM 0.125MG Oral Tab 100 Pack	01/01/2025	47.91	742.32	08/11/2031	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000036	United Therapeutics	04/24/2025	66302030201	ORENITRAM 0.25MG Oral Tab 100 Pack	01/01/2025	95.82	1484.57	08/11/2031	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000036	United Therapeutics	04/24/2025	66302031001	ORENITRAM 1MG Oral Tab 100 Pack	01/01/2025	383.30	5938.43	08/11/2031	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000036	United Therapeutics	04/24/2025	66302032501	ORENITRAM 2.5MG Oral Tab 100 Pack	01/01/2025	958.26	14846.12	08/11/2031	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000036	United Therapeutics	04/24/2025	66302035001	ORENITRAM 5MG Oral Tab 100 Pack	01/01/2025	1916.52	29692.22	08/11/2031	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000036	United Therapeutics	04/24/2025	66302064803	TYVASO DPI 48MCG Inhalation powder 1 single dose cartridge	01/01/2025	1357.30	24362.37	04/01/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000036	United Therapeutics	04/24/2025	66302066403	TYVASO DPI 64MCG Inhalation powder 1 single dose cartridge	01/01/2025	1357.30	24362.37	04/01/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000036	United Therapeutics	04/24/2025	66302061002	TYVASO DPI 16MCG/32MCG/48MCG Inhalation powder 1 Single dose cartridge	01/01/2025	1357.30	24362.37	04/01/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000036	United Therapeutics	04/24/2025	66302061603	TYVASO DPI 16MCGInhalation powder 1 single dose cartridge	01/01/2025	1357.30	24362.37	04/01/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000036	United Therapeutics	04/24/2025	66302063203	TYVASO DPI 32MCG 1 Inhalation powder single dose cartridge	01/01/2025	1357.30	24362.37	04/01/2035	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000036	United Therapeutics	04/24/2025	66302001401	Unituxin 17.5 MG/5ML Intravenous Solution1 Vial in 1 Carton	01/01/2025	1715.81	19047.27	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000450	Vericel Corporation	04/29/2025	69866103005	MACI®; (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) 1 BAG in 1 BOX (69866-1030-5) > 1 BOTTLE, PLASTIC in 1 BAG (69866-1030-4) > 1 IMPLANT in 1 BOTTLE, PLASTIC (69866-1030-3)	03/03/2025	5157.00	65822.00	11/25/2033	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Please note that while Vericel acquired MACI in 2014, the product was not launched until 06/27/2017, under the NDC # 69866-1030-01. The product was relabeled and given a new NDC # 69866-1030-05 with a market entry date 05/10/2021.
Rx0000450	Vericel Corporation	04/29/2025	69866103008	MACI®; (Autologous Cultured Chondrocytes on Porcine Collagen Membrane) 2 BAG in 1 BOX (69866-1030-8) > 1 BOTTLE, PLASTIC in 1 BAG (69866-1030-7) > 1 IMPLANT in 1 BOTTLE, PLASTIC (69866-1030-6)	03/03/2025	10314.00	131644.00	11/25/2033	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Please note that while Vericel acquired MACI in 2014, the product was not launched until 06/27/2017, under the NDC # 69866-1030-02. The product was relabeled and given a new NDC # 69866-1030-08 with a market entry date 05/10/2021.
Rx0000155	Vertical Pharmaceuticals, LLC	03/17/2025	68025005230	Corvite 150 - Iron Supplement multivitamin/ multimineral, Oral Tablets, 1 Package with 30 Count	01/01/2025	17.56	194.95	04/21/2029	Single Source Drug	None	None	None	1	Price increase for this product is based on the increase in the cost of materials and goods that we must purchase in order to manufacture and distribute the product	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000155	Vertical Pharmaceuticals, LLC	03/17/2025	68025006030	Corvite Fe- Iron Supplement, Oral Tablet, 1 package with 30 count tablets	01/01/2025	23.10	256.43	04/27/2029	Single Source Drug	None	None	None	1	Price increase for this product is based on the increase in the cost of materials and goods that we must purchase in order to manufacture and distribute the product	None	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000066	ViiV Healthcare	04/04/2025	49702024613	Dovato Oral Tablet 50-300 MG 30 tablets per bottle	01/01/2025	119.06	3095.69	01/24/2031	Single Source Drug	None	None	None	1	None	1	The price increases listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, WAC_1 YEAR PRIOR TO ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	04/04/2025	49702024213	Juluca Oral Tablet 50-25 MG, 30 tablets per bottle	01/01/2025	140.49	3652.73	09/05/2038	Single Source Drug	None	None	None	1	None	1	The price increases listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, WAC_1 YEAR PRIOR TO ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	04/04/2025	49702023113	Triumeq Oral Tablet 600-50-300 MG, 30 tablets per bottle	01/01/2025	149.90	3897.42	06/08/2030	Single Source Drug	None	None	None	1	None	1	The price increases listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, WAC_1 YEAR PRIOR TO ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000066	ViiV Healthcare	04/04/2025	49702025837	Triumeq PD Oral Tablet Soluble 60-5-30 MG, 90 tablets per bottle	01/01/2025	44.97	1169.23	06/08/2030	Single Source Drug	None	None	None	1	None	1	The price increases listed are not related to any identified or claimed change or improvement.	None	None	None	None	None	None	None	None	None	None	None	Note on Patent Expiration Date: Pursuant to Sec. 96070(d), if the drug is under patent, the patent expiration date is provided.  The date provided is the latest expiration date of all patents listed with the USFDA under 21 CFR 314.53. Note on Acquisition Fields: This drug was developed by ViiV Healthcare, therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, WAC_1 YEAR PRIOR TO ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000315	Y-mAbs Therapeutics Inc.	04/10/2025	73042020101	Danyelza 40 mg/10 mL in a single dose vial	01/01/2025	1705.25	26065.90	02/15/2034	Single Source Drug	None	None	65981000	None	Price is determined after a careful analysis of a number of factors such as: cost of manufacturing, warehousing, storage, distribution, shipping, marketing and regulatory costs.	None	The change in price of the product is not necessarily related to changes in the product but is determined after a careful consideration of how to remain competitive and continue our mission of developing oncology products addressing clear unmet medical needs.	None	None	None	None	None	None	None	None	None	None	None	None
None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None	None